var title_f10_14_10464="Lead flecks";
var content_f10_14_10464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lead flecks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abdominal radiograph demonstrates flecks of lead in the pelvis of a child who ingested lead paint chips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Hurwitz, MD and Dean A Lee, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10464=[""].join("\n");
var outline_f10_14_10464=null;
var title_f10_14_10465="Algorithm for cough evaluation";
var content_f10_14_10465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 598px\">",
"   <div class=\"ttl\">",
"    Evaluation of subacute or chronic cough in adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 578px; height: 735px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GERD: gastroesophageal reflux disease; ACE: angiotensin-converting enzyme.",
"     <br>",
"      * Also consider post-infectious etiology for subacute cough (3 to 8 weeks duration).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10465=[""].join("\n");
var outline_f10_14_10465=null;
var title_f10_14_10466="Fructose, dextrose, and orthophosphoric acid: Drug information";
var content_f10_14_10466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fructose, dextrose, and orthophosphoric acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/51/36659?source=see_link\">",
"    see \"Fructose, dextrose, and orthophosphoric acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F188409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Emetrol&reg; [OTC];",
"     </li>",
"     <li>",
"      Formula EM [OTC];",
"     </li>",
"     <li>",
"      Kalmz [OTC];",
"     </li>",
"     <li>",
"      Nausea Relief [OTC];",
"     </li>",
"     <li>",
"      Nausetrol&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F188417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiemetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F188410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Nausea:",
"     </b>",
"     Oral: 15-30 mL; repeat dose every 15 minutes until distress subsides; do not take for more than 1 hour (5 doses)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F188413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Nausea:",
"     </b>",
"     Oral",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-12 years: 5-10 mL; repeat dose every 15 minutes until distress subsides; do not take for more than 1 hour (5 doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F188411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F188404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid, oral: Fructose 1.87 g, dextrose 1.87 g, and phosphoric acid 21.5 mg per 5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Emetrol&reg;: Fructose 1.87 g, dextrose 1.87 g, and phosphoric acid 21.5 mg per 5 mL (120 mL) [cherry flavor; lemon mint flavor] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Formula EM, Nausea Relief: Fructose 1.87 g, dextrose 1.87 g, and phosphoric acid 21.5 mg per 5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Kalmz, Nausetrol&reg;: Fructose 1.87 g, dextrose 1.87 g, and phosphoric acid 21.5 mg per 5 mL (120 mL) [cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F188396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F188406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May chill or drink after pouring over ice to improve taste. Should not be diluted or followed with other fluids immediately before or after administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F188405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of nausea associated with upset stomach that occurs with intestinal or stomach flu, and food indiscretions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3068796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; hereditary fructose intolerance",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3068797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Not for self-medication (OTC use) in patients with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lack of improvement: Contact healthcare provider if nausea continues or recurs frequently.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Emetrol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.87-1.87-21.5 (118 mL): $6.36",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8705 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-41.78.124.10-D68EE5DB58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10466=[""].join("\n");
var outline_f10_14_10466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188409\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188417\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188410\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188413\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188411\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188404\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188396\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188406\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188405\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3068796\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3068797\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299369\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220530\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323310\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8705\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8705|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/51/36659?source=related_link\">",
"      Fructose, dextrose, and orthophosphoric acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_14_10467="Contact derm vulva";
var content_f10_14_10467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contact dermatitis vulva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from&nbsp;Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10467=[""].join("\n");
var outline_f10_14_10467=null;
var title_f10_14_10468="Infertility treatment with gonadotropins";
var content_f10_14_10468=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/14/10468/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/14/10468/contributors\" id=\"au1356\">",
"       Bart CJM Fauser, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/14/10468/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/14/10468/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/14/10468/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/14/10468/contributors\" id=\"de5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?10/14/10468?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Infertility is defined as a couple's inability to become pregnant within one year of unprotected intercourse. In any given year, about 15 percent of couples in North America and Europe who are trying to conceive are infertile.",
"    </p>",
"    <p>",
"     Gonadotropins are hormones (LH and FSH) that can be given in an injection to stimulate a woman's ovaries to produce follicles, which contain an oocyte (egg). Women who have not been able to become pregnant with clomiphene (Clomid&reg;, Serophene&reg;) may be encouraged to try gonadotropins as a next step.",
"    </p>",
"    <p>",
"     This topic will review who should consider gonadotropins, how they are given, the side effects of treatment, and other procedures that may be used with gonadotropins to increase the chances of pregnancy. The use of clomiphene and the evaluation of infertility are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"      \"Patient information: Ovulation induction with clomiphene (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=see_link\">",
"      \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PREPARING FOR INFERTILITY TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Before any infertility treatment begins, a woman and her partner should undergo an evaluation to determine the best course of treatment. This evaluation may include a complete history and physical examination, a semen analysis (for men), blood testing, and other tests depending upon the individual situation. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=see_link\">",
"      \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      WHAT ARE GONADOTROPINS?",
"     </span>",
"    </p>",
"    <p>",
"     Gonadotropins are two hormones, luteinizing hormone (LH) and follicle stimulating hormone (FSH), which are normally produced by the pituitary gland. These hormones stimulate the ovaries to produce a follicle, which contain an egg (oocyte).",
"    </p>",
"    <p>",
"     Most gonadotropin preparations used for infertility treatment are created in a laboratory (called recombinant preparations) and must be injected under the skin to be effective. For most women, a preparation containing only FSH injections is recommended. Women who do not have regular menstrual periods and who have very low levels of LH and FSH require a preparation containing both LH and FSH.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      WHO SHOULD CONSIDER INFERTILITY TREATMENT WITH GONADOTROPINS?",
"     </span>",
"    </p>",
"    <p>",
"     There are two categories of women who may benefit from treatment with gonadotropins:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Women who do not ovulate at all or who ovulate irregularly (called anovulation and oligoovulation). Gonadotropins are given in this group to stimulate development of a single follicle and ovulation of a single egg. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"        \"Patient information: Absent or irregular periods (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Women who ovulate normally. Gonadotropins may improve the chances of becoming pregnant (with in vitro fertilization or intrauterine insemination) by stimulating the ovaries to produce more than one follicle.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Depending upon the situation, one of several infertility treatments may be recommended. In women who do not ovulate, clomiphene, rather than gonadotropins, is often recommended as an initial treatment. The advantages of clomiphene compared to gonadotropins include ease of oral administration, fewer side effects, lower cost (of the medication itself, as well as the monitoring), lower risk of multiple pregnancies, and reduced time commitment (related to monitoring during treatment). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"      \"Patient information: Ovulation induction with clomiphene (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If the woman has tried clomiphene or if clomiphene is unlikely to be helpful, the next step is often to try ovulation induction with injectable gonadotropins. Gonadotropins may be used along with intrauterine insemination (IUI) or in vitro fertilization. Another option that is sometimes considered for women with polycystic ovary syndrome is laparoscopic minimal surgery of the ovaries. This may help restore ovulation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      GONADOTROPIN PROTOCOL",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of protocols for the type, dosing, and timing of ovulation induction with gonadotropins [",
"     <a class=\"abstract\" href=\"UTD.htm?10/14/10468/abstract/1\">",
"      1",
"     </a>",
"     ]. The protocol used will depend on the woman's situation and the clinician's preferences. The protocol described below is an example and may differ from your instructions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The first day of menstrual bleeding is considered day one of the cycle. Most providers ask that you call on the first day of bleeding to schedule an appointment for blood tests and an ultrasound.",
"      </li>",
"      <li>",
"       On day three to five, you may be asked to have blood testing to measure hormone levels and a pelvic ultrasound to be sure that there are no large pre-existing cysts on the ovaries. You will be given instructions about the dose and timing of your first injection based upon the results of these tests.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Women vary considerably in their response to FSH injections. Some women require only small doses of FSH to stimulate follicle growth. Other women require large doses of FSH to stimulate follicle growth. In an average patient, the greater the dose of FSH, the greater the likelihood of the growth of many follicles and the greater the likelihood of multiple gestation. Most clinicians prefer to start with small doses of FSH to minimize the risk of the growth of many follicles. If small doses of FSH are utilized, extra days of injections may be required to stimulate follicle growth.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In most cases, you will give an injection of gonadotropins once per day, in the evening (between 5 pm and 8 pm, for example). The injection can be given under the skin in most cases.",
"      </li>",
"      <li>",
"       After a few days of injections, you will be asked to have a pelvic ultrasound to measure follicle growth, and possibly a blood test to measure hormone levels. Depending upon the results of these tests, the gonadotropin dose may be increased or decreased. Blood testing and pelvic ultrasound may be repeated three or more times during a cycle.",
"      </li>",
"      <li>",
"       For women who do not ovulate on their own, the goal is to have one follicle that is approximately 15 to 18 mm in size. If three or more follicles (greater than 15 mm each) are seen, the cycle may be cancelled due to the risk of becoming pregnant with twins, triplets, etc [",
"       <a class=\"abstract\" href=\"UTD.htm?10/14/10468/abstract/2\">",
"        2",
"       </a>",
"       ]. In some situations, the cycle may be converted to in vitro fertilization, so that the clinician can control the number of embryos that are placed in the uterus.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If the cycle is cancelled, you should stop the injections and follow up with your healthcare provider.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       When blood testing and ultrasound measurements show that the follicle is \"ready,\" you will be instructed to give an injection of hCG to trigger ovulation. hCG is also called human chorionic gonadotropin, Ovidrel&reg;, Pregnyl&reg;, and Novarel&reg;. hCG is usually injected under the skin in the evening.",
"      </li>",
"      <li>",
"       Some women will be instructed to have intercourse at a particular time the following day. In other cases, intrauterine insemination (IUI) will be recommended. (See",
"       <a class=\"local\" href=\"#H8\">",
"        'Intrauterine insemination'",
"       </a>",
"       below.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Side effects of treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gonadotropins usually do not cause side effects directly. However, the ovaries become somewhat enlarged during treatment, which can cause abdominal discomfort, and in more severe cases, nausea and vomiting. The main risks of gonadotropin therapy are the development of ovarian hyperstimulation syndrome and conceiving a multiple pregnancy [",
"     <a class=\"abstract\" href=\"UTD.htm?10/14/10468/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Ovarian hyperstimulation syndrome (OHSS)",
"     </span>",
"     &nbsp;&mdash;&nbsp;OHSS is a condition in which the ovaries become moderately to severely enlarged and multiple follicles develop on the ovaries. In severe cases, the woman may develop severe abdominal pain, vomiting, blood clots in the legs or lungs, and fluid imbalances in the blood. Moderate OHSS occurs in less than 6 percent of cases and severe OHSS occurs in less than 2 percent of women undergoing treatment with gonadotropins.",
"    </p>",
"    <p>",
"     OHSS can be prevented most of the time by cancelling the cycle when blood estrogen levels are too high or there are too many follicles seen on ultrasound. If the cycle is cancelled, no more injections of gonadotropins are given and the hCG injection will not be given. Depending upon how enlarged the ovaries become, other treatments may be necessary. The next cycle of treatment may be resumed when the ovaries have returned to their normal size.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      INTRAUTERINE INSEMINATION",
"     </span>",
"    </p>",
"    <p>",
"     Intrauterine insemination (IUI) places sperm directly inside the woman's uterus, which may increase her chances of becoming pregnant. IUI, in combination with gonadotropins, may be recommended if the woman does not ovulate or when there is another known issue, such as a low sperm count, difficulty ejaculating, or a narrow cervical opening [",
"     <a class=\"abstract\" href=\"UTD.htm?10/14/10468/abstract/1\">",
"      1",
"     </a>",
"     ], or if the couple's infertility is unexplained [",
"     <a class=\"abstract\" href=\"UTD.htm?10/14/10468/abstract/2\">",
"      2",
"     </a>",
"     ]. IUI in combination with gonadotropins may increase overall pregnancy chances, but it also increases the chances for multiple pregnancy.",
"    </p>",
"    <p>",
"     The male partner is usually instructed to obtain a semen sample by masturbating and ejaculating into a sterile container. The man should avoid ejaculating two to three days before collecting the sample. The semen is then prepared in a laboratory to separate the active sperm from the inactive sperm and seminal fluid. The process is similar if donor sperm is used.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Procedure",
"     </span>",
"     &nbsp;&mdash;&nbsp;IUI is usually performed 12 to 36 hours after the woman injects hCG. During IUI, the woman lies on her back on an examination table and rests her feet in supports. A speculum is inserted in the vagina and a long, thin, flexible tube is used to insert the prepared sperm sample through the vagina and cervix inside the uterus. This takes less than five minutes.",
"    </p>",
"    <p>",
"     The woman may feel some cramping during the procedure, although this usually resolves quickly. After the sperm sample is inserted and the tube is removed, the woman is usually asked to continue lying down for a few minutes. The woman may then resume her normal activities.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Postprocedure care",
"     </span>",
"     &nbsp;&mdash;&nbsp;Serious complications of IUI are uncommon. Common reactions include pelvic cramping, light bleeding, and vaginal discharge. If these problems are persistent or become severe, it is important to call a healthcare provider as soon as possible.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      TESTING FOR PREGNANCY AFTER INFERTILITY TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Blood testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately two weeks after IUI or intercourse, a blood or urine test for pregnancy (called hCG) can be done. Home urine pregnancy testing is not as sensitive for detecting an early pregnancy as blood testing.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If the first blood hCG level is &lt;5",
"       <span class=\"nowrap\">",
"        IU/L,",
"       </span>",
"       the woman is not pregnant.",
"      </li>",
"      <li>",
"       If the first hCG level is &gt;10",
"       <span class=\"nowrap\">",
"        IU/L,",
"       </span>",
"       the test is usually repeated 48 hours later to confirm that the levels are increasing. The hCG level should double every 29 to 53 hours during the first 30 days.",
"      </li>",
"      <li>",
"       If the second hCG level does not double or decreases, the blood test may be repeated again 48 hours later. Depending upon the situation, there is a possibility that the pregnancy is not viable. hCG levels do not increase or begin to decline when the pregnancy is not progressing normally. (See",
"       <a class=\"local\" href=\"#H15\">",
"        'When infertility treatment is not successful'",
"       </a>",
"       below.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Ultrasound",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the hCG levels increase as expected, a pelvic ultrasound may be done three to four weeks after ovulation. At this time, it is usually possible to see a gestational sac inside the uterus. The gestational sac is a fluid-filled sac containing the embryo (",
"     <a class=\"graphic graphic_diagnosticimage graphicRef76430 \" href=\"UTD.htm?10/21/10583\">",
"      image 1",
"     </a>",
"     ). At five to six weeks of pregnancy (four to five weeks after ovulation), the yolk sac is usually visible. The yolk sac provides nourishment to the embryo early in development. A heart beat is usually visible by 5.5 to six weeks of pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Pregnancy care",
"     </span>",
"     &nbsp;&mdash;&nbsp;In most cases, prenatal care begins at 6 to 10 weeks of pregnancy. At this time, the woman will begin to see her clinician or nurse on a regular basis. These visits allow the provider to monitor the woman and baby's health and to answer any questions.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHEN INFERTILITY TREATMENT IS NOT SUCCESSFUL",
"     </span>",
"    </p>",
"    <p>",
"     Ovulation induction using gonadotropins and intrauterine insemination has a high rate of success in most cases. However, more than one cycle of treatment is often necessary before pregnancy occurs. Some women will not become pregnant despite multiple attempts. Depending upon the situation, the next step may be to consider in vitro fertilization. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/62/40932?source=see_link\">",
"      \"Patient information: In vitro fertilization (IVF) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     It can be difficult to deal with the emotional highs and lows of infertility treatment. This is especially true if the woman (and her partner) have been trying to conceive for a long time, if treatment is not covered by insurance, and if there are any underlying problems in the couple's life (eg, medical, family or partner, job, financial).",
"    </p>",
"    <p>",
"     Support groups and counseling services are available at many infertility treatment centers, as well as on the internet. (See",
"     <a class=\"local\" href=\"#H17\">",
"      'Where to get more information'",
"     </a>",
"     below.) To find a reputable group, talk to your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      COSTS OF INFERTILITY TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The costs of infertility treatments can be high, depending upon what tests are required, the type and dose of medication(s) used, and the number of cycles required to become pregnant. Insurance policies cover the costs of infertility treatment in some states, although this varies by location and individual insurance policy. Less than half of the states within the US have laws requiring insurers to cover infertility treatment.",
"    </p>",
"    <p>",
"     More information about a state's laws can be obtained by calling your state Insurance Commissioner's office. Information can also be found by visiting the website for Resolve, a National Infertility organization [",
"     <a class=\"abstract\" href=\"UTD.htm?10/14/10468/abstract/3\">",
"      3",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287566815\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10151799\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11523?source=see_link\">",
"      Patient information: Infertility in women (The Basics)",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/42/40610?source=see_link\">",
"      Patient information: Infertility in men (The Basics)",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/25/6547?source=see_link\">",
"      Patient information: Infertility in couples (The Basics)",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/8/5251?source=see_link\">",
"      Patient information: Endometriosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10151791\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"      Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=see_link\">",
"      Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/62/40932?source=see_link\">",
"      Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=see_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/58/934?source=see_link\">",
"      Long-term complications of pelvic inflammatory disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=see_link\">",
"      Clinical manifestations and diagnosis of early pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=see_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"      In vitro fertilization",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=see_link\">",
"      Reproductive surgery for female infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37976?source=see_link\">",
"      Management of couples with recurrent pregnancy loss",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link\">",
"      Overview of ovulation induction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=see_link\">",
"      Pathogenesis and treatment of infertility in women with endometriosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/25/16794?source=see_link\">",
"      Preconception evaluation and counseling",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22647?source=see_link\">",
"      Prevention of ovarian hyperstimulation syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25351?source=see_link\">",
"      Procedure for intrauterine insemination",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"      Treatment of male infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25496?source=see_link\">",
"      Unexplained infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39865?source=see_link\">",
"      Use of assisted reproduction in HIV and hepatitis infected couples",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society for Reproductive Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.asrm.org/\">",
"      www.asrm.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Resolve: The National Infertility Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.resolve.org/\">",
"      www.resolve.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Patient Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Infertility Conditions Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://infertility.about.com/forum\">",
"      file://infertility.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?10/14/10468/abstract/1,2,4,5\">",
"      1,2,4,5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?10/14/10468?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10468/abstract/1\">",
"      Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev 2006; 27:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10468/abstract/2\">",
"      Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet 2005; 365:1807.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.resolve.org/family-building-options/insurance_coverage/state-coverage.html (Accessed on August 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10468/abstract/4\">",
"      Cantineau AE, Heineman MJ, Cohlen BJ. Single versus double intrauterine insemination (IUI) in stimulated cycles for subfertile couples. Cochrane Database Syst Rev 2003; :CD003854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10468/abstract/5\">",
"      Bayram N, van Wely M, van Der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2001; :CD002121.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f10_14_10468=[""].join("\n");
var outline_f10_14_10468=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PREPARING FOR INFERTILITY TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           WHAT ARE GONADOTROPINS?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           WHO SHOULD CONSIDER INFERTILITY TREATMENT WITH GONADOTROPINS?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           GONADOTROPIN PROTOCOL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           INTRAUTERINE INSEMINATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           TESTING FOR PREGNANCY AFTER INFERTILITY TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHEN INFERTILITY TREATMENT IS NOT SUCCESSFUL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           COSTS OF INFERTILITY TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          DIAGNOSTIC IMAGES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/21/10583\" title=\"diagnostic image 1\">",
"           Ultrasound image of embryo in gestational sac",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f10_14_10469="Langerhans histiocytosis PA II";
var content_f10_14_10469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph reveals reticular and nodular&nbsp;opacities in mid-lung zones, cysts, costophrenic angle sparing, and increased lung volumes in a 58 year-old man with pulmonary LCH.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAXMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WRGdgqKWY9ABk1N9juiMi2m/79mtHwggk8Q2qMMg7+2f4Gr0WLSYnOWj2/7tAHlQsLwni1uD/wBsz/hTxpl+elldH6RN/hXrqaRsHyYKj161cgWFQN0G4jrmgDxgaRqR6afeHnH+pbr+VP8A7D1b/oF33/gO/wDhXucUlssbhrNtpGCQ3H5VqRwWUqFYnaNs5UScc/WgD54/sTVc4/sy+/8AAd/8KU6FqwGTpd+B727/AOFfSR0vI6DnuvehLAINpAKn9KAPmj+ytR5/0C7/AO/Lf4UHS9QAybG7A/64t/hX0hc6Al0DJGAjd2xxVCXRVizGV57+poA+ezp16Bk2dyB/1yb/AApPsF3/AM+s/wD37Ney63pP2VwhXIblT6isv7GT1/AUAeX/ANn3v/Ppcf8Afpv8KUabfHpZXJ/7ZN/hXqK2pA5FWbe0JbOOKAPKU0bU3OE069Y+0DH+lWE8M68/3dE1RvpaSH+le46JYNnODn3ru7G2EEOCcsefp7UAfKw8KeIj00DVj/25yf4U/wD4RDxL/wBC7rH/AIBS/wDxNfWkK4OcZz2q6g3KCcLx0oA+Px4O8THp4d1n/wAAZf8A4mlHg3xOTx4c1r/wBl/+Jr7Ejz0HKj25qaJ8HnBoA+Nf+EM8Uf8AQt61/wCAEv8A8TUZ8J+Ih10DVx9bOT/4mvttVEiEAAjHFZU6gMRtAI/WgD47Hg/xMwyPDuskeosZf/iaevgvxSwyvhrWyPawl/8Aia+woZAhWPHDD5s1a09iwZQO+RQB8aHwV4qHXwzrf/gBL/8AE0w+DvEykA+HdZBPTNjLz/47X25IgZQqniqskOwgkL9KAPi3/hDvE+P+Rc1n/wAAZf8A4mkPhDxKBk+HtYA/68pf/ia+yLh+CD9Oec1kXt3FFnzCAfVj/SgD5MPhPxEOugauP+3OT/Co28M68v3tE1QfW0k/wr6dm8QWUbbS25fUdqhuNRtpNuWADdCD1oA+Y20LV0OH0u/U+ht3H9KjfSdRTG/T7tc+sLD+lfS1zaQXceEdQ/UCsa400q2yRAy+hHBFAHgH9mX/APz5XX/fpv8ACnJpGpOQE0+8YnoBCx/pXtz6Gd2+2BKk8x9T/wDXrqPD/h3aFeWM+aentQB85J4Z16THl6Jqbf7tpIf6VJ/wifiPn/iQavx/05yf/E19c2enJbAtgbyO3arDWgZlbbnaOKAPj/8A4RLxISAPD+r5/wCvKT/4mmy+FfEMQzLoOrIPVrOQf0r64uZfsa4AZnx1x0qg101yAt3Ekq54HTFAHyrB4W8QXDlLfQtVlcDJVLORjj14FSL4P8TMMr4d1kj2sZf/AImvqu1smhlM2nMA5XaUkQNwevXiuq1CWR5TdpqE5jknc+RHGqnZk4CtjgjjJPXtigD4pg8I+JLguIPD+sS7Dh9llI20++F4pZvCHiWCIyTeHtYjjBxueylAz9StfZ89lbxx6W91CkdsrN56xS/e3YIJGc54JNZOtCM+UuqXDXN7kmUo4ZMZXaWx1AXcNoweetAHx4dB1gZzpWoDHX/Rn/wpg0TVSMjTL4j/AK93/wAK+0Tt+12JjzIwD+UhmXKxlT9xhwi5/hbcfes3XLNmvWkaeWSZlG8SMrsuBgAuoCnjB4Ax0oA+PX0rUEzvsLtcesLD+lQSW08SlpIZUUd2QgV9Yy2TEMSeOua4b4p2+PBGpPk4Hl7R7eatAHgNFFFAHSfDuPzvGOnp6+Z/6Laval04AjaPrXjvwrXf490tcZ/1vH/bJ6+jI7FXILYDdCR3oA5xLHDYA6npVk6ZHIMMNrdjjmt42SAgsT9c1NHAgx8nPqTQBz0ejyE4IXy+mSOtWZNJMa7shh39q6a2hLkgqauxWAYZAwPSgDjbYTW7AQZxnBXqK3bOAXce4oqTDorcA1YNmkMjBYwSD1I4/wDr1BNFIxBZjkdPQUAWDbNFhFIwOvHWoLixWZcgfN6+lXbOQsm2Uc+verqwjqvbvQBxOq6WtxEIpR8wOQ2OlctLpjRSMsgww9uor1q5slmTGAGHesq+0pZl2uBvHRhQB5nJaYbhc+1aunaVkgzKQMdBXQf2K1tLmVMv1GemPWrlvY8EkZA5JoAZp1sNwCrhF56dK10VAeSM+9Z0l0kETGNwoH8WOvsDWW+qhA7qThc856mgDqN8YO1QS3t2p0U0ZYKXz656muDPiCRlKsxJJz/k0lpqMrvxIyEdCDQB6RDJET8sgz71aiwW5AOK4y0v5H/1h+Y98frW7YXhyMtkD17UAdNGAUwoAGKybsFJG6cdzVy3nV/uNx6VBeRiRhuJBzxmgDJuJgjli+09Kv6NJvY4/MnrSf2ZHLE7biSDkAVY0qBY5gMnHXFAGjGM/NyM+tRzhlZmLZJPp0H0q8UVQOBgnpWRqcz7mWIDGKAMHWL8W4ZYz8/Tce30ritXleQNvcjPU1v6vhXYE5bHJNc3qDK0R3naPrigDm7h9jleOnPOc1LbSRSIUYEFRlee3pVS6uIA2AS3PYdKqC8SKRT5ZJB596ANe3vHifAldMHoeQa6fS7lrh0hkCvuHy4Oea5SG2W5kXeHiUnO4jP6V2Gh2cUaEWjoWz8zvwQKAOk03RwriTGXJ4PpXQxWQRSVUbu+Kg0aYIio3I7v2rcRNwyD16Z5oAy1hLHJ6VFOc5WPOO9aF0hC/LnGecVRKYJz/wDroAy5IDzgkYJOTyOabsIGWwQPmAArSaLntz7VXkiw5HbvQBACee2egzV+zmbZtLZz2NVAgKgjB+lSxZUDqaALhtYbhiNvlufQZFUbjRlR8h1x14qXzGX7rYx6HFSQ3h4Rzx+hoAoLYJEuERcE56daFt88Dj9MVrbQy7o8jjoaIERsAgfhQBg3UYJ8sgY/rXB/GC32fD3VnHT90fp++SvTZrf524zXDfGqLZ8MdYyOgh/9HR0AfLFFFFAHY/CElfiJpJHUeb/6KevpqCE+WGyrf7oxXzP8HRu+I+kAjOfO/wDRL19T2Ee1yp6YoAbHCWHIytPjsIg2FZs/3cVbCnOB29KmO2FcnOP50AECRwrhucdhTxKvQdaqM5c5J47ClGSMGgB0mXbOcj0qvJEO469qse3GKcRk8kDvQBTSLY2QADnPSr1u42jd+NIsR6v19MYAqVVxjB5oAlEYYArjpxT1thIu4rz2NSRJ5qmNuBjGRwavbQFwOAP0oAx57JCMSgFR61yXiK4mijCWyMYj36fn6V2Gp3iAbAA3b/PrXGatFNK+8vuiP5D8KAOXvLgZVJZ1OOoXnFZeq3sUUARVdi3PJwMVtalZxv8APEvXn5elc1q9jOWjOOOmc0AUkvixIWMAdsGtCyuozywZSfTtVC3sgHHmOQDxhRmta3gjUARAYzzjmgDcsJXIBiKuB1Of0rorSbG1ZVKk8DPpWBZx4hyoBYnqOK07WZlJVju46Hk470AdPp+BJwcH/PNXb4sr7QNwPcGqFhho9y9Mc1cvG+bOPlx0oAfDJiJDjox71ctEAn3IOo71jRXBztKfKeRzWxprlicrjAoA05CAuPTpWTqH3G2nHJwa03ztGRyRnOKzL5SNx2nBORkUAcRrSybmyAAe5rg9aWbfh2LBugBr0nWISWZm4zx7VxOtqpQmMANjr3PNAHIvauQeM+1OitHAG6InBFaFrbzzN+4QsDx9K6DS9PEThpP3kg5A7LQAlhYSSiMyIyR4HJHJ+ldBaxlE8uJdqqMBcdT70xEkZy218Zx7flV6BjF13ZxzkUATWc7R9GIJ4Nb1hrMciiCUAr6j2rirrVI3LRoen3jjtT7OVWK+U2PY80AemxMsiBlIZD3/AMahmtjklFyuM89qxNKvJIyGDHn8q6WGRLiPMeQw5wKAKAhPTHfNV54MtkrWwY88jg+mMZFQTRAngZoAx9mACFLZPbtS7Nwznr6CrkkQC9MVEq89OMUAVnjz6Z6dKieI55z+FXmiJ+62OCBkZwe1DxewzQBXsGKOEclk9T2rRaAoxOODgj2ql5fPI/CtSzIlgKNyydD6igChJH8zHnB5rgPjguPhfrfBH+o/9Hx16W8ODkYDCvPfjrGF+FWuY4x5H/o+OgD5HooooA7f4LjPxL0YDP8Ay26f9cXr6rtRnnGMCvlT4LqH+JejqwyrecCPbyZK+srWMBQMdB0oAsRooO8n5VFU3JlfP8PUe1Xbk7Ylj6FvmYe1VgoPPpQAwJzTlQge3Ye9SDAZVyQzZwPUgZI/KpQvNAEJjwRjn3qVI+cj86cV59v51PDHz/Q0ACRAZ6YHPNSJFuPPTuasKmegH49qmCD6IOf/ANdAEIXy1+bgf54rPvdRChgx2jtipb653sypkBcDpj8R61zuoyKo+Z9xJzz2oAfKxmJIHXnNVTGA4yQefwrOnvWt3zIwRD0Hcj2FEGqxSY8kblz1c8j8KAH6jaLPzHmNhyeMggGsHVNOdIW80qADkEc1vTztNHy5I/SspPNSSbzWVkLfu154XAGDkdcgnv1oA5TYqkszx+yrn+dPjQMQqsP5VtXOnW8pO2FgWOSVqB9IEWGWQkgd15oAltDLGArAYxzg1tWabzkAegBrDhtJQcrKpA7EGtjTwyyAZGR6HNAHSWCGMoUJVTxitueIMc4XOM9KzbDnuTjv0rckXIXaAAVA/GgDPjhjZuIxnFalhCiZUDt0qO2hG4tgkDqa0IIgjH2FAD3UFVxge1Zd1HuYkjJ962wuBzyKoX+2O3aVRwB+RoA4PXoWaUruAQVyt3BaRgBmLMedp71v6vNJPLIBkg85PpWBcQSk5C5B4z3zQBQeUghIVEQ9B3q7ZRPIrFmOcUQ2Bd/3sqqF9OTV0tbwx7Vd/MYZ6c4oAhkcQwl3ZgE53g1l3GpyzBjFK6KOgB60y/ZZlffK+OgAXjNZM3lrGQs5zjuuKAJRqtwr4Lh+edwBrSstViZgHRo/9qPkfiDXLCJmbETqTmpovMiOCN3uDnFAHqWj3ZkTMcglHqDgj6iun067w4wwB9q8n0S4KpvV+p4IbvXZ6VqZIAnG7H8Q+9/9egD0eF1mj3KRn0oZN4OQc1i6deEFXRt6e3UV0KlZF3oRyOaAM6ZMrxggVVKBF6cj1rVlh2s7bnO85wx4XjoPQd/rmqUkZBYZ5IoApJIzJ8y7G7jOR+dSMuevJHfNPC4OMGhVAAB6epoAj2gMTn61LaEpOrZ9vwoKgfxZb3owcDjnPSgDQaNXXHGR2rzr4+QlfhLrxxgfuP8A0fHXorHKbhz/AFrz34+N/wAWi14HnHkc5/6eI6APjmiiigDufgiM/E/RR/12/wDRMlfW9qoUZOCe1fJPwRO34oaKf+u3/omSvraBicfXrQBHMd8zEjpxzQAc0KN0jHOcmpVX86AEVBuG4AnqD/WplXpTVwOxNS7QR74oAZGhLe3rVy3jI649qiiQ5wetXogPwFAD0XAx05yeKgvZBGu0dTzVossaBnPJ6D19awNQugpZpD16L3P/ANagCvdzcMdwVB3Ncvrt7sA+zjGT989RVnUrsuecnsB2/CsPUVeSAsQVA5560AYt3MWdiSS5OTzmobZ5EkMisV460tzKEG6NfmPHvVCS5ZTmVhGncMeaAOrsr6IoI5uWxkGr6yI2DGF254K1wa6rDG67d7+hzgVftdVcyfu0CY9KAOpumIjIwS1UQZDIpBJUjGc9KpxazJI5E+GUg5I4Iqa0voXcRuQsg/v8D8KANi2jDKuMD1q5aWolmCgd/SqyzKZcknJ/KtbTw27dgD3oA0bOJw3A+QdO5FbzJ90DAwMc+tZNipaRSN2Djt0rphGp5I7UAU7bKFlbAyOtX4Bvc9gB1pqwo5HAq9axhSdq4FAELZC49B1rG1HOJIyNquMj610sydQOD3rn9VQoWbr60AcDfWzK7bh8oPeqNyqCEvIRGq9Sa09WkjXdJI4CjsfSuN1fVopyURjhTwP8aAK093NdTNEgZUxjHdh70jTJHwGzjg85P41SMrp8wI3EHp/jVETgkqOHP8VAFnUJoEO1pHRiT2rAmuYlmG6ViOm0r1q3qCsVMzyREJww6H2rmp5/Ml3Ae2TQBrLcRPyJ0X0UnBFXrTeei7we681yruGJOfpmr9i8kW1kdlf2OMUAd1amJ4lDYGOp6HNbFiWDZjkJ46E81x9nqbblW4QTDjkcEfjXTabPCy5gcmT/AJ5scN/9egDqLC7aOcbXII9a7bQtQWQbScHuOxrzyzmV+GU++/qK6HTmaMhlJPt3oA7/AGgrg8elUZlK/KeMHrmpNPuRNCAfv49afIBKN6diR3GcUAZ7rhs9D3pMY4/LmrEg4Py8+9IqBiGoAg2HI9PTNIyjvU5ADKHwMnA560koHT0oAniJaIbutee/H0H/AIVFr3XgW/X/AK+I69Btxlcdf61wPx/z/wAKi1/j/n3/APSiOgD42ooooA7n4Jf8lP0X/tt/6Jkr63g4XkV8k/BH/kp+i/8Abb/0RJX1tF8qE4ycYyKAGRgH2z1qyF9elQxDBz/I1MDz6UAPCnB2gE9gTgVLtx/+qmoRuHY1Ix5/DtQA+BTnHGzrnvmr0a5HAAHSq0IzgDI96tM2yMtjGBQBV1O4EMWc8emeprir+V5JWK/MxOSTyK6LU5DLXOXQ3ZEeMdz6fWgChcSLFz95z39Kxb25hjINxIckfcHJP19Kn1HUBHmKAlnzzMf6Dt9a5W/lKMe79cGgCvqt48chEGyOJumOv4k1z8gkMrNkuf7xOc1qTbpRgjC9OazLmAwsCkhPoM0AQpPmPIHzdcH1rU0+4WRMbhuPTJrOjkRs74xkn0q/Zv8AZyjRqODngDmgDZjI83YiljwMim36MWOM47g9vf6Gte2nMtus0a7hkdKbbS7ZSJcSbicAjOKAF0a8aNAsr5HRQf4a6uzuZETKMWJ9axFS2KpiAZB4YHBxXR2ESSKvlkBscCgDpNGZnRRnD59OK6sHhcDqMEiuT0ZT5yqQQK6tMZUH8xQBLCmCPU9quwryOPrUNuvTODiriLg9cf1oAbIMZ6VzuvAmN8cnHSunccHIzWTqFoJSQV4IzyKAPF9ZjSSYpJk4OOtYN1pMW0yAM5/iUnAA/wA969O8SaGU3T2/DAfMuP5H1rjLiTykyF3NnBB/rQBzF5aPI3ysqIq4VBzj3zWJd2hjUSSSADB6Dp+tdhKYJ45XTMTgfMOxrjdddvmSNgBnkCgCjLbNcP5jS4jKYBY4rn2tykzh3DRj7oC4I/HPNblxxZwqTltx4B7VSaINJkspLDOM0AV7e1UgyOzY/hq0kRLARuc+460jPltqMvHHBFTW6jaG3KAD8xzQBatleEgldx9ewrSjnBwoOT7GqULvHMW+8D3XpWhAqScyIFY85HFAHR6RqTbhHODKox8x+8v49/xrr9OlztkjfzI84yO31rgbOEI37jLdiTxxXRaXcNC6lCdx4I7fjQB6Pp83KN0NdCCGjBXof0NcVp9xvxtABHYH+Vdbpc3nQlCfmAyKAEmUbs8nJxx2qAYVzntWg6HocZNUnXmgCI7UOVUbsYLHr9M9cUwnnj8afjnA/Co3HTHfvQBNb/UHiuE/aBK/8Ki10Ac4t/8A0ojruovvYPSuF/aB5+EevEdP3H/pRHQB8bUUUUAdz8Ef+SoaL9Zv/RL19aZIQjHOK+S/gj/yU/RcjPM3/ol6+sycJ9KAJIsHIHb2qVQcnOagiJHJOasxt6DBNAEobH4nBqVASwz19ai2g4zx68dangXJ7UAWYuAKZfOFUKSOmcZqeNct0461n30m522n260AZl2PlYbz1J+Y/dH4dq4/Wrv70cZwnf1b/wCtXQ390pBijPB+8fWuWvIQWYzAbsnv1/GgDnrwPIxwSB3Y1UcRiPrvfH3n4/Kr90WchFBJ/uKO1YV/LFbvukYu4/gU5x9TQBXunG0hmyeoxWe5JyW6eppLvUDKCAiIAeq9RWdMWcBtxbPWgC40kYIAdcdhU8N1Ggyylm/z2rHdXVucgYzSwNhh060Addpt6u9znYGB4Hf61v20AuAkqyqueOTzXFWU5WZSpK5BBHqKvLM0XypIY03ZABxQB2Em6E7CFUg8EHmt3RJTtBJ5rzuPWLlW2yBXx/F0NdX4c1ZZFzOpUjgY7UAer6M3mGM4HTmujt0Fc14XZXiDhtwI4NdXGRtBx+J70ATQxgMasKCeajiAAA6/jmphyefyoAHHHt61WmAx157VayMAAc1BJyOv60AYGox7kIwD+FeR+MJIbC9kRyMN8wxXrmryfI/JC9OK8D+ILifWZArZCrjA+tAGXJqZMm3BVHzjPPPauXuw+8g/NnnNXPm3HERJ6gHtT5rKRirqgKkE5z0oAzWX92ynICjtWY+AWPbFdHdQmFZEBRhjGeTzWTLYSALvkQMTnbjrQBmbRgk4HoO9CscDPQdBVia3YOQj7vU9BTGgCYaV93+yKALFndywMGjchu3cVv2N8shH2tcZ/jT/AANc4gO/iMgfmRV23l2t1IY9Ce1AHd2eDCWgAlQc7h2HuK2tMIZl8zjb0I6ivPtPuGjdTDJIr9mHHNdxpF0ksQS5KRXH94DAb2PpQB1NmXiZSDx/errdHu8tEVB64YelcjZsykLIMH0Irb09/LuEdW+XvQB2zqGy+T0qtKmH9R161PayBo0II6UTqQ/HQ0AZknDZ6CkKgYz0qxKnyk+npUJwwoAavXjGa4P4/kn4R69k/wDPA/X/AEiOu99s1wXx+/5JFruf+nfH/gRHQB8cUUUUAdz8Es/8LP0XHX99/wCiZK+r0J59PcV8n/BTj4m6L/22/wDRL19Wox2jIANAE6YyCcY6ZFWo+gH5VWj5PFWkXA7+tAEqkkgDoatwjHfntVaEfMMmrluu4njGBnntQBMSEj5POM4rA1CUqNijJPWty6fbCfTHSucvCAXY4LE/lQBk3X7vJBG4j8vpWFqbK0BeZlRB09T9BWvfOiLvcZx91fX/AOtXKajO8km+XDdhjsKAMXU795f3cY8lDyQp5b6mucvNpTamQ688963NRgyCyfLg5Hc1lXVjMcPIuMjjB/lQBhzEKcqcj6U1RIVDLnHXJrRnSKMZMYyeCD3qtKS6DA7cDHSgBhdZwscx2lRjI5qeGGIqE3AHPDY61R+YNyOfpR5m3ncAD1FAGxFCIpULjPPr0rRC27NyNqg8k84NZWmyRPE5Y7XTpjpVyKRxfOpXcrjAHX8aALz2OVDKAeST2FdJokKAKNhOcE471lQhksCrAlutdJ4btxPHHhsEdPrQB6R4ZT7PZr/DurrYeQCB161z1lEUWJOCVHODW/aglRkAUAXocAY9T1NTg4NQQjI5GCPWph90etADxyfSoZgQD6U9QQOc+/HWmyjsf50Ac14hPl2UrAjcRgE14JrKO95cSNuLjPIGc817v4rJ+zkA4rxTUQ0MtxCcEdQxHSgDk1IllIkO0AEnPFSM5jQKpYhMnIHYVBerErgpIZGc9BxUeoef5IIIIxg7c+lAEaTloJCFAVjgt3P0rMnkCE4cswzj1qO9dorFEjOATg1j72Zm5I7CgC27ux29CKbjnJY5HtzVMuyjAY+3vUizsMFsM30oA1IDsyzHr0APWrqBZHyygn1/pWPBNtOZACc9BWxp5jkYGSQxkcjI4/SgC7b2537ouV6BTW3p8gBCyghhzj1qnbgLwGBGf9ZjIrTgjQBfNdG75oA6XSdQKqI52yvRWPVa63TGI29CDyPeuAtomwDHhkBznOSPrXW6Dc5URMSFyACetAHoGlONqr6+/StGQFo+eo55/lWJp0hWRRnGCM5rcdgGxnOaAKrrkY9etVWXaxHWrsi4yAM1VlTLDpQBHjAHPB6V598fgR8I9eB/6d//AEojr0PaOffsOteefH85+Emu5GP9R/6PjoA+OaKKKAO4+Cn/ACU3Rv8Att/6Jkr6sj7cYr5S+Cxx8TNGP/Xb/wBEvX1ZG/zYGaALUXNW0PA659qqRgAknvjqeB9Ktx8EENn69qALUSjgsOhyMjvVqAEL06mq8Y46GrcQOcDg9aAIbp8ZyfwrnNQdUR3bgLW5dOHY45965bW5NzHbyoPIPrQBzepXJZyz5AP6VhyiVgSrDBPXsK2ZrffkyEgdl71QmSTIREYduRkke1AGcCY8hckngnHNZtzE6ghehOQSelaF88cBIMnmzDqqnhfrXP312875Y5UdAeBQBXnnhHErBnz1UVnlwXzGu0Hjceanl2zHLLtPqBVW8iMYG3LAjpQBDc2k6vgsCOzA8GqrwSYIwSRVtZpFj8vG4ZyBmpYXckMVVRnoelACaZZXMwPlqdijrjNanl+SIHyQxAySD71uaFJdRELEU8sLkAAZx71JPCt67uGwQPuE/rigCO3kndcI6t6gc5rvvCFsojgaVCrDn5q4C0gKgiIEn1BxXo/hkSi2j8xjyAAGoA7ewYs249e1dHa/w9T7YrlrFjgFDkeldLatlVHXjrQBprjA96fwBn371DF15BIx39am4YEH8hQADr2xUcxAB7cd6exI9MD9KgudwTv+VAHM+JmTyjuUe1eSa9btNMdqAgnnd0xXrusx+bgZGD+lcVq2n7y4jIU/T7xoA8uvNP2zllUYHIOOKq3VnMohZR1PIx613i2Um8JIAy54yvSnPpOZChj+VTgjtQB49q9ssTyhmZSD8qkfmc1iFVIxH0z+de3eIbWyns/skQgaRAQdyc/XpXll3pbxTMsJVlzjAB4oAxPIyBjG7rzTysajC/MehJ6Z9qum0MIx8rN/EQc1W8h25I+X0WgB9uEQBup9u1XEmwxOzO5cHPpVREI+ZkwB2qYAgAHJJ5FAGvptysGdnKkZIPT8q6KxuLW6bZEvly4/1bE4+oP9K5YQtCirMCHI3YA59q0tO2+ao2Fs9SxxQB2enNJAQu0EfSul0yMbvMVcEc4HrXKaVf8AmKqXGAvQOOCvsfaut0sNAqg9xkHqCKAOo0yXfjBIK9feuqiYvbqc4rjrT5WDpn3FdXYPui+negBzg9/zqvIvY45q5IMc44PSq8g9QPb1oAqE7e+K88+P5P8AwqbXc4/5YD/yYjr0NyVOOP8AGvO/j9/ySbXsf9MP/SiOgD47ooooA7b4Mf8AJStH/wC23/ol6+qoMbhnGcYzXyn8Gzj4kaP/ANtv/RL19U25wc9aANGM89OPX0q5BxgYxVGMkkAmtGAAYDA8+1AFqPGQAOAKsqdqEnjAPU1XiU59ulWJceUxB9KAMe/cqrdieAfSufmQqv7xixx1/rW1d/MxLZIHAHr71h6is0kUqwOqTYO1mG5FPbI70AZNypLEBQTnIPT8a57VLoYeO3ZyxHL+v0rZvbh5IFindc4wzrkAn19h7VzuoKoUlSAgH3h3oAwJl2H5mP8AM1TuHQYwfmB44zzV+VGdwEUgnPPXNVXs3bLECNfQ8k0AUWdpMqBtPrnFMa3kCDYCQc5Y9KvLboq4OM55yMn8qXcPlK5JXt70AZbWh9SDnqKmjskR/myQeR2wa0rVj5nzp8p5J9DWhFGs0m+VFEQ7k9aAH6LELVIzkANyynv9TWzFMJ5RiNFQc8LWJdyQbgkUqnb1X/69bfh795buj7SAQyMOcA9jQBq6ZaRM+/CqxPIA611mm27L95eh7Vz+mweY6+Uw2g8ketdrpEO6Ib8Zz3oAvWURD5I69RXQWkeMe1ULe3fCbNp5wc+ntWzAgA/woAlXO0AYzU2cA5pkfRc5qVRwSBxQAxhkdx/SorpSYjwM1Pgc0ki7lIoA5TUd3nDoQe2KyruyEq71HzD2rptRiAIKjHpWS4KklsrjqfWgDkruP/SEGzJJ5I4qy6xKAWT3b3FRazexwy5TGScZPbFVJLvzIwSFHNAHNeK4WDCWCMrI4PA7/hXJRW1zJGPtMZjkXIIxjI967TV4ZbuZJUBKqfvk4Uf59K5zVdRea58qCRSFJVpCPvkcflmgDm7nTU83cCoBPK5ziqc1uI3I+9j24q/d3lwlywmWNlXjGMiqctwowsq7foeTQAwDc4VIwcn+7k1IlqivnIjl9+g/Cn2uppGxWFgDj+7zTo5Y5nDsmcnj5v60AVnt50kLySeYufvZzVu1Dl8DBPfuAKuxzICFWGPaB7nFWliinclUEWepTjPtQBd0yIkq7YCg8DPJ/wDrV2Gk3WT5cmNh6YP3a5CK3EY+Q5UnqecVrWJ8vb8xJ9e1AHeWTlHUdq6rSOI+uVI4GelcRpU4lUAZ3KK7DSW5GSRnrQBsSYKfSq7jIGP0qdlzuzjPTPWqzEorZ5x6DNAFOcBSc9M5rzX4+Pn4U66Ov+oP/keOvTLtiVZexryz47n/AItbrg/64f8Ao+OgD5HooooA7L4QHHxF0g5xzLz/ANsnr6ot3BUeg6g18q/CRtvxC0kj1l/9FPX1DavgDGKANq2OT1HpWrAPQ9fasm07VqwtkcYoAuwYwWGDS3BHkNg89c0lvjH170t4G8lSABjJ569uKAMK6GTWBqc7fMoVSPWty7dYoztGMcAAdK5e8YENIVJx1oAybjO7kEZ6Lmsy5j8xmd23Adug+lbFyvmjLn5McjoTWTdM7SfIPlXhVX9KAMuddr7lPbqBWdM2SN/T2NaF7IsWS3bjaDWJfXDSZyQgHYdaAElZVbdkBh1APNQmcBJNgSMjncTkk+lUmb5WznPr/Sq/mHdnGeeaALwnmwZCzMh4z0Gas2Fz8xjcZWTg9yDWbJdySRbBxGvSMDpT7Jym5kJIx1PUUAaEkIDlWzkH6g10/hASfMqk47etYOhSvcyNHcp5iAckjqa9M8O2cEdis8aZ3ccjp2oAu2FqjM8qsqHjccdDXW6MX8kBvmGT0rAgSO3SRlIAxzWvoby+VgHPoG/xoA6uzYEhfQetake0g4wcHB+tZdgJMDeqhfUH9a04N5HzIB75zQBOo9BzTpPMELGBEeTIwHYge5P0pEJ47nsamXvQA04yQMYzxSEfIeKcSegJpG4HQ4+tAGbfIGHTk9xWFqKMiMR87fyrorpSSeOSePpWVdQkpkZyOtAHBa9bMtm8rRkcZU9g3vXMabJcXEZEqS4yOdpORXourWjvC6oM7uqnkGuYt92lu6xgqzcYYZAHpQBT1B4rWxKzuh3dAcde1ee/aITO5AVsE52jr612uvvHdAq+FGPvAc15xqVm1tfu3GCMlh0+tADbvzZlby0AY5we9YE0UqErcZ3ds1qx3kqlo1c89/Ws+acicI6kKT1I60AUWkKkqgx6kU+3dlfKkCpZkg83puB6EH+dKIzGwLKCDngD+dAGtp98wUiRdyH7x7/nXRWsYlZTbyAr1Cgc/SuQidz8oJA9PSr1tcfZpAUfc69weBQB2lp8shDKNmcEEZFX4oiMmJSFU8g9fw9axLDWVuSou1RD/wA9VGB+NdDaDa/RueeDxQBq6QxV1JyO+TXcafIfLDKCfYVxUKoXDRj94BkjFdTo83Kx57DigDrW/wBWrDHI71Wl5Jwc5/wqeP8A1QyG4/Ko5BjFAFGdQc569K8u+PYx8L9d69IP/R8derS4wcmvLv2gFH/CrNbI/wCmH/o+OgD4/ooooA6v4WEDx5peemZP/RT19O2rD5PWvmD4Ynb450s+hk/9FtX01YuWCEdKAOls+i8VqwKMZI596ybMnaM56VrW+SBxyaANGAHKqTzin3eCuOOODjnH1pIVw446Cn3f3CeDgZoA5TVW+YrnAHFc88WwAFiyjjLHJ61016q4LZ+b2rDlGWPA4BOT296AMSaPMjbMknJYngY9TWFqmojLJbMABwWArR1y6Z0aOMZhPfP3v/rVxV7IcnBwQw6dKAIrmTIJOWJ71lTBh6Yz61akuCi4bac8jA61CIWuE+Rck9PpQBDiQxN1J7VAY5GXAXIPHPArUttOLZ86URj0HJPtTktYemXOP73AoAzI4GVwFBLd62LGwLh1lRlI5yDjNWYljEfICntnrU4ZyqKgGCeDjmgDU0SyjRFdlCE8ggEiu+hgktLeNAGwRkH198YrC0C0ZbVFZXcgZYdq6C5kmZrdQoVVXnf3+lAFW7ul2rEVySfmJziuv8Ko8kZMiYOOlc9Bpy3EolwTjGB/Wuz8OxeWpUnPOOe1AG3bqcdOnar0YOB2/CoYkI/wqwq5xzk0ASKMZ/wqVTxTFHINSDnpkelACYPPHBpSDj5vT8KXGQfSlHTJzn0oApzjGB+NVjDnORwavSgHleAahC45OBQBl3FrySoGK5bX9N3fvFGGHOa7eRcFuv5daydRjR1PB3H9aAPHtQhJYxs2STyCw4NYWuWKNZnaUHZuxNdt4zsFtoGvFjm3KcnAAIFYOmix1DSZd7MZguDuHJH1oA8+XTIZJ9nnbe+Se9M1HSCkgEk6s7n5AeMjtW9d6WVut1v84XOSfSs0zbVMM0eY8kdct+dAGALF7cM8sahfrmonkJBxIOe2OlacrvG3ls27+6o7Cq91bAxBgoJbr6/WgCCJ0aPAkBbHOBU0KCPrjgdM9aoMvlZZfnx6danhuN/3Rtz04zmgDVtJAWDEAD+VdfoV75aKkpLxY4PQoa421kVpQcgHuBxXR6buABwvB6qOaAPQbIkEFnGwc7sjBFbtr8squv44rl9DuSIxHLgIeh/u109ouJVBBAoA7S2bdAjAnHWiXOcN1/SodM+a0IIBAP6VPKMp+PIzQBTlFeXftAf8kr13PrBj/v8Ax16nNyMdPwryz9oHP/Cq9cyO8HP/AG3joA+PqKKKAOn+Gv8AyO2m/WT/ANFtX0npLksi559K+bPhp/yO2m/9tP8A0W1fR+nHE0ZB70AdlY52LxWzbjgc/mKxtPOVHHPr0rbthkUAaMK9AM0zUCPIIPQ9alhHA646nmoNWbYFHqOfWgDnLhX8zgcmuf1t1MbJE3A6jP3j/hXQ37iJCc/Me57CuH1WfY7Z24x2PFAGBqbMpYlwvXjrXP3UsMjAmMtkZ+U4rdvoTPuKZyVyR61nLbxxfdA8wfw9t3rQBkrbxMN7B44x/e5P5Ug8tU/d7mX16VbkI3t5xTYeu0VRlMat+6Y7T1OOKAHFwWDH5MHnuKnimSaQKHAbu7DArMndNoXeB6kHrUSReYcmXKj88UAbPnWqtl5d46ExDr+NdLp0sSRK6IIoh/ERuP8A+uuJt4YwigF1JOOB1rqvtMTLBboWXGAFHc/TtQB0NnfvJchYGbYOcd2+tbuC1uJA7OR/tdBXLaTG0U8oU5AXHynAJ9K3JbkxW8cYIJC5JoAvQ6i8BEZcuF5AB/Su48OXcssYd8cDp0rzeO6Fw0NrDCic7mY/e/PtXofh9xGEAXgevWgDsoTuQGrKc9RVW1YMgJGKtR8Hk5yaAJQOeOfenj8DikHXOPenD1OKADPbv/KlAx70c8dz6Uv160AQSD5RUG3HNWpR0OMfSoG6n060AQN94Z/TmqNzbhxgjA9K0COcgEc1Ex2EjHPrQBz+oWKXELxSxhkYd6801LRX0ia4aFMQucbs8AHtivYblmyFCIc9icVg6vbi5gnhKqydOR1oA8O1AGIkxHL45xx+lYV8QjCT5cjqR6+ldJ4mtbnRbxzJCJbRidki8bT6GuNu5Ek+dGyHHIB6GgBt1dQSRAEDzAenc1XSUPGWVeB1XBJFVvMXcFkiJwf73SlKFgwgc/NwQev0oAmcMHDbFIPI96XykmfcdsR9VPT8KhtpSXaC4cYJ69atx26JJhW8wjv0zQA8xtAMqC3o/Y1uaTKVCmRQQR1PBzVS0QSsyhWAPVSeGA/rWlFYlSXjDYGOO9AHRafdbyNwBPTpXZ6TcedEOcsOh9q8/tJtjLj5D3x3rpdCuyJxgnjrx1/GgD1DQ3LQuD0HTmr7AbGBxxWRoTgE474ArXfg4OR3xQBTmHy4647V5V+0F/ySvXOnWD/0fHXqs2cE9a8q/aDx/wAKs1zkdYP/AEfHQB8e0UUUAdP8NOPG2m/WT/0W1fR1hkOvNfOPw0/5HbTfrJ/6Lavo+xXGznOPSgDrdPPyAnJzgcDP410VoOK52wPCnp7CugtDgcnmgDVhGQv061V1fnaxPAHWrduePWsvxA5S0ZhjduzkntQByOr3e+Qjdx+lc7eK0pIJG3rkVqXK+czbjgZ5NZsuIxiRv3YOOKAMGYlY8R5BJJ561nzxtMrDhW9uv/162NRRF3SB9ynoucE1zd3dNA7SJLiReAq9B/jQBnTgJG8kjqi54BHJrNnu2ddiSbV7gDGakvZZLlvnHsDj86qCEhgXzg8YoASOISuBvySeauxWhVC0mAnQY5pIBGqGTYdoyMZxSNO0hxjCDoM0ALukZtsO70rotAdbT99JmSYnByO9YqTtGoK8A9gK2tEtHnuVeT5U7lhwKAN+0uWnvMRDagXJGMc1swxbztZRhh1qjYQ28CkxYdS2N3pWs8bm5hCsSijOPagC1pGmKL9pcjYfau70qDBBydvpisDREZo0WMfLnOK7PT4Nh5PP8qANS1UCPnrV1V6DjnkVWgXCjAH4DFXEzwOmaAHKDnnPXsaeM/TFJz+PrTh6UAAo9KMfSlA9qAI5eozjGRioCPTPHU1Zf7tRFTyOc/XrQBAy446ZqGSPngdatlTkcYHvTCuDnqMUAUZYw2ARgiqEiEucqvz9q1ghKYc5OOo4z+FVngBY9sUAef8AivR4bmKRmjDQupDrjOD64r571rTLjRr10fLKSSknZh6V9Y3lpuLjg4BGD3zXmPjbw0t5azROu3+JSR37YoA8M3pOpVwPNXjOaghkaGfa5/8Ar1PfWUlldyQyod6k9ehFVirZEe7PHDZ4oAfOr28+5BkZyrAdvSr9k5aQN90AgtuqKzuJQVikVWVeu4dPcVLht3yuQrHmgDagOWDR52k54PWuh0qYR4LgsewzXF6dctDNsfcFPGK6KxmRxtV8ODwCelAG+6qVzAg3HmtPTZcIgIbjpng1kWG9XwwIJPBI5+tasMLGTegH+1jvQB6R4bnDWa72AO7HNdLMcAE4/OuN8NSBI0jIyrDBB9K68cqoA7YoAqzdD15/SvK/2gefhXrZHT9x/wCj469SnO1m9TXlv7QJ/wCLV63zn/Uf+j46APj2iiigDp/hp/yO2m/WT/0W1fSViOE5xXzb8NTjxtpp95P/AEW1fSFgWON2AvG3B5989qAOsshhQa3rdsJ1J79KwbLO0YBz7VuWnOAQOT+BoA2ISfMT7uzHPXOf8Kx9ZfeXUMMDitYsEjZueBgcdKxLw7twHJoA5W/AhkVE285IB6n1wPasa+kVVDSnc5/hFdFqYijj3yqpkAIQ4GR689QK4fUJ23ySSbsqMAds0AZeo3zJKVypGOcc5rDmCEM5UKueCO9Xr4ltzN8oA59axLnzJCGAwPSgB7urqFjQbyc7vQVFGEXJdOSeveliVIk3sCW7DPFRgtKy8nB74/lQBMQjIpUfKGxipo7VGTcY2RScAnmn2cO6QhF3KM9a3YLULbxvKdpLY45oAz7KxXzV2k7P4ie1bLFIT5YLZY4K+tBhReC6rH6kdfwqWC6t4kEyRlpz92RyOB6igC7b27Iu1m2qCPbHtXTR7DhlYtgD2BGP51yBkefflmDOclj3Fb1gx+xg7iTjAoA7HSrkCVI44x5aj6YrrbKUOFyAR15PSuH0eV0jRXwTjuOa7DS8MV2g8HvQB0MZyBn9KtJzyQTj061Uh6Z61bi4oAmHJzSgU3B6Dg/TNOHB9hQAv4Ud6MUtACHGPrxUbHk+tSHAHJ/WotwYnaCffPFACHjAFMY/Lgj6088k8Zx6Ux+OMAY7UARjAPyjBqFkBPGKm4BJznNRSDDAgYOe1AFK6izjrmsfULYyxuo79Qe9bs2QM5JzWddfeBHagDxTx74TW58+W3/dzLyo7N7V5isLBAvkBWU9Vr6X121SaMuQMj0rxvxZpptLsyx5AmJDegP/ANegDkZIPOhIRP369WHeqVszRExtzg556g1ovEdxeJsOB93PBqncQh5iSmDjODxigCSWQxnc/wAyN0OKu2xA2ypls84BrPhnjKASxludpG7FXIGWKIsgI+YEHrigDsNMuQ6qJNyseOTnFdLpimR1z06DtxXBafNuceW2w/xD1ru9JuP3CgcEj5SR2HagDrNOyjLtOFHT2rsraUSwIwIPHNcRYSAQAk/e+7XU6NIfKeI87ADxQBPdnDMOQDzXlfx/P/Fq9cBPP7j/ANHx16jeH5cn3HNeU/Hw/wDFrtbHB/1H/o+OgD5EooooA6X4cnb40049OX/9FtX0lpz/ACKfwr5o8Ats8W6ex7F//QGr6L0qZvLywXbxg9/xoA7XTjkAgfSt6yxvU+grmtKdXQFSCD3rpdPwSe3Hc0AaEsm21we9Yd3IoO9mOzbk5rVunBjCr78VyuuXJ8sKOVU4/H1oAytXuC8pYYweB3ArkNWIkkBU7SOntW1eXiujKWy4GOKwp3Vz9zOOQD2/GgDBuwxBQj5gck561RdBu5BVPcV0dxBHKmQRnoQOufb2qrNEIYiZVAkJyny9qAMaa1aQggEIvCgjr70+K3IbghiavSRu8W05AHzEnjFQyyhFUptOF7cYoAtF4bSJUXPmZwT1FWjeiGBVDJvXk57CsG03TTrucHJzuJ4FSX8u27IjKkg59etAFu4vXnbc5Ij9OhY1JDMrcMxLYwF7Zqgoluh8uflGCAO1XLOH5iZEdgD2GM0Ab1i7NAQ2DsGV/wAK29PZ1jQu5CYyQBWJYxlpFjgiIDkcH+Gt6dHjuo4IjuSPG70+n+fWgDrtNRZgssXyocY9RXW6amEB5JPrWD4cgHkqCvB5we1dPawkHB4xQBqQZKjJq+gwF449qpwIEwB6dKtxrhmPPzds0ASL7Y+lOHYUncd6UdRQAvWl9aTNKKABv8mozUhyBTMHINADM9c9qY44PHtUoH5Z5pH9cCgCA9CRnOKibGQSMGp2wBzj3qLA9SfegCvKDtP8qzbkAhiykDHTPNakobBxjNU54ywLAc0AYF2waJlABGOjV5v4qtlkSSOVTh/ukjpXpd9HkNgHIrjtWhW6do5MZP8AF/WgDxW5BtZ5EZc84PHXFWI4ElQBlG3qAD8wNT+JIJLS+Vjkrkq3HX3qhBMcBkZtwPAI/WgCLULCRULwp5gDcHHf3pmjq0Q+z3BMhd9zsegJ7D2HtW/bTG6gAcbSvBI4p4063WISiTy25O0jJb6UANtrf7K4G7LDoa2LK4ZLhWRiVJ6nIrCMu1lDcpnAPcVbhnRXVN+ex55FAHo9heLcqpB6cEe9dTpFz/pZB/jXFeYaNfmK4XngDkeo/wAa7TQ7o/bl9+5/nQB1d0f3cm3C856d68o+PT5+GWsjt+5/9HpXqkx3Bh6juK8m+O7Y+GusKc5Jh/8AR0dAHyhRRRQBu+CTjxPYn3f/ANAavoPSmDRL0/OvnfwiceIrQ+m7/wBANe+6M+Yo8cCgD0DTXyikkfhXT2BCwO3t3rktKY4QCumEgS2VFGTnB9qAC/nCQEE/fXGM9q46/l3xtGhHIwPb2rR8QagqzLhiQo2jP65rj9Ru2MrAEkeo45oAp3Uo3EbskdcHFU5JSVK5UORhcf4VFdMFJlODngE/570+1hkuG2QRPNck9V5x7UAPRMFeQHGC3oPX8fepZWDKC4w3QEnqP6V0Wk+FriX5tRkESDHyrz+ZrpbPw7Z28h8uBd2MFm5JoA8qOnahekLaW08qnqdu0fiTVu18FahI2yZkiy2TtyxJr2azsFTI2Dn25GPQ1bt9OQAnaMj17UAeYaX4ItYOZg8kinvwD+VasPg+zjcv5A3t1JFd+ttHH8pG4nv2FKLUGUxFSMY2v6+1AHFReHIU+7Gox0OKvf2BCefLXfjpjr712P2EY4XnI+UdqfHahQGlKovAyT+lAHJWfh1Y13hFyegI+7T10RT8569OetdmlvuztJwenFItnk9OvegChp8CxKgUY7c1vQqCAT07VQMSQnLttXOBn1rQhwFwORQBaRRwKtp09/5VVQ5x296sIM4IPH86AHjkdc04deOlIODjrQM57Y9qAHdvalPXn+dIKUdMCgBD+tNPuadimtwKAGkgn/61L3OfyqJjnn8qTdjIoAVxkjk4HYd6iYc/060pYYwajYgg0ARyHnpx37Yqo7ZOQePWrMp3DgZPvWfdNtYgjJPpQBSvkBDYOAw6k1xOpQssrvkcdRng12l2FkRlP159a5jU4C0m73zzQB594qsDLbyBF+ZhkHHQiuEtbd0nKyoxYcE+let3cYljKSHnqpHavPdfhW21B8EYbkKDjmgCqkyxSNnkggfL0Iq8pHmAqS2R0z0rBmuFUMVCkZOcnkcVDHqAA/dtls9Qe9AG5f5ADR4808FcYB+vv71QjuEQ8Aoyj7pPSlt78FPLm5yMgZ6GqN2okYNC2T39/wD69AG9b6gREGLAE9RjtXZ+DtS82UKSN0Y4yc5FeWR3QXGGG31963/Dupm1uVcEZzg+470Ae+wy+amSevBryf46n/i3usj0MX/o5K9F0i4ErBVztddw5rzf47N/xQOsDH8UX/o5KAPlqiiigDX8KHHiC0Pu3/oJr3XRn+ROegrwfwyca5an3b/0E17bojKUTIyMcj1oA9L0JtxQ9cDNbuoT+XaFtwyBgc+tc94dJ8kspUD7p4OfwqbxLd+XGIsnjnI7UAc/4hvAWReo2muUvLoEgKwL55I9ava7c7kV0J5O0Y+8a0vCmgGMrd3aBpP4UPIX/wCvQAuh+H5dQVZLsbExwnfH9K7rTNKhs0EcUSxx9MKOvvViziEacKWAGSF6n6VrW8KvhkI2thsgfeFACRw7UVTx9aswwhR82SexApkU0LXptfmaReuOinrWokPI4oAbBGBnOMn17VYVMZHYdzT4o8Hlh6fjVmJAePyyaAKjWkZDr5XMgOc9CenNSwRp1K4bGBx2qwgSSJipV1IIORwQMg5/WpbUpJFHJH8yOoKnBGR2680ANWLOM/lT2jU8EA/UfrUuML93npgUpXk7sEDoPSgCILuI4G31z1poXPUEHnvVgjPJ6dKXbzQBVaHcOQD655zUkaZ68ip9nFAQjHHGOaABBtzjg+9WF4AGc47k81Go5+lSjrkUALnBxinD86QUv4HNAC+9Ln0pPxwOvNKOmRigBDj86idc9alzikJ56UAVz19c9MUwqxAwD68VZbBGCOvb1pCTj2NAFZoyBycAfjQsSnqxIqxyOoGaZzjLEAevtQBEbaNjk89+tMe0hb7yZ/GrCg5LHAz0HpRgAHofrQBnPptocfuunuarTaRYOTm2U/Uk/wBa2GXnkEn+dNZMgkcUAYB0exQgrZw5B4ytZuraHp8mWaxgZhyD5Y4NdW6k9eT0qGeJSmMDNAHll14c0uaRt9lEN3/TMAVi3XgrRZCxFqiv6qSK9LubIB328Cs24smOXA+tAHj2p/D7JL2NxIMnoecVhaj4d1LTYy0kXmJjlk7Ad8da9xNowbdjA9D0qO4hWVCsqg574oA+bbnCkvGMr/Fjp9al02dpLmJg2cEAe1eo+LPBkF2jzWiCK5I4YDr9a8wi0+fTNUW3uIyjA8elAHtnhK+MnlDOTG2PwNc18e+PBGrDJ5MR/wDIqUeC7sx6xHC5xvBXH8qT47nzPh5qEn+3Gv8A5FSgD5cooooA0vDxxrNsfc/+gmvZdCl/dqQcivF9DONUgPuf5GvXdBfdHgjnGeaAPVtAYiCFORuXf+Oaw/FF+G1O9UE4RgOvQDitjRQubcgkbQPx46V5zqN9JLrVwFIZppGULnuTxQB0vhnTjqlyZ5FBjiPyA9zXodnaxhAqKuxRgewHasnwtZfZbGKIKTtGWIxyf0rqrdEjxtXGT2U0AS2kJUAdMetaEafK+GK8HBAzioIgu/GV9cE81dh4PGce9AEOm232dJ2lBYs+8MwG7PfnvyTWtEoz71V2q/lhyCynII4Gf89qvoFwCCDxjg54oAWEKxAxh8dMfyqXy8PuH3T8p4oQqGVc8nkD1qdAv3Tn+dAD1XPOMe1PA5OaRRz708DAxigBAMdOQKXbgnjqaXHp/OnYwenFACBcgdPrQAOemfSnLg5AzQB3PGP0oAFBzRjp/Klxz2x2zSj1/H6UAJt9+fapBz6VHGiooRFwo6DtUgGeTn6mgBR1PIwPSl+gpBx1I/Cl+hoAOMY6+oNKPfFICO3b0paAF7YpmOT2+lO5/wAikzknnpQAgGP/AK9IMsoLKVPoSDj8RSsQAR1+vemFjjPWgByqAXwWOTnBPA+lIyDOdufTnpSKxLELjH1qQcev0oAYVwO2aY/HU9KlI45OaYRlfegBhyPp9KafvH1p3PakyoYLuUNg4GaAIXDNIoAdVHzF1YYJ5G0jqRzn8uaZKBtPGRjGasHI64qJ/mTjOOnSgDKkiA4A+UDAqq0JYnIP41qyLtBLAn6daikXj0IFAGLPCrjBGPYcYrKmgMb7hnA710UqjeRzn6VRnjyCDyKAMN4g/Xn271yPi7wzHqVq8kSgXEeWRh612s0flNlRgd+KYYw6EHOOmaAPBdGvWtNWjlmJVo2AbPYg966X4zsH+G2r8E/6hwT/ANdU/wAay/iVpTaXqv2qNQIrg4OP71Xfi4/mfCy7kAPz29sTn/rpHQB8z0UUUAXNIONRh+p/ka9V8PSfKvJ9DXk1jIsN1G7nCr1P4V2+k+ItOt1Aludvf7jH+lAHvGmyhIgx4AQY/KvPdCtWvPE4YDcY3LDHr2/rVq1+InhtLRFfUiH2gEeRL/8AE1B4V8beFNPmnnutUCySMcf6PKePXhaAPbNLj2RIBj1JxWxGOcj6c15fa/FnwXGBu1oA/wDXrP8A/EVfi+MPgdf+Y7j/ALdJ/wD4igD0tFIX5Aue2RxVmCNCdyqATxnvivM0+MngQYZtfIPTi0n/AD/1dTp8Z/AKgD+3hjPIFncD/wBp0AeoRYwAzOe5BORVpA20dz2BHH515cnxr+HoIJ1/n1Flcf8AxurEfxw+HYPPiE4HpZXH/wAboA9Py3JVY8++akRiTggE9evSvMF+Ofw7CADxDnAxzY3H/wAbqQfHT4c4wfEXB6j7Dc//ABugD1JW4p4IOK8tX46/Dgf8zFj/ALcrn/43Sr8d/hz1/wCEj69f9Buf/jdAHqgxjHWlAB5wK8sHx4+HGP8AkYvzsbn/AON07/hfPw3/AOhjP/gDc/8AxugD1E+oJ47Cg9MivLv+F8/Dft4jx/243P8A8bpsXx6+HDJufxAY25BX7Fcn15/1f+c/hQB6ljPelwQDzzXl/wDwvr4b5/5GPp/043P/AMbpf+F8/DYAf8VH/wCSNz/8boA9QViMbsA/Wn5zzjmvLB8evhtnP/CRken+g3P/AMbp3/C+/htj/kYx/wCANz/8boA9Txn396d0PSvLB8fPhtnnxJ/5I3P/AMbpR8fPhr/0Mn/kjc//ABugD1LnHH60jAl0bceM5AJwfqO9eX/8L9+Gv/Qyf+SFz/8AG6P+F+/DXP8AyMn/AJIXP/xugD1Ln1xQ3XmvLf8Ahfvw1wf+Kk/8kbn/AON0x/j58N8HHiQ5P/Tjc/8AxugD1I845oIH4+prytfj38N8c+JP/JG5/wDjdOHx8+G3/Qyf+SNz/wDG6APTwMHNSfQYNeXf8L8+GvGfEmfX/Qbn/wCN0D4+fDUf8zJ/5I3P/wAboA9RA444NNIODgYavMD8fPhr/wBDJx/143P/AMbpv/C/PhtjnxHz3xY3P/xugD02RRICjYxxkA/lSnDHI/OvLJfjv8NSHK+IVDkdRYXIJOOMny+aVfj18OMAt4jG7HJFjc9f+/dAHqPrUbjBztya8x/4Xz8N/wDoYiP+3G5/+N0n/C+fhx1/4SM5H/Tjc/8AxugD0pxznoarSryB09PevO5Pjv8ADg9PEWff7Dc//G6rT/HL4duQB4hHHf7Dccf+Q6APQpMMDg5qpIvBBHNcE/xu+HjD/kP8/wDXlcf/ABuqh+NXgPB/4qLfx3srjP57P6UAdxcxgsRVKTKk5OSK4uT4z+BWB/4nuD/16XHP/jlULn4veCXI2a4SB/06TjP/AI5QBueNtLi1jRpInI3qNyt6GuD+LCtF8KJ0Y5ZYLdD9RKlar/FfwVIrK+sZUjBBtZjn/wAcriPif468Oa14PvtP0rUvPuJBGETyJFziRWPLKB0BoA8MooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10469=[""].join("\n");
var outline_f10_14_10469=null;
var title_f10_14_10470="Cryptococcosis skin";
var content_f10_14_10470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous lesions of disseminated cryptococcosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the resemblance of these papules to those of molluscum contagiosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10470=[""].join("\n");
var outline_f10_14_10470=null;
var title_f10_14_10471="Transfusion transmitted bacterial infection";
var content_f10_14_10471=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transfusion transmitted bacterial infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/14/10471/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/14/10471/contributors\">",
"     Denis Spelman, MBBS, FRACP, FRCPA, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/14/10471/contributors\">",
"     Graeme MacLaren, MBBS, FCICM, FRACP, FCCP, FCCM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/14/10471/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/14/10471/contributors\">",
"     Anthony Harris, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/14/10471/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/14/10471/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/14/10471/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion transmitted bacterial infection (TTBI) is an important complication of blood product administration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The incidence of TTBI is higher than the incidence of transfusion transmitted viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to TTBI will be reviewed here. Issues related to laboratory testing of donated blood for infectious agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus definition for transfusion transmitted bacterial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One paper published by a French group separated reports into definite, probable, and possible cases [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/1\">",
"       1",
"      </a>",
"      ]. In \"definite\" cases, the same bacteria were isolated from both the blood product and the transfusion recipient. In \"probable\" cases, bacteria were isolated from the blood product, but the recipient's blood was either not cultured or was culture negative. In \"possible\" cases, no bacteria were isolated from the blood product (either because culture was not performed or was negative) and the blood culture from the recipient was positive with no other apparent source.",
"     </li>",
"     <li>",
"      A British group defined transfusion transmitted bacterial infection as bacterial infection following transfusion (in the absence of infection prior to transfusion), with evidence of blood product contamination or infection in the donor [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A United States group defined transfusion transmitted bacterial infection as presence of organisms cultured from both the blood product bag and the recipient that were identical on pulsed-field gel electrophoresis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1968901\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide spectrum of organisms has been associated with transfusion transmitted bacterial infection, including skin, enteric, and environmental organisms (",
"    <a class=\"graphic graphic_table graphicRef79680 \" href=\"UTD.htm?35/33/36379\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/1-3,7-10\">",
"     1-3,7-10",
"    </a>",
"    ]. The organisms causing TTBI can come from donor blood, donor skin, the phlebotomist's skin, or environmental contamination during production or packaging (eg, contaminated water baths used to thaw blood products) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A source for TTBI is not always identified [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report of 25 cases of red blood cell contamination, gram-negative rods were the most common source of contamination. The same report described 16 cases of platelet contamination in which gram-positive organisms were the most common source of contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reports in the older literature emphasized the importance of cryophilic organisms (eg, organisms capable of multiplication at low temperatures), especially Yersinia enterocolitica and Pseudomonas fluorescens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], but also can include enterobacter [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/13\">",
"     13",
"    </a>",
"    ] and Serratia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/14\">",
"     14",
"    </a>",
"    ]. These organisms can survive and multiply in cold stored bank blood [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tick-borne infections (eg, Babesia, Anaplasma phagocytophilum, Rickettsia rickettsii, Colorado tick fever virus, and tick-borne encephalitis virus) can also be transmitted by transfusion of blood products [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Transfusion is associated with risk for transmission of parasitic infection in endemic countries (eg, malaria, trypanosomiasis, and leishmaniasis). The blood supply is not routinely tested for these pathogens and donor questionnaires are not sufficient to screen out donors in the early phases of infection with these organisms. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=see_link\">",
"     \"Blood donor medical history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of TTBI incidence are variable due to differences in definitions used and the means of reporting suspected cases. In addition, the risk varies with the type of blood product and the underlying conditions(s) of patient transfused. Platelet transfusions carry a higher risk of contamination because they are stored at room temperature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings have been noted in different studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A French study reported an overall TTBI incidence of 6.9 events per million units transfused; this included noncellular blood products [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/1\">",
"       1",
"      </a>",
"      ]. The rate was 7.4 per million allogeneic transfusions and 1.9 per million autologous transfusions. Compared with red blood cell transfusion, the rate was higher with platelet transfusion (threefold), platelet pool transfusion (12-fold), and apheresis platelet transfusion (5.5-fold).",
"     </li>",
"     <li>",
"      A United States surveillance study reported a TTBI rate of 0.2 per million red blood cell units, 10 per million single donor platelets units, and 10.6 per million pooled platelet transfusions [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A Canadian study estimated that the incidence of severe septic episodes with transfusion of blood components is 1 in 50,000 platelet units and 1 in 500,000 red blood cell units [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of TTBI is increased in stem cell transplant recipients. This was illustrated in a prospective study of 161 stem cell transplant recipients who received 3584 platelet transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/20\">",
"     20",
"    </a>",
"    ]. The risk of TTBI was 1 in 350 pooled platelet transfusions and 1 in 2000 per individual platelet unit [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study found a higher risk of TTBI in patients receiving red blood cells for pancytopenia (odds ratio [OR] 7.3, 95% CI 1.3-41.0) or platelets for thrombocytopenia (OR 5.3, 95% CI 1.2&ndash;24.1) compared with the risk for red blood cells transfused for treatment of anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estimated incidence of transfusion transmitted bacterial infection is higher than estimated incidence for transfusion transmitted HIV or hepatitis C transmission (approximately 1 in 2 million units transfused) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20325142\">",
"    <span class=\"h2\">",
"     Blood product contamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of blood product contamination is significantly higher than the incidence of transfusion transmitted infection. In the United States, the incidence is approximately 1 in 2000 for platelets and 1 in 30,000 for red blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/6,21,22\">",
"     6,21,22",
"    </a>",
"    ]. Others have reported rates of 0.2 to 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Contamination has been observed less frequently among leukodepleted units [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/24\">",
"     24",
"    </a>",
"    ]. Skin flora are common organisms associated with contamination.",
"   </p>",
"   <p>",
"    The difference in incidence between blood product contamination and transfusion transmitted bacterial infection may be due to insufficient bacterial inoculum to cause clinical manifestations, death of the bacteria in refrigerator stored cell components, or contamination of the blood product during the testing.",
"   </p>",
"   <p>",
"    Autologous blood transfusion has been associated with risk of blood product contamination. Among 287 autologous blood transfusions in Japan, 6 percent of units tested immediately prior to transfusion were culture positive; the most common organisms were coagulase-negative staphylococci. [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/11\">",
"     11",
"    </a>",
"    ]. The incidence of contamination was highest with intraoperative blood salvage (33 percent). With exclusion of intraoperative blood salvage samples the residual rate was 3 percent.",
"   </p>",
"   <p>",
"    The duration of storage appears to be an important factor in blood product contamination. In one series including over 3000 random donor platelet pools, the incidence of contamination detected by Gram stain was much lower in units stored for &le;4 days than for units stored for 5 days (1.8 versus 11.9 per 10,000 units) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, among the contaminated units the magnitude of contamination was less in those stored for &le;4 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of transfusion transmitted bacterial infection include fever &gt;39&ordm;C (or an increase of &gt;2&ordm;C following transfusion), rigors, tachycardia (&gt;120 beats per minute or increase of 40 beats per minute following transfusion), and rise or fall in systolic blood pressure (&gt;30 mm Hg) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/3\">",
"     3",
"    </a>",
"    ]. Distinguishing between TTBI and other conditions on these grounds is unreliable, however, since these manifestations can also be associated with nonhemolytic transfusion reactions, acute hemolytic reactions, allergic reactions, and other causes. In addition, TTBI can also occur in the absence of the above findings. Therefore, clinicians managing patients who become unwell during or following blood product administration must maintain a high degree of suspicion for TTBI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The median interval between completion of transfusion and appearance of symptoms is 30 minutes (range 0 to 5 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. In a report of 158 cases of suspected TTBI, the interval was shorter in cases due to gram-negative bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/1\">",
"     1",
"    </a>",
"    ]. Infection with gram-negative organisms have been associated with the greatest risk of death (odds ratio [OR] 7.5, 95% CI 1.3&ndash;64.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The variation in presentation of TTBI is due to a number of factors including the size of the bacterial inoculum, bacterial virulence, and the recipient's immune status. In one study including 41 cases of TTBI, 19 patients had minor symptoms, 16 had life-threatening severe sepsis or shock but recovered, and 6 patients died [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/1\">",
"     1",
"    </a>",
"    ]. Fever and chills were the most common symptoms. Abdominal pain, back pain, nausea, vomiting, and hypothermia were also reported. No difference in the severity of clinical features with different blood components was observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion transmitted bacterial infection and acute hemolytic transfusion reactions can be clinically indistinguishable and the initial steps in supportive care and investigation are similar [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If TTBI is suspected, the following steps should be taken:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stop the transfusion immediately.",
"     </li>",
"     <li>",
"      Resuscitate the patient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"       \"Evaluation and management of severe sepsis and septic shock in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Collect blood from the opposite arm from that used for the transfusion and send for culture, direct antiglobulin (Coombs) test, plasma free hemoglobin, and repeat crossmatch and typing. Urine should be analyzed for free hemoglobin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link\">",
"       \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Check for clerical error. If an error is found, investigate the status of the unit intended for the recipient (so that it is not administered to another patient unintentionally).",
"     </li>",
"     <li>",
"      If there is high suspicion for TTBI (eg, in the setting of fever together with hypotension, shock, or respiratory failure), begin empiric broad-spectrum antibiotics. The choice of antibiotics should be determined by local resistance patterns; the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      and a broad spectrum beta-lactam or an aminoglycoside should provide coverage for the most likely pathogens. (See",
"      <a class=\"local\" href=\"#H1968901\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alert the hospital blood bank and microbiology laboratory.",
"     </li>",
"     <li>",
"      Seal the blood product bag and send to the microbiology laboratory for Gram stain and culture. A sample from the bag should be obtained using aseptic technique with a needle and syringe. If there is no residual blood product in the bag, then culture broth should be added to the bag and an aspirate of the broth be used for culture [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Co-components from the same donation should be quarantined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The yield from microbiologic investigation of suspected TTBI is variable. In one study of 158 cases of suspected TTBI there was a positive culture in the blood product",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recipient in 77 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/1\">",
"     1",
"    </a>",
"    ]. A Gram stain of the residual contents of the blood product was positive in 56 percent of cases.",
"   </p>",
"   <p>",
"    Most hospitals have protocols for management of patients with suspected TTBI. Cooperation between the clinician, blood bank, and microbiology services is important. Antibiotic therapy should be adjusted based on culture results, or discontinued if an alternate diagnosis is made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1969736\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive strategies to reduce TTBI include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/7,8,28-30\">",
"     7,8,28-30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Donor screening &mdash; Exclusion of donors with identifiable infectious diseases and deferral of donors for 24 hours after dental extraction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=see_link&amp;anchor=H19#H19\">",
"       \"Blood donor medical history\", section on 'Bacterial infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skin preparation &mdash; Careful donor arm disinfection; the preferred skin disinfection solution is a product combining 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      in 70 percent isopropyl alcohol [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sample diversion &mdash; Discarding the first aliquot of donor blood has been proposed in order to prevent infection due to skin contaminants [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increasing culture volume &mdash; In one study doubling the volume of blood cultured resulted in a 54 percent relative increase in culture sensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preferential use of apheresis &mdash; A single donor product (apheresis platelets) carries a lower risk of TTBI than whole-blood-derived platelet concentrates, since bacterial contamination may result from a contaminated venipuncture.",
"     </li>",
"     <li>",
"      Reduced storage time &mdash; The risk of TTBI increases with storage time between blood donation and blood product administration.",
"     </li>",
"     <li>",
"      Leukodepletion",
"     </li>",
"     <li>",
"      Bactericidal treatments (eg, ultraviolet light exposure after psoralen sterilization) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1969743\">",
"    <span class=\"h2\">",
"     Detection of contamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine (100 percent) testing of platelet components was instituted in the United States in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], and this is now performed in some blood banks internationally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1970468\">",
"    <span class=\"h3\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly employed protocol is the use of automated bacterial culture systems to screen platelet products for bacterial contaminants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/35\">",
"     35",
"    </a>",
"    ]. If the culture remains negative after 24 hours, the platelet components are released for transfusion.",
"   </p>",
"   <p>",
"    A study evaluating the BACTEC 9240 blood culture system for detection of nine species of bacteria commonly associated with platelet contamination noted a detection sensitivity of &lt;10 CFUs per mL for all pathogens tested except for Streptococcus mitis (detection limit of 61 CFUs per mL) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/36\">",
"     36",
"    </a>",
"    ]. The time to detection ranged from 6.5 to 17.6 hours.",
"   </p>",
"   <p>",
"    The impact of screening platelets was illustrated in a report from the American Red Cross Regional Blood Centers, which performed control testing for bacterial contamination in apheresis platelet products using the",
"    <span class=\"nowrap\">",
"     BacT/ALERT",
"    </span>",
"    system [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/37\">",
"     37",
"    </a>",
"    ]. In the first 10 months of screening, 68 of 350,658 samples (0.019 percent or 1 in 5157 platelet products) were confirmed positive. Three high-probability septic transfusion reactions from screened negative components were identified; in all cases, the etiologic organism was a coagulase-negative staphylococcus. Thus, this new screening procedure was effective in identifying and preventing transfusion of most bacterially contaminated platelet units.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1970460\">",
"    <span class=\"h3\">",
"     Other methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-culture methods include Gram staining, use of a dipstick to screen for metabolic markers of bacterial colonization (eg, pH or glucose concentration), or observing for a \"swirling\" effect in platelet components [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/36,38,39\">",
"     36,38,39",
"    </a>",
"    ]. Bacterial detection using fluorescence-activated cell sorting (FACS) and an immunoassay for the detection of both Gram positive and Gram negative bacteria have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The sensitivity of these methods is lower than that of culture-based methods [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Molecular techniques for detecting bacterial contamination continue to evolve and appear to be more sensitive than older methods [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10471/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1970477\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transfusion transmitted bacterial infection (TTBI) is an important complication of blood product administration. A wide spectrum of organisms has been associated with transfusion transmitted bacterial infection, including skin, enteric, and environmental organisms (",
"      <a class=\"graphic graphic_table graphicRef79680 \" href=\"UTD.htm?35/33/36379\">",
"       table 1",
"      </a>",
"      ). Gram-negative rods have been observed more frequently as red blood cell contaminants, while gram-positive organisms have been observed more frequently as platelet contaminants. (See",
"      <a class=\"local\" href=\"#H1968901\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Estimates of TTBI incidence are variable due to differences in definitions used and the means of reporting suspected cases. In addition, the risk varies with the type of blood product and the underlying conditions(s) of patient transfused. Platelet transfusions carry a higher risk of contamination because they are stored at room temperature. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of transfusion transmitted bacterial infection include fever, rigors, tachycardia, and rise or fall in systolic blood pressure. Distinguishing between TTBI and other conditions on these grounds is unreliable, however, since these manifestations can also be associated with nonhemolytic transfusion reactions, acute hemolytic reactions, allergic reactions and other causes. In addition, TTBI can also occur in the absence of these findings. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the setting of suspected TTBI, the transfusion should be stopped, the patient should be resuscitated and blood should be collected for culture and evaluation for evidence of transfusion reaction. The blood bank and microbiology laboratory should be alerted; checks for clerical error should be performed, and the blood product bag should be sent for culture. If suspicion for TTBI is high (eg, in the setting of fever together with hypotension, shock, or respiratory failure), we suggest initiating broad spectrum empiric antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); reasonable regimens include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      plus a broad spectrum beta-lactam or an aminoglycoside. Antibiotic therapy should be adjusted based on culture results, or discontinued if an alternate diagnosis is made. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preventive measures are outlined above. The common preventive strategies include donor selection protocol, skin disinfection, sample diversion, leukodepletion, and detection of contamination by culture. (See",
"      <a class=\"local\" href=\"#H1969736\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/1\">",
"      Perez P, Salmi LR, Foll&eacute;a G, et al. Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM Case-Control Study. Transfusion 2001; 41:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/2\">",
"      Williamson LM, Lowe S, Love EM, et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ 1999; 319:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/3\">",
"      Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001; 41:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/4\">",
"      Vasconcelos E, Seghatchian J. Bacterial contamination in blood components and preventative strategies: an overview. Transfus Apher Sci 2004; 31:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/5\">",
"      Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003; 361:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/6\">",
"      Jacobs MR, Palavecino E, Yomtovian R. Don't bug me: the problem of bacterial contamination of blood components--challenges and solutions. Transfusion 2001; 41:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/7\">",
"      Brecher ME, Hay SN. Bacterial contamination of blood components. Clin Microbiol Rev 2005; 18:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/8\">",
"      Wagner SJ. Transfusion-transmitted bacterial infection: risks, sources and interventions. Vox Sang 2004; 86:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/9\">",
"      Morduchowicz G, Pitlik SD, Huminer D, et al. Transfusion reactions due to bacterial contamination of blood and blood products. Rev Infect Dis 1991; 13:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/10\">",
"      Bryant BJ, Conry-Cantilena C, Ahlgren A, et al. Pasteurella multocida bacteremia in asymptomatic plateletpheresis donors: a tale of two cats. Transfusion 2007; 47:1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/11\">",
"      Sugai Y, Sugai K, Fuse A. Current status of bacterial contamination of autologous blood for transfusion. Transfus Apher Sci 2001; 24:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/12\">",
"      Casewell MW, Slater NG, Cooper JE. Operating theatre water-baths as a cause of pseudomonas septicaemia. J Hosp Infect 1981; 2:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/13\">",
"      Arduino MJ, Bland LA, Tipple MA, et al. Growth and endotoxin production of Yersinia enterocolitica and Enterobacter agglomerans in packed erythrocytes. J Clin Microbiol 1989; 27:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/14\">",
"      Roth VR, Arduino MJ, Nobiletti J, et al. Transfusion-related sepsis due to Serratia liquefaciens in the United States. Transfusion 2000; 40:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/15\">",
"      Leiby DA, Gill JE. Transfusion-transmitted tick-borne infections: a cornucopia of threats. Transfus Med Rev 2004; 18:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/16\">",
"      Wells GM, Woodward TE, Fiset P, Hornick RB. Rocky mountain spotted fever caused by blood transfusion. JAMA 1978; 239:2763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/17\">",
"      Cable RG, Leiby DA. Risk and prevention of transfusion-transmitted babesiosis and other tick-borne diseases. Curr Opin Hematol 2003; 10:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/18\">",
"      Herwaldt BL, Neitzel DF, Gorlin JB, et al. Transmission of Babesia microti in Minnesota through four blood donations from the same donor over a 6-month period. Transfusion 2002; 42:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/19\">",
"      Blajchman MA, Goldman M. Bacterial contamination of platelet concentrates: incidence, significance, and prevention. Semin Hematol 2001; 38:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/20\">",
"      Chiu EK, Yuen KY, Lie AK, et al. A prospective study of symptomatic bacteremia following platelet transfusion and of its management. Transfusion 1994; 34:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/21\">",
"      Kleinman SH, Kamel HT, Harpool DR, et al. Two-year experience with aerobic culturing of apheresis and whole blood-derived platelets. Transfusion 2006; 46:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/22\">",
"      Kleinman S, Reed W, Stassinopoulos A. A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/23\">",
"      Kunishima S, Inoue C, Kamiya T, Ozawa K. Presence of Propionibacterium acnes in blood components. Transfusion 2001; 41:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/24\">",
"      Soeterboek AM, Welle FH, Marcelis JH, van der Loop CM. Sterility testing of blood products in 1994/1995 by three cooperating blood banks in The Netherlands. Vox Sang 1997; 72:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/25\">",
"      Yomtovian R, Lazarus HM, Goodnough LT, et al. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 1993; 33:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/26\">",
"      Dellinger EP, Anaya DA. Infectious and immunologic consequences of blood transfusion. Crit Care 2004; 8 Suppl 2:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/27\">",
"      Transfusion Transmitted Injuries Section, Blood Safety Surveillance and Health Care Acquired Infections Division, Public Health Agency of Canada. Guideline for investigation of suspected transfusion transmitted bacterial contamination. Can Commun Dis Rep 2008; 34 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/28\">",
"      Seidl S, K&uuml;hnl P. Transmission of diseases by blood transfusion. World J Surg 1987; 11:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/29\">",
"      de Korte D, Curvers J, de Kort WL, et al. Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands. Transfusion 2006; 46:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/30\">",
"      Eder AF, Kennedy JM, Dy BA, et al. Limiting and detecting bacterial contamination of apheresis platelets: inlet-line diversion and increased culture volume improve component safety. Transfusion 2009; 49:1554.",
"     </a>",
"    </li>",
"    <li>",
"     WHO guidelines on drawing blood: best practices in phlebotomy file://whqlibdoc.who.int/publications/2010/9789241599221_eng.pdf (Accessed on September 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/32\">",
"      Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001; 38:4.",
"     </a>",
"    </li>",
"    <li>",
"     Information for AABB members www.aabb.org (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     Commission on Laboratory Accreditation. Laboratory Accreditation Program transfusion medicine checklist: September 2007 file://www.cap.org/apps/docs/laboratory_accreditation/checklists/transfusion_medicine_sep07.pdf (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/35\">",
"      Brecher ME, Hay SN, Rothenberg SJ. Validation of BacT/ALERT plastic culture bottles for use in testing of whole-blood-derived leukoreduced platelet-rich-plasma-derived platelets. Transfusion 2004; 44:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/36\">",
"      Yazer MH, Triulzi DJ. Use of a pH meter for bacterial screening of whole blood platelets. Transfusion 2005; 45:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/37\">",
"      Fang CT, Chambers LA, Kennedy J, et al. Detection of bacterial contamination in apheresis platelet products: American Red Cross experience, 2004. Transfusion 2005; 45:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/38\">",
"      Wagner SJ, Robinette D. Evaluation of swirling, pH, and glucose tests for the detection of bacterial contamination in platelet concentrates. Transfusion 1996; 36:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/39\">",
"      Werch JB, Mhawech P, Stager CE, et al. Detecting bacteria in platelet concentrates by use of reagent strips. Transfusion 2002; 42:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/40\">",
"      Schmidt M, Hourfar MK, Nicol SB, et al. FACS technology used in a new rapid bacterial detection method. Transfus Med 2006; 16:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/41\">",
"      Jacobs MR, Smith D, Heaton WA, et al. Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. Transfusion 2011; 51:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/42\">",
"      Burstain JM, Brecher ME, Workman K, et al. Rapid identification of bacterially contaminated platelets using reagent strips: glucose and pH analysis as markers of bacterial metabolism. Transfusion 1997; 37:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/43\">",
"      Centers for Disease Control and Prevention (CDC). Fatal bacterial infections associated with platelet transfusions--United States, 2004. MMWR Morb Mortal Wkly Rep 2005; 54:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/44\">",
"      Sen K. Rapid identification of Yersinia enterocolitica in blood by the 5' nuclease PCR assay. J Clin Microbiol 2000; 38:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10471/abstract/45\">",
"      Ribault S, Harper K, Grave L, et al. Rapid screening method for detection of bacteria in platelet concentrates. J Clin Microbiol 2004; 42:1903.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3805 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10471=[""].join("\n");
var outline_f10_14_10471=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1970477\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1968901\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20325142\">",
"      Blood product contamination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1969736\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1969743\">",
"      Detection of contamination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1970468\">",
"      - Culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1970460\">",
"      - Other methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1970477\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3805\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3805|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/33/36379\" title=\"table 1\">",
"      Organisms in transfusion-associated infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=related_link\">",
"      Blood donor medical history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_14_10472="Sirolimus: Pediatric drug information";
var content_f10_14_10472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sirolimus: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"    see \"Sirolimus: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27190?source=see_link\">",
"    see \"Sirolimus: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rapamune&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F221227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rapamune&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1761842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Immunosuppressant Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       mTOR Kinase Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1761854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"      see \"Sirolimus: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Sirolimus tablets and oral solution are not bioequivalent due to differences in absorption; however, clinical equivalence has been demonstrated at the 2 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;13 years of age and &lt;40 kg: Loading dose: 3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1; initial maintenance dose: 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 12 hours or once daily; adjust dose to achieve target sirolimus trough blood concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Low- to moderate-immunologic risk renal transplant patients:",
"      </i>",
"     </b>",
"     Dosing by body weight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;40 kg: Loading dose: 3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1, followed by maintenance dosing of 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">",
"     &ge;40 kg: Loading dose: 6 mg on day 1; maintenance: 2 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       High-immunologic risk renal transplant patients",
"      </i>",
"     </b>",
"     : Adults: Loading dose: Up to 15 mg on day 1; maintenance: 5 mg/day; obtain trough concentration between days 5-7 and adjust accordingly. Continue concurrent cyclosporine/sirolimus therapy for 1 year following transplantation. Further adjustment of the regimen must be based on clinical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Intestinal transplant:",
"      </i>",
"     </b>",
"     Initial loading dose: 2-3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; maintenance dose: 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily to achieve blood concentrations of 8-10 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dosage adjustment: Sirolimus dosages should be adjusted to maintain trough concentrations within desired range based on risk and concomitant therapy. Maximum daily dose: 40 mg. Dosage should be adjusted at intervals of 7-14 days to account for the long half-life of sirolimus. In general, dose proportionality may be assumed. New sirolimus dose",
"     <b>",
"      equals",
"     </b>",
"     current dose",
"     <b>",
"      multiplied by",
"     </b>",
"     (target concentration/current concentration).",
"     <b>",
"      Note:",
"     </b>",
"     If large dose increase is required, consider loading dose calculated as:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Loading dose",
"     <b>",
"      equals",
"     </b>",
"     (new maintenance dose",
"     <b>",
"      minus",
"     </b>",
"     current maintenance dose)",
"     <b>",
"      multiplied by",
"     </b>",
"     3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maximum dose in 1 day: 40 mg; if required dose is &gt;40 mg (due to loading dose), divide over 2 days. Serum concentrations should not be used as the sole basis for dosage adjustment (monitor clinical signs/symptoms, tissue biopsy, and laboratory parameters).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Maintenance therapy after withdrawal of cyclosporine:",
"      </i>",
"     </b>",
"     Cyclosporine withdrawal is not recommended in high-immunological risk patients. Following 2-4 months of combined therapy, withdrawal of cyclosporine may be considered in low-to-moderate risk patients. Cyclosporine should be discontinued over 4-8 weeks, and a necessary increase in the dosage of sirolimus (up to fourfold) should be anticipated due to removal of metabolic inhibition by cyclosporine and to maintain adequate immunosuppressive effects. Dose-adjusted trough target concentrations are typically 16-24 ng/mL for the first year post-transplant and 12-20 ng/mL thereafter (measured by chromatographic methodology).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment necessary (in loading or maintenance dose); however, adjustment of regimen (including discontinuation of therapy) should be considered when used concurrently with cyclosporine and elevated or increasing serum creatinine is noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment: Reduce maintenance dose by ~33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe hepatic impairment: Reduce maintenance dose by ~50%",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rapamune&reg;: 1 mg/mL (60 mL) [contains ethanol 1.5%-2.5%, propylene glycol, soy]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rapamune&reg;: 0.5 mg, 1 mg, 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F11310396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM235958.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM235958.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1761855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . May be taken with or without food, but take medication consistently with respect to meals to minimize absorption variability. Initial dose should be administered as soon as possible after transplant. Sirolimus should be taken 4 hours after oral cyclosporine (Neoral&reg; or Gengraf&reg;). Tablets should not be crushed, split, or chewed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Oral solution: Use amber oral syringe to withdraw solution from the bottle. Empty dose from syringe into a glass or plastic cup and mix with at least 2 ounces of water or orange juice. No other liquids should be used for dilution. Patient should stir vigorously and drink the diluted sirolimus solution immediately. Then refill cup with an additional 4 ounces of water or orange juice; stir contents vigorously and have patient drink solution at once.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1761851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets at controlled room temperature [20&deg;C to 25&deg;C (68&deg;F to 77&deg;F)] and protect from light. Refrigerate oral solution and protect from light; store oral solution in original container and use contents within one month after opening. Oral solution bottle may be stored at room temperature for a short period of time not to exceed 15 days; amber syringe containing solution may be stored at room temperature or in the refrigerator for a maximum of 24 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1761844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis of organ rejection in renal transplant patients at low-moderate immunologic risk in combination with corticosteroids and cyclosporine (cyclosporine may be withdrawn after 2-4 months in conjunction with an increase in sirolimus dosage) (FDA approved in ages &ge;13 years and adults); prophylaxis of organ rejection in renal transplant patients at high immunologic risk in combination with cyclosporine and corticosteroids for the first year (FDA approved in ages &ge;18 years and adults); studied as primary immunosuppression in heart and intestinal transplantation (given in conjunction with a calcineurin inhibitor, as a substitute for a calcineurin inhibitor to reduce side effects, or to eliminate steroid use); rescue agent for acute and chronic organ rejection (rescue due to calcineurin toxicity or to treat resistant acute or chronic rejection despite calcineurin inhibitor therapy); prevention of acute graft-versus-host disease (GVHD) in allogeneic stem cell transplantation; treatment of refractory acute  or chronic GVHD",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4288698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Rapamune&reg; may be confused with Rapaflo&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sirolimus may be confused with everolimus, pimecrolimus, tacrolimus, temsirolimus",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F221258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation, CHF, DVT, edema, facial edema, hyper-/hypotension, hypervolemia, orthostatic hypotension, palpitation, peripheral edema, peripheral vascular disorder, syncope, tachycardia, thrombosis, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, confusion, depression, dizziness, emotional lability, headache, hypoesthesia, insomnia, malaise, neuropathy, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, cellulitis, dermal ulcer, dermatitis (fungal), ecchymosis, hirsutism, pruritus, rash, skin carcinoma (includes basal cell carcinoma, squamous cell carcinoma, melanoma), skin hypertrophy, wound healing abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, Cushing's syndrome, dehydration, diabetes mellitus, glycosuria, hypercalcemia, hypercholesterolemia, hyperglycemia, hyperphosphatemia, hypertriglyceridemia, hypocalcemia, hypoglycemia, hypomagnesemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdomen enlarged, abdominal pain, anorexia, constipation, diarrhea, dysphagia, eructation, esophagitis, flatulence, gastritis, gastroenteritis, gingival hyperplasia, gingivitis, ileus, mouth ulceration, nausea, oral moniliasis, stomatitis, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, pelvic pain, scrotal edema, testis disorder, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, hemolytic-uremic syndrome, hemorrhage, leukopenia, leukocytosis, polycythemia, thrombocytopenia, TTP",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Abnormal liver function tests, alkaline phosphatase increased, ascites, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthrosis, bone necrosis, CPK increased, hyper-/hypotonia, leg cramps, myalgia, osteoporosis, paresthesia, tetany",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Albuminuria, bladder pain, BUN increased, dysuria, hematuria, hydronephrosis, kidney pain, nephropathy (toxic), nocturia, oliguria, pyelonephritis, pyuria, serum creatinine increased, tubular necrosis, urinary frequency, urinary incontinence, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, atelectasis, bronchitis, cough, epistaxis, hypoxia, lung edema, pleural effusion, pneumonia, pulmonary embolism, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal vision, cataract, conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ear pain, otitis media, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Abscess, diaphoresis, flu-like syndrome, hernia, herpesvirus infection, infection (including opportunistic), lymphadenopathy, lymphocele, lymphoproliferative disease/lymphoma, peritonitis, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: ALT increased, alveolar proteinosis, anaphylactoid reaction, anaphylaxis, anastomotic disruption, angioedema, ascites, AST increased, azoospermia,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     colitis, cytomegalovirus, Epstein-Barr virus, exfoliative dermatitis, fascial dehiscence, focal segmental glomerulosclerosis, hepatic necrosis, hepatotoxicity, hypersensitivity reaction, hypersensitivity vasculitis, hypophosphatemia, incisional hernia; interstitial lung disease (dose-related; includes pneumonitis, pulmonary fibrosis, and bronchiolitis obliterans organizing pneumonia [BOOP] with no identified infectious etiology); joint disorders, lymphedema, myocardial infarction, mycobacterial infection, nephropathy (BK virus-associated), nephrotic syndrome, neutropenia, pancreatitis, pancytopenia, pericardial effusion,",
"     <i>",
"      Pneumocystis",
"     </i>",
"     pneumonia, progressive multifocal leukoencephalopathy (PML), proteinuria, pulmonary hemorrhage, reversible posterior leukoencephalopathy syndrome (RPLS), tamponade, tuberculosis, wound dehiscence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Hepatic artery thrombosis [HAT] and graft failure have been reported in liver transplant patients (not an approved use); bronchial anastomotic dehiscence has been reported in lung transplant patients (not an approved use).",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1761846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sirolimus, its derivatives, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1761862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment; a reduction in the maintenance dose is recommended. Use with caution in patients with hyperlipidemia (sirolimus may increase serum cholesterol and triglycerides), renal impairment, or when used concurrently with medications which alter renal function (sirolimus may decrease GFR and increase serum creatinine). In renal transplant patients,",
"     <i>",
"      de novo",
"     </i>",
"     use without cyclosporine has been associated with higher rates of acute rejection. Sirolimus should be used in combination with cyclosporine initially. Sirolimus may delay recovery of renal function in patients with delayed allograft function. Monitor renal function closely when combined with cyclosporine; consider dosage adjustment or discontinue in patients with increasing serum creatinine. Separate dosing; sirolimus should be administered 4 hours after oral cyclosporine doses.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use caution in the perioperative period due to increased chance of surgical complications from wound dehiscence and impaired wound and tissue healing (patients with a body mass index &gt;30 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     are at increased risk for abnormal wound healing). Antimicrobial prophylaxis for",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia should be administered for 1 year following transplantation; CMV prophylaxis is recommended for 3 months after transplantation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Adequate laboratory and supportive medical resources must be readily available. Sirolimus concentrations are dependant on the assay method (eg, chromatographic and immunoassay) used; assay methods are not interchangeable. Variations in methods to determine sirolimus whole blood concentrations, as well as interlaboratory variations, may result in improper dosage adjustments, which may lead to subtherapeutic or toxic concentrations. Determine the assay method used to assure consistency (or accommodations if changes occur) and for monitoring purposes, be aware of alterations to assay method or reference range. The manufacturer recommends high performance liquid chromatography (HPLC) as the reference standard to determine sirolimus trough concentrations. Should only be used by physicians experienced in immunosuppressive therapy and management of transplant patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1761847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Immunosuppression with sirolimus may result in increased susceptibility to infection",
"     <b>",
"      [U.S Boxed Warning]",
"     </b>",
"     . Immunosuppressive agents, including sirolimus, may be associated with the development of lymphoma or other malignancies",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Immunosuppressant therapy is associated with an increased risk of skin cancer; limit sun and ultraviolet light exposure; use appropriate sun protection. Hypersensitivity reactions, anaphylaxis, angioedema, exfoliative dermatitis, and hypersensitivity vasculitis have been reported following administration of sirolimus. Sirolimus is not recommended for use in lung transplant patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Cases of fatal bronchial anastomotic dehiscence have been reported in lung transplant patients who received sirolimus in combination with other immunosuppressants. Sirolimus is not recommended for use in liver transplant patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Hepatic artery thrombosis, graft loss, and death have been reported in liver transplant patients who received sirolimus in combination with other immunosuppressants.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Increased urinary protein excretion has been observed when converting renal transplant patients from calcineurin inhibitors to sirolimus during maintenance therapy. A higher severity of proteinuria prior to sirolimus conversion correlates with a higher degree of proteinuria after conversion. In some patients, proteinuria may reach nephrotic levels. Increased risk of BK viral-associated nephropathy which may impair renal function and cause graft loss; consider decreasing immunosuppressive burden if evidence of deteriorating renal function. Use has been associated with an increased risk of fluid accumulation, impaired wound healing, and lymphocele. Peripheral edema, lymphedema, and pleural and pericardial effusions (including significant effusions and tamponade) were reported; use with caution in patients in whom fluid accumulation may be poorly tolerated, such as in cardiovascular disease (heart failure or hypertension) and pulmonary disease. Cases of interstitial lung disease [eg, pneumonitis, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis] have been observed (some fatal); risk may be increased with higher trough concentrations.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Concurrent use with strong inhibitors of CYP3A4 and/or p-glycoprotein (ie, erythromycin, ketoconazole, voriconazole, itraconazole, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or p-glycoprotein (rifampin or rifabutin) is not recommended. Concurrent use with a calcineurin inhibitor (cyclosporine, tacrolimus) may increase the risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral solution contains propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities,  which can include metabolic acidosis, seizures, renal failure, and CNS depression; use dosage forms containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F221246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Sirolimus may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Sirolimus. Management: Significant sirolimus dose reductions may be required if used with boceprevir.  Concurrent use should be performed with great caution and close monitoring of both sirolimus concentrations and clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Sirolimus may enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described. CycloSPORINE (Systemic) may increase the serum concentration of Sirolimus. This is of specific concern with cyclosporine [MODIFIED].  Management: Administer oral doses of sirolimus 4 hours after doses of cyclosporine.  Monitor for toxic effects of sirolimus if used with cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Sirolimus. Management: Closely monitor sirolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of sirolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Sirolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sirolimus. Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Sirolimus. Management: Monitor for decreased sirolimus concentrations if fosphenytoin/phenytoin is initiated/dose increased. Monitor for increased sirolimus concentrations with phenytoin discontinuation/dose decrease. Sirolimus dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Sirolimus. Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Sirolimus. Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Sirolimus.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Sirolimus. Management: Avoid sirolimus during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Sirolimus. Management: Monitor for decreased sirolimus serum concentrations if phenytoin is initiated/dose increased. Monitor for increased sirolimus concentrations with phenytoin discontinuation/dose decrease. Sirolimus dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Sirolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): May enhance the adverse/toxic effect of Sirolimus. Sirolimus may enhance the adverse/toxic effect of Tacrolimus (Systemic). Sirolimus may decrease the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus and sirolimus should only be used concomitantly as part of a protocol with a known risk:benefit profile and an established safety record.  Several regimens combining these agents have been associated with excess morbidity and/or mortality.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Sirolimus. Sirolimus may enhance the adverse/toxic effect of Tacrolimus (Topical).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Sirolimus. Management: Significant sirolimus dose reductions are likely to be required if used with telaprevir.  Concurrent use should be performed with great caution and close monitoring of both sirolimus concentrations and clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1761850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid administration with grapefruit juice (may reduce metabolism of sirolimus); ingestion with a high fat meal decreases peak concentration but increases AUC by 35% (take sirolimus consistently either with or without food to minimize variability)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F221210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated embryotoxicity and fetotoxicity, as evidenced by increased mortality, reduced fetal weights and delayed ossification. There are no adequate and well-controlled studies in pregnant women. Effective contraception must be initiated before therapy with sirolimus and continued for 12 weeks after discontinuation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The National Transplantation Pregnancy Registry (NTPR, Temple University) is a registry for pregnant women taking immunosuppressants following any solid organ transplant. The NTPR encourages reporting of all immunosuppressant exposures during pregnancy in transplant recipients at 877-955-6877.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1761856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Whole blood sirolimus trough concentration, serum cholesterol and triglycerides, serum creatinine; blood pressure, CBC with differential, liver function, urinary protein;",
"     <b>",
"      Note:",
"     </b>",
"     Concentrations and ranges are dependant on and will vary with assay methodology (chromatographic or immunoassay); assay methods are not interchangeable.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1761857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Sirolimus concentrations are dependant on the assay method (eg, chromatographic and immunoassay) used; assay methods are not interchangeable. Determine the assay method used to assure consistency (or accommodations if changes occur) and for monitoring purposes, be aware of alterations to assay method or reference range.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Whole blood trough concentration goals for renal transplantation (based on HPLC methods):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Low to moderate immunologic risk (after cyclosporine withdrawal):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     First year after transplant :16-24 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     After 1 year: 12-20 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     High immunologic risk (with cyclosporine): 10-15 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1761852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sirolimus reduces T-cell activation and proliferation by inhibiting cytokine-induced signal transduction pathways resulting in the suppression of IL-2 or IL-4 driven T-cell proliferation. Sirolimus inhibits antibody production. Sirolimus binds to FKBP-12, an intracellular protein, to form an immunosuppressive complex which inhibits the regulatory kinase, mTOR (mammalian target of rapamycin). This inhibition suppresses cytokine mediated T-cell proliferation, halting progression from the G1 to the S phase of the cell cycle. It inhibits acute rejection of allografts and prolongs graft survival.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1761853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 12 &plusmn; 8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~92%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: By liver and intestinal cytochrome P450 enzyme CYP3A4; undergoes counter-transport from enterocytes of the small intestine into the gut lumen by the p-glycoprotein drug efflux pump; metabolized by O-demethylation and/or hydroxylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral solution: 14%; tablet: 18%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children:  13.7 &plusmn; 6.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 62 &plusmn; 16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral solution: 1-3 hours; tablet: 1-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily eliminated via feces (91%) and urine (2.2%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1761858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27190?source=see_link\">",
"      see \"Sirolimus: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the increased risk for skin cancer, avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]. Advise women of childbearing potential to avoid becoming pregnant; use effective contraception prior to starting sirolimus therapy, during therapy and for 12 weeks after sirolimus has been stopped.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/14/10472/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Balfour IC, Srun SW, Wood EG, et al, \"Early Renal Benefit of Rapamycin Combined With Reduced Calcineurin Inhibitor Dose in Pediatric Heart Transplantation Patients,\"",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2006,  25(5):518-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/14/10472/abstract-text/16678029/pubmed\" id=\"16678029\" target=\"_blank\">",
"        16678029",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Castillo RO, Zarge R, Cox K, et al, \"Pediatric Intestinal Transplantation at Packard Children's Hospital/Stanford University Medical Center: Report of a Four-Year Experience,\"",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 2006,  38(6):1716-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/14/10472/abstract-text/16908259 /pubmed\" id=\"16908259 \" target=\"_blank\">",
"        16908259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ettenger RB and Grimm EM, \"Safety and Efficacy of TOR Inhibitors in Pediatric Renal Transplant Recipients,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2001, 38(4 Suppl 2):S22-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/14/10472/abstract-text/11583941/pubmed\" id=\"11583941\" target=\"_blank\">",
"        11583941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta P, Kaufman S, and Fishbein TM, \"Sirolimus for Solid Organ Transplantation in Children,\"",
"      <i>",
"       Pediatr Transplant",
"      </i>",
"      , 2005, 9(3):269-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/14/10472/abstract-text/15910380/pubmed\" id=\"15910380\" target=\"_blank\">",
"        15910380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lobach NE, Pollock-Barziv SM, West LJ, et al, \"Sirolimus Immunosuppression in Pediatric Heart Transplant Recipients: A Single-Center Experience,\"",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2005, 24(2):184-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/14/10472/abstract-text/15701435/pubmed\" id=\"15701435\" target=\"_blank\">",
"        15701435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sarwal M and Pascual J, \"Immunosuppression Minimization in Pediatric Transplantation,\"",
"      <i>",
"       Am J Transplant",
"      </i>",
"      , 2007, 7(10):2227-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/14/10472/abstract-text/17711553/pubmed\" id=\"17711553\" target=\"_blank\">",
"        17711553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schubert M, Venkataramanan R, Holt DW, et al, \"Pharmacokinetics of Sirolimus and Tacrolimus in Pediatric Transplant Patients,\"",
"      <i>",
"       Am J Transplant",
"      </i>",
"      , 2004, 4(5):767-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/14/10472/abstract-text/15084173 /pubmed\" id=\"15084173 \" target=\"_blank\">",
"        15084173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12761 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10472=[""].join("\n");
var outline_f10_14_10472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709411\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221226\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221227\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761842\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761854\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221201\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221186\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11310396\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761855\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761851\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761844\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288698\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221258\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761846\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761862\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761847\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221246\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221195\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761850\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221197\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221210\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761856\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761857\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761852\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761853\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761858\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12761\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12761|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=related_link\">",
"      Sirolimus: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27190?source=related_link\">",
"      Sirolimus: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_14_10473="Infectious causes of neutropenia";
var content_f10_14_10473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infectious causes of neutropenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/14/10473/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/14/10473/contributors\">",
"     Thomas D Coates, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/14/10473/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/14/10473/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/14/10473/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/14/10473/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/14/10473/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia can be caused by infection with microorganisms. Conversely, neutropenia can lead to infection, typically from bacterial organisms.",
"   </p>",
"   <p>",
"    This review will discuss the neutropenias that can occur during bacterial, viral, parasitic, or rickettsial infections. A number of different mechanisms are involved, including infection of hematopoietic precursor cells, infection of endothelial cells, increased neutrophil adherence to endothelium, development of antineutrophil antibodies, and enhanced neutrophil utilization at the site of infection associated with hypersplenism. Drugs given to treat these infections may also cause neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link\">",
"     \"Drug-induced neutropenia and agranulocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infections in patients with neutropenia can range from mild to life-threatening, depending on the cause of the neutropenia. Fever in a neutropenic patient is considered a medical emergency unless the patient is known to be low risk. This issue is discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"       \"Overview of neutropenic fever syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=see_link\">",
"       \"Risk of infection in children with fever and non-chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link\">",
"       \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link\">",
"       \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=see_link\">",
"       \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1155994\">",
"    <span class=\"h1\">",
"     DEFINITIONS AND INFECTIOUS RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia is defined as an absolute neutrophil count (ANC) of less than",
"    <span class=\"nowrap\">",
"     1500/microL.",
"    </span>",
"    The ANC is equal to the product of the white blood cell count (WBC) and the percentage of polymorphonuclear cells (PMNs) and band forms noted on the differential analysis:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;ANC &nbsp;= &nbsp;WBC",
"    <span class=\"nowrap\">",
"     (cells/microL)",
"    </span>",
"    &nbsp;x &nbsp;percent (PMNs &nbsp;+ &nbsp;bands) &nbsp;&divide; &nbsp;100",
"   </p>",
"   <p>",
"    Neutrophilic metamyelocytes and younger forms are not included in this calculation. The risk of infection begins to increase at an ANC below",
"    <span class=\"nowrap\">",
"     1000/microL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef63903 \" href=\"UTD.htm?10/19/10555\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Leukopenia and granulocytopenia are generally used interchangeably with neutropenia, although they are somewhat different. Leukopenia refers to a low WBC that may be due to lymphopenia as well as neutropenia, while granulocytopenia refers to a reduced number of granulocytes (neutrophils, eosinophils, and basophils). Agranulocytosis literally means the absence of granulocytes, but the term is often used to indicate severe neutropenia (ie, ANC less than",
"    <span class=\"nowrap\">",
"     500/microL).",
"    </span>",
"   </p>",
"   <p>",
"    Most cases of neutropenia are acquired and are due to decreased granulocyte production or increased destruction. Acquired neutropenia is most often due to accelerated turnover, usually resulting from immunologic mechanisms. The key questions that arise in the patient with infection and neutropenia are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the patient infected because of the neutropenia?",
"     </li>",
"     <li>",
"      Is the patient neutropenic because of the infection?",
"     </li>",
"     <li>",
"      Are the two events totally unrelated?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The critical clinical question is whether or not the patient is at increased risk of overwhelming infection because of the neutropenia, as this will determine the immediate management of the infection. The propensity to infection from neutropenia is related to the adequacy of the bone marrow reserve pool and other factors such as presence of vasculitis or immune deficiency. Certain patients with normal marrow reserve and an ANC of zero may be at no increased risk because of the neutropenia. These distinctions are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACTERIAL INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocytosis with an increased number of band forms (ie, a shift to the left) is the usual response to bacterial infection. Certain infections, however, such as typhoid fever, Shigella enteritis, brucellosis, tularemia, and tuberculosis are often associated with neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Typhoid fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typhoid fever is a severe systemic illness characterized by sustained fever and abdominal symptoms. Leukopenia with neutropenia and an increased percentage of band forms is seen in approximately 25 to 50 percent of adults with this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/1\">",
"     1",
"    </a>",
"    ]. Thrombocytopenia and anemia are even more frequent, while pancytopenia is found in less than 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several consequences of infection in the early phase of the disease contribute to the neutropenia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The bone marrow shows granulocytic hyperplasia with hemophagocytosis followed by granuloma in the later phases [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. Hemophagocytosis, if extensive, contributes to peripheral blood cytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=see_link\">",
"       \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Plasma concentrations of endotoxin, tumor necrosis factor (TNF)-receptors, interleukin (IL)-6, and interferon-gamma, blood leukocyte expression of TNF-alpha and IL-1 beta genes, and extracellular phospholipase A2 are elevated. These mediators of inflammation up-regulate expression of vascular endothelial cell adhesion molecules and shift circulating PMNs onto sticky endothelium [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/6-10\">",
"       6-10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Shigella enteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The white blood cell (WBC) count varies widely from leukopenia to leukocytosis in both children and adults with Shigella enteritis, but a striking shift to the left (increased percentage of band forms) is a common feature that helps to distinguish this disorder from Salmonella infection or viral enteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which Shigella infection causes neutropenia is not well understood. The outer membrane proteins from two antigenically different strains of Shigella (Shigella flexneri and Shigella sonnei) caused fever and leukopenia followed by transient leukocytosis when injected intravenously into rabbits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Shigellosis can be associated with a number of systemic complications such as septicemia, hemolytic-uremic syndrome, and a leukemoid reaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\"",
"    </a>",
"    .) PMNs from children with complicated Shigellosis are more likely to be activated (as determined by in vitro testing) than PMNs from children with uncomplicated Shigellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=see_link\">",
"     \"Neutrophil functions other than movement\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Brucellosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia occurs in 20 to 30 percent of adults and children with brucellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Most of these patients are anemic and up to 20 percent are pancytopenic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/16,18\">",
"     16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypersplenism, hemophagocytosis by marrow macrophages (which correlates with hypersplenism), and granulomatous lesions of the bone marrow appear to contribute to the development of these abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Brucella melitensis can almost always be cultured from the bone marrow during the acute stage of the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, in one report of 16 patients with pancytopenia who underwent bone marrow biopsy, noncaseating granulomas were present in eleven [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous injection of mice with Brucella abortus results in a similar type of chronic infection with splenomegaly characterized by massive numbers of macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/21\">",
"     21",
"    </a>",
"    ]. Cases of reactive hemophagocytosis with clinical features of fever, wasting, splenomegaly, and pancytopenia have been associated with Brucellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tularemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tularemia is a zoonosis caused by the Gram negative, facultative intracellular coccobacillus, Francisella tularensis. Clinical manifestations are varied and include ulceroglandular disease and pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"    </a>",
"    .) The mean WBC and differential are usually normal, as neutropenia occurs in only a small percentage of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PMNs are essential for host defense against primary infection in tularemia. Mice rendered agranulocytic by treatment with a granulocyte specific antibody and then infected with Francisella tularensis became lethally infected in their lungs, liver, and spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic abnormalities are common in patients with hematogenously disseminated miliary tuberculosis. In one study of 109 such patients, the WBC was less than",
"    <span class=\"nowrap\">",
"     4000/microL",
"    </span>",
"    in 15 percent, and 87 percent were lymphopenic with absolute lymphocyte counts less than",
"    <span class=\"nowrap\">",
"     1500/microL.",
"    </span>",
"    Neutropenia was seen as part of pancytopenia in six patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/26\">",
"     26",
"    </a>",
"    ]. In another series of 380 patients with pulmonary tuberculosis, leukopenia with neutropenia and lymphopenia was observed in 16 percent of those with very severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PARASITIC INFESTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kala azar and malaria are two parasitic infections with characteristic neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Kala azar",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with Leishmania donovani causes fever, hepatosplenomegaly, and neutropenia as part of pancytopenia. All patients have anemia and approximately 43 percent later develop neutropenia. The disease occurs in individuals who have resided in endemic areas (Mediterranean countries, India, East Africa, South America). There is also a hemolytic anemia that may in part be due to the generation of oxidative metabolic products. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=see_link\">",
"     \"Extrinsic nonimmune hemolytic anemia due to systemic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several mechanisms contribute to the neutropenia. Leukokinetic studies on two patients with kala azar found that the PMN half-life was reduced with shifts of circulating PMNs to pooling and destruction in an enlarged spleen and, to a lesser extent, in the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=see_link\">",
"     \"Normal neutrophil development and kinetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the bone marrow reserve of PMNs has been noted to be markedly reduced in some [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/28\">",
"     28",
"    </a>",
"    ], in general the marrow shows myeloid hyperplasia and increased megakaryocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/29\">",
"     29",
"    </a>",
"    ]. Rapid destruction of antibody-coated blood cells could contribute to the pancytopenia. Immunologic studies of the pancytopenia in one series revealed membrane-associated antiplatelet, antineutrophil, and antierythrocyte IgG antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The size of the spleen, hemoglobin level, platelet level and number of bone marrow plasma cells are related to the parasite load. The degree of parasitization, spleen size, and duration of illness generally correlate with the severity of the pancytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/31\">",
"     31",
"    </a>",
"    ]. Amastigote forms of Leishmania donovani are found in bone marrow macrophages, PMNs, and eosinophils in 60 to 85 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/32\">",
"     32",
"    </a>",
"    ] but the yield is close to 100 percent if the bone marrow aspirate is cultured and then evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/33\">",
"     33",
"    </a>",
"    ]. A likely contributor to the anemia is hyperactive bone marrow macrophages which phagocytose immature erythroblasts and cause ineffective erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/29,34\">",
"     29,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The marked leukopenia in visceral leishmaniasis contributes to secondary infections. Susceptibility to secondary infection can be significantly reduced by treatment with recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The effects of GM-CSF on neutropenia and the rate of infection were evaluated in 24 patients with an ANC less than",
"    <span class=\"nowrap\">",
"     1500/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients treated with GM-CSF for 10 days, with pentavalent antimony given daily for 20 days, experienced a three- to fourfold increase in ANC at day five and 10, respectively. The incidence of secondary infection was reduced in the patients randomly assigned to treatment with &nbsp;to GM-CSF (21 versus 80 percent with placebo). Importantly, all patients, regardless of treatment, had complete resolution of leishmaniasis at three months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild neutropenia is common in malarial infection although neutrophilia occurs in severe disease. The hyperreactive malarial splenomegaly syndrome (also called the tropical splenomegaly syndrome) occurs throughout Africa, India, and Southeast Asia. It is associated with massive splenomegaly, pancytopenia, high levels of malarial antibodies, and hyper-IgM syndrome, which resolves after prolonged antimalarial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/36\">",
"     36",
"    </a>",
"    ]. The overall prevalence of neutropenia is approximately 21 percent at presentation with recovery during follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4394?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of non-falciparum malaria\", section on 'Hyperreactive malarial splenomegaly'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism of the neutropenia has been studied in six subjects with untreated malaria due to Plasmodium vivax and a mean ANC of",
"    <span class=\"nowrap\">",
"     1700/microL;",
"    </span>",
"    all had moderate splenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/38\">",
"     38",
"    </a>",
"    ]. The number of circulating band forms was increased, the PMN half-life was prolonged, and the total blood granulocyte pool was normal or increased. The marginating PMN pool was greatly enlarged while the circulating PMN pool was reduced, indicating that the apparent neutropenia was due to a shift of circulating PMN into the marginating pool primarily in the spleen and lung. These patients had decreased numbers and reserves of bone marrow PMNs, presumably due to their premature release into the circulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=see_link\">",
"     \"Normal neutrophil development and kinetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is some evidence that sequestration of CD11a&ndash;bearing PMNs, due to tumor necrosis factor-induced upregulation of the endothelial expression of intercellular adhesion molecule (ICAM)-1, contributes to the mortality and microvascular lesions with severe malaria. In an experimental model in which mice were infected with murine malaria, the administration of a monoclonal antibody against PMN induced profound neutropenia, abolished PMN sequestration in the lung, and prevented mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RICKETTSIAL INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia is common in rickettsialpox and human ehrlichiosis and is also seen in severe cases of Rocky Mountain spotted fever (RMSF). Leukopenia occurs in approximately 75 percent of patients with rickettsialpox [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/40\">",
"     40",
"    </a>",
"    ]. Although the differential count is usually normal, there is a relative lymphocytosis in some patients and a left shift of band forms in others.",
"   </p>",
"   <p>",
"    Leukopenia, accompanied by a shift to the left, occurs in 50 to 90 percent of patients with human granulocytic ehrlichiosis (HGE) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The leukopenia is caused by either lymphopenia, early in the course of the disease, or neutropenia that increases in severity with more prolonged duration of symptoms prior to institution of therapy. Thrombocytopenia and anemia are also frequently seen. The agent of HGE infects mostly neutrophils. Monocytes are resistant to infection by this agent due to reduced binding and uptake of the organisms and the ability of monocytes to kill internalized organisms; in comparison, granulocytic differentiation results in enhanced binding and uptake, and granulocytic cells are unable to kill internalized ehrlichiae [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23525?source=see_link\">",
"     \"Biology of ehrlichiae\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cases of RMSF are associated with a normal white blood cell count or leukocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/44\">",
"     44",
"    </a>",
"    ]. However, leukopenia and neutropenia can occur in patients with severe disease associated with occlusive fibrin microthrombosis, shock, and multiple organ failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Rocky Mountain spotted fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     VIRAL INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infections which can present with neutropenia include HIV, infectious mononucleosis, cytomegalovirus, hepatitis A, and the viral exanthematous diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4002046\">",
"    <span class=\"h2\">",
"     Common childhood viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient mild to moderate neutropenia can be caused by a variety of common viral infections during childhood, including respiratory syncytial virus (RSV), influenza A and B, and parvovirus. In most cases, neutropenia occurs during the first few days of the viral illness and persists for 3 to 8 days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/45\">",
"     45",
"    </a>",
"    ]. Similar patterns may occur after Epstein-Barr virus (EBV) and human herpes virus 6 (HHV6) infections, as discussed below. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Human immunodeficiency virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of hematologic abnormalities are associated with infection by human immunodeficiency virus (HIV). Anemia, neutropenia, and thrombocytopenia are seen with increasing prevalence as the disease becomes more severe [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Neutropenia is seen in approximately 40 percent of patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/49\">",
"     49",
"    </a>",
"    ] either on an autoimmune basis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/50\">",
"     50",
"    </a>",
"    ] or as a side effect of drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/51\">",
"     51",
"    </a>",
"    ]. Lymphopenia occurs in 75 percent of patients due primarily to the fall in the CD4 cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link\">",
"     \"Drug-induced neutropenia and agranulocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44039?source=see_link\">",
"     \"Hematologic manifestations of HIV infection: Neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a significantly higher risk of hospitalization for bacterial infection among HIV-infected patients with neutropenia, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 2047 patients, the risk for developing a bacterial infection requiring hospitalization occurred at ANCs below",
"      <span class=\"nowrap\">",
"       750/microL",
"      </span>",
"      and increased progressively as the ANC fell below this level (",
"      <a class=\"graphic graphic_figure graphicRef81371 \" href=\"UTD.htm?10/62/11246\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a case-controlled study, the adjusted relative risk for the occurrence of bacterial infection was 2.3 for patients with an ANC below",
"      <span class=\"nowrap\">",
"       1000/microL",
"      </span>",
"      and 7.9 for those with an ANC below",
"      <span class=\"nowrap\">",
"       500/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/48\">",
"       48",
"      </a>",
"      ]. The incidence of severe infection was 3 to 5 per 100 patient-months at an ANC below",
"      <span class=\"nowrap\">",
"       500/microL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increasing the ANC by the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    ) or granulocyte-monocyte colony-stimulating factor (GM-CSF, leukine) reduces the incidence of infection in patients with advanced HIV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. As an example, a multicenter trial randomized 258 HIV-infected patients with a CD4 cell count below",
"    <span class=\"nowrap\">",
"     200/microL",
"    </span>",
"    and an ANC between 750 and",
"    <span class=\"nowrap\">",
"     1000/microL",
"    </span>",
"    to placebo or increasing doses of daily or intermittent filgrastim to maintain an ANC between 2000 and",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/53\">",
"     53",
"    </a>",
"    ]. The incidence of severe neutropenia or death was much lower in the treated patients (10 versus 34 percent) who also had 31 percent fewer bacterial infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Epstein-Barr virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epstein-Barr virus (EBV) infection produces an acute sporadic infection called infectious mononucleosis (IM) that usually affects young adults. Clinical manifestations of IM include fever, severe pharyngitis, adenopathy, and splenomegaly.",
"   </p>",
"   <p>",
"    EBV infects B lymphocytes resulting in peripheral blood lymphocytosis with many \"atypical\" lymphocytes and antibodies against heterologous red cells and EBV. Antineutrophil antibodies may be seen during acute IM, resulting in either a transient PMN aggregation or severe neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]; the latter is more common in children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cytomegalovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) infection produces fever, sore throat, adenopathy, splenomegaly, and myalgias in otherwise healthy individuals. It is also a major cause of morbidity and mortality in patients with AIDS and in bone marrow or solid organ transplant recipients. The blood picture resembles IM except for the absence of IM-associated antibodies. Neutropenia is not part of uncomplicated CMV infection but can occur after the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or in disseminated disease in immunosuppressed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hepatitis virus group",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis A virus infection is associated with transient neutropenia and lymphopenia that usually occur during the second week of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/61\">",
"     61",
"    </a>",
"    ]. The hematologic manifestations can be severe and are independent of the severity of liver disease. Agranulocytosis has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutropenia can be seen in patients with chronic hepatitis B or C infection. It is usually related to the development of cirrhosis and hypersplenism, or treatment with interferon alfa [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aplastic anemia is a rare complication of hepatitis but may account for 2 to 5 percent of cases of aplastic anemia in the West [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The mechanism may involve T cell activation with release of cytokines. The disease most often affects boys and young men, with aplasia developing two to three months after an episode of acute hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/65\">",
"     65",
"    </a>",
"    ]. The responsible virus has not been identified; neither hepatitis A, B, C, nor G appears to be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/65,67\">",
"     65,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Human herpesvirus-6",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human herpesvirus-6 infection can cause leukopenia in association with roseola infantum in children or after organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In one report of four liver transplant recipients, severe cytopenia was seen in all patients with leukopenia being most prominent (mean",
"    <span class=\"nowrap\">",
"     1400/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Viral exanthematous diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukopenia and mild neutropenia and lymphopenia are common in infections with measles, rubella, and varicella.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Measles",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the incubation period in measles, there may be leukocytosis with a white blood cell count of 14,000 to",
"    <span class=\"nowrap\">",
"     19,000/microL",
"    </span>",
"    lasting three days before the onset of fever. This is followed by leukopenia during the week of cough, coryza, conjunctivitis, Koplik spots and rash [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/70\">",
"     70",
"    </a>",
"    ]. The mean ANC varies widely from 2000 to",
"    <span class=\"nowrap\">",
"     8000/microL",
"    </span>",
"    during the incubation period and falls to less than 500 to",
"    <span class=\"nowrap\">",
"     5000/microL",
"    </span>",
"    with the nadir occurring at the onset of the rash (",
"    <a class=\"graphic graphic_figure graphicRef65459 \" href=\"UTD.htm?12/6/12398\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Measles virus antigen is localized in circulating neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/71\">",
"     71",
"    </a>",
"    ] and neutrophil functions of chemotaxis and bacterial killing are impaired during active infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=see_link\">",
"     \"Neutrophil functions other than movement\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Live measles virus vaccine also results in transient decrease in white blood cell count from day 3 to day 16 after vaccination. Mild neutropenia is evident by day 8 when low grade fever occurs and returns to baseline two weeks after vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Rubella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia occurs in one-third to one-half of patients with Rubella and slowly recedes over six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/76\">",
"     76",
"    </a>",
"    ]. Changes in lymphocyte count are variable, ranging from lymphocytosis to, less often, lymphopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella infection is usually associated with mild leukocytosis and neutrophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/77\">",
"     77",
"    </a>",
"    ]. However, profound leukopenia and neutropenia of less than",
"    <span class=\"nowrap\">",
"     1000/microL",
"    </span>",
"    with an associated increase in band forms has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia can occur during the course of a number of other viral infections. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dengue fever virus, in which leukopenia, thrombocytopenia, and a hemorrhagic diathesis are the typical hematologic findings; a low white blood cell count is apparent early in the illness, reaching a nadir after seven days of fever and then returning to normal by the end of two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/79,80\">",
"       79,80",
"      </a>",
"      ]. A direct action of dengue virus on the bone marrow is thought to be responsible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=see_link\">",
"       \"Pathogenesis of dengue virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Colorado tick fever virus, in which leukopenia (1800 to",
"      <span class=\"nowrap\">",
"       3400/microL)",
"      </span>",
"      is the major laboratory finding [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/81\">",
"       81",
"      </a>",
"      ]. The differential shows increased band forms and occasional metamyelocytes and myelocytes, and bone marrow examination reveals depletion of the normal reserve of neutrophils, so called \"myeloid arrest.\" The virus infects human bone marrow hematopoietic progenitor cells and the leukopenia is thought to reflect a direct toxic action on the marrow [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/82,83\">",
"       82,83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Yellow fever, in which neutropenia occurs during the first week of infection.",
"     </li>",
"     <li>",
"      Phlebotomus fever virus, in which an initial leukopenia is followed by a protracted neutropenia [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10473/abstract/84,85\">",
"       84,85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/59/25521?source=see_link\">",
"       \"Patient information: Neutropenia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13221343\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial infections ��� Leukocytosis with an increased number of band forms (ie, a shift to the left) is the usual response to bacterial infection. Certain infections such as typhoid fever, Shigella enteritis, brucellosis, tularemia, and tuberculosis are often associated with neutropenia. Hypersplenism, hemophagocytosis by marrow macrophages, and granulomatous lesions of the bone marrow contribute to the development of these abnormalities. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Bacterial infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parasitic infestation ��� Both Kala-Azar and malaria can be associated with neutropenia, often secondary to sequestration of neutrophils within an enlarged spleen. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Parasitic infestation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rickettsial infection ��� Neutropenia is common in rickettsialpox and human ehrlichiosis and is also seen in severe cases of Rocky Mountain spotted fever. Peripheral destruction appears to be the most common mechanism. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Rickettsial infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Viral infection ��� Neutropenia can be seen in a large number of viral infections. The mechanisms differ widely, and include antineutrophil antibodies, hypersplenism, infection-induced bone marrow suppression or aplasia, and toxicity of the drugs used to fight the infection. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Viral infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/1\">",
"      Abdool Gaffar MS, Seedat YK, Coovadia YM, Khan Q. The white cell count in typhoid fever. Trop Geogr Med 1992; 44:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/2\">",
"      James J, Dutta TK, Jayanthi S. Correlation of clinical and hematologic profiles with bone marrow responses in typhoid fever. Am J Trop Med Hyg 1997; 57:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/3\">",
"      Mallouh AA, Sa'di AR. White blood cells and bone marrow in typhoid fever. Pediatr Infect Dis J 1987; 6:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/4\">",
"      Shin BM, Paik IK, Cho HI. Bone marrow pathology of culture proven typhoid fever. J Korean Med Sci 1994; 9:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/5\">",
"      Sood R, Roy S, Kaushik P. Typhoid fever with severe pancytopenia. Postgrad Med J 1997; 73:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/6\">",
"      Suyasa IG, Reka IG, Inada K, et al. Plasma endotoxin in typhoid fever. Kobe J Med Sci 1995; 41:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/7\">",
"      Keuter M, Dharmana E, Kullberg BJ, et al. Phospholipase A2 is a circulating mediator in typhoid fever. J Infect Dis 1995; 172:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/8\">",
"      Netea MG, Drenth JP, De Bont N, et al. A semi-quantitative reverse transcriptase polymerase chain reaction method for measurement of MRNA for TNF-alpha and IL-1 beta in whole blood cultures: its application in typhoid fever and exentric exercise. Cytokine 1996; 8:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/9\">",
"      Keuter M, Dharmana E, Gasem MH, et al. Patterns of proinflammatory cytokines and inhibitors during typhoid fever. J Infect Dis 1994; 169:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/10\">",
"      Butler T, Ho M, Acharya G, et al. Interleukin-6, gamma interferon, and tumor necrosis factor receptors in typhoid fever related to outcome of antimicrobial therapy. Antimicrob Agents Chemother 1993; 37:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/11\">",
"      Fried D, Maytal J, Hanukoglu A. The differential leukocyte count in shigellosis. Infection 1982; 10:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/12\">",
"      Halpern Z, Averbuch M, Dan M, et al. The differential leukocyte count in adults with acute gastroenteritis. Scand J Infect Dis 1992; 24:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/13\">",
"      Witkowska D, Czarny A, Mulczyk M. Some biological properties of outer membrane proteins of Shigella. Arch Immunol Ther Exp (Warsz) 1987; 35:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/14\">",
"      Azim T, Islam LN, Halder RC, et al. Peripheral blood neutrophil responses in children with shigellosis. Clin Diagn Lab Immunol 1995; 2:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/15\">",
"      al-Eissa Y, al-Nasser M. Haematological manifestations of childhood brucellosis. Infection 1993; 21:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/16\">",
"      Crosby E, Llosa L, Miro Quesada M, et al. Hematologic changes in brucellosis. J Infect Dis 1984; 150:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/17\">",
"      Galanakis E, Bourantas KL, Leveidiotou S, Lapatsanis PD. Childhood brucellosis in north-western Greece: a retrospective analysis. Eur J Pediatr 1996; 155:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/18\">",
"      al-Eissa YA, Assuhaimi SA, al-Fawaz IM, et al. Pancytopenia in children with brucellosis: clinical manifestations and bone marrow findings. Acta Haematol 1993; 89:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/19\">",
"      Gotuzzo E, Carrillo C, Guerra J, Llosa L. An evaluation of diagnostic methods for brucellosis--the value of bone marrow culture. J Infect Dis 1986; 153:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/20\">",
"      Kokkini G, Giotaki HG, Moutsopoulos HM. Transient hemophagocytosis in Brucella melitensis infection. Arch Pathol Lab Med 1984; 108:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/21\">",
"      Cheers C, Young AM. Serum colony stimulating activity and colony forming cells in murine brucellosis: relationship to immunopathology. Microb Pathog 1987; 3:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/22\">",
"      Palomera Bernal L, Garc&iacute;a D&iacute;ez I, Barbudo Merino A, et al. [The reactive hemophagocytic syndrome associated with infection: a study of 3 cases]. An Med Interna 1990; 7:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/23\">",
"      Pullen RL, Stuart BM. Tularemia. JAMA 1945; 129:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/24\">",
"      Syrj&auml;l&auml; H. Peripheral blood leukocyte counts, erythrocyte sedimentation rate and C-reactive protein in tularemia caused by the type B strain of Francisella tularensis. Infection 1986; 14:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/25\">",
"      Sj&ouml;stedt A, Conlan JW, North RJ. Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection. Infect Immun 1994; 62:2779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/26\">",
"      Maartens G, Willcox PA, Benatar SR. Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. Am J Med 1990; 89:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/27\">",
"      Boz&oacute;ky G, Ruby E, G&oacute;h&eacute;r I, et al. [Hematologic abnormalities in pulmonary tuberculosiss]. Orv Hetil 1997; 138:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/28\">",
"      Musumeci S, D'Agata A, Schiliro G, Fischer A. Studies of the neutropenia in kala-azar: results in two patients. Trans R Soc Trop Med Hyg 1976; 70:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/29\">",
"      Rai ME, Muhammad Z, Sarwar J, Qureshi AM. Haematological findings in relation to clinical findings of visceral Leishmaniasis in Hazara Division. J Ayub Med Coll Abbottabad 2008; 20:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/30\">",
"      Pollack S, Nagler A, Liberman D, et al. Immunological studies of pancytopenia in visceral leishmaniasis. Isr J Med Sci 1988; 24:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/31\">",
"      Marwaha N, Sarode R, Gupta RK, et al. Clinico-hematological characteristics in patients with kala azar. A study from north-west India. Trop Geogr Med 1991; 43:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/32\">",
"      Benjamin B, Annobil SH, Bassuni WA. Diagnostic and management problems in childhood visceral leishmaniasis in south-western Saudi Arabia. Ann Trop Paediatr 1994; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/33\">",
"      Sinha R, Datta U, Sehgal S. Importance of bone marrow culture for diagnosis of Kala azar. Scand J Infect Dis 1993; 25:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/34\">",
"      Wickramasinghe SN, Abdalla SH, Kasili EG. Ultrastructure of bone marrow in patients with visceral leishmaniasis. J Clin Pathol 1987; 40:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/35\">",
"      Badar&oacute; R, Nascimento C, Carvalho JS, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J Infect Dis 1994; 170:413.",
"     </a>",
"    </li>",
"    <li>",
"     Weatherall DJ, Kwiatkowski D. Hematologic manifestations of systemic diseases in children of the developing world. In: Hematology of Infancy and Childhood, 5th ed, Nathan D, Orkin (Eds), WB Saunders, Philadelphia  p.1902.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/37\">",
"      Olliaro P, Djimd&eacute; A, Dorsey G, et al. Hematologic parameters in pediatric uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Am J Trop Med Hyg 2011; 85:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/38\">",
"      Dale DC, Wolff SM. Studies of the neutropenia of acute malaria. Blood 1973; 41:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/39\">",
"      Senaldi G, Vesin C, Chang R, et al. Role of polymorphonuclear neutrophil leukocytes and their integrin CD11a (LFA-1) in the pathogenesis of severe murine malaria. Infect Immun 1994; 62:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/40\">",
"      ROSE HM. The clinical manifestations and laboratory diagnosis of rickettsialpox. Ann Intern Med 1949; 31:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/41\">",
"      Bakken JS, Krueth J, Wilson-Nordskog C, et al. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 1996; 275:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/42\">",
"      Fritz CL, Glaser CA. Ehrlichiosis. Infect Dis Clin North Am 1998; 12:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/43\">",
"      Klein MB, Hayes SF, Goodman JL. Monocytic differentiation inhibits infection and granulocytic differentiation potentiates infection by the agent of human granulocytic ehrlichiosis. Infect Immun 1998; 66:3410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/44\">",
"      Hall GW, Schwartz RP. White blood cell count and differential in Rocky Mountain spotted fever. N C Med J 1979; 40:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/45\">",
"      Segel GB, Halterman JS. Neutropenia in pediatric practice. Pediatr Rev 2008; 29:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/46\">",
"      Zon LI, Arkin C, Groopman JE. Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol 1987; 66:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/47\">",
"      Jacobson MA, Liu RC, Davies D, Cohen PT. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection. Arch Intern Med 1997; 157:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/48\">",
"      Moore RD, Keruly JC, Chaisson RE. Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arch Intern Med 1995; 155:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/49\">",
"      Murphy MF, Metcalfe P, Waters AH, et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol 1987; 66:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/50\">",
"      Ribera E, Oca&ntilde;a I, Almirante B, et al. Autoimmune neutropenia and thrombocytopenia associated with development of antibodies to human immunodeficiency virus. J Infect 1989; 18:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/51\">",
"      Perkocha LA, Rodgers GM. Hematologic aspects of human immunodeficiency virus infection: laboratory and clinical considerations. Am J Hematol 1988; 29:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/52\">",
"      Scadden DT, Bering HA, Levine JD, et al. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol 1991; 9:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/53\">",
"      Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS 1998; 12:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/54\">",
"      Manfredi R, Mastroianni A, Coronado O, Chiodo F. Recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in leukopenic patients with advanced HIV disease. J Chemother 1996; 8:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/55\">",
"      Schooley RT, Densen P, Harmon D, et al. Antineutrophil antibodies in infectious mononucleosis. Am J Med 1984; 76:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/56\">",
"      Guibaud S, Plumet-Leger A, Frobert Y. Transient neutrophil aggregation in a patient with infectious mononucleosis. Am J Clin Pathol 1983; 80:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/57\">",
"      Sumaya CV, Ench Y. Epstein-Barr virus infectious mononucleosis in children. II. Heterophil antibody and viral-specific responses. Pediatrics 1985; 75:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/58\">",
"      Roberts WD, Weinberg KI, Kohn DB, et al. Granulocyte recovery in pediatric marrow transplant recipients treated with ganciclovir for cytomegalovirus infection. Am J Pediatr Hematol Oncol 1993; 15:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/59\">",
"      Salzberger B, Bowden RA, Hackman RC, et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997; 90:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/60\">",
"      Farrugia E, Schwab TR. Management and prevention of cytomegalovirus infection after renal transplantation. Mayo Clin Proc 1992; 67:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/61\">",
"      HAVENS WP Jr, MARCK RE. The leukocytic response of patients with experimentally induced infectious hepatitis. Am J Med Sci 1946; 212:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/62\">",
"      Nagaraju M, Weitzman S, Baumann G. Viral hepatitis and agranulocytosis. Am J Dig Dis 1973; 18:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/63\">",
"      Rakela J, Wood JR, Czaja AJ, et al. Long-term versus short-term treatment with recombinant interferon alfa-2a in patients with chronic hepatitis B: a prospective, randomized treatment trial. Mayo Clin Proc 1990; 65:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/64\">",
"      Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26:112S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/65\">",
"      Brown KE, Tisdale J, Barrett AJ, et al. Hepatitis-associated aplastic anemia. N Engl J Med 1997; 336:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/66\">",
"      Mary JY, Baumelou E, Guiguet M. Epidemiology of aplastic anemia in France: a prospective multicentric study. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood 1990; 75:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/67\">",
"      Issaragrisil S, Kaufman D, Thongput A, et al. Association of seropositivity for hepatitis viruses and aplastic anemia in Thailand. Hepatology 1997; 25:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/68\">",
"      Linnavuori K, Peltola H, Hovi T. Serology versus clinical signs or symptoms and main laboratory findings in the diagnosis of exanthema subitum (roseola infantum). Pediatrics 1992; 89:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/69\">",
"      Singh N, Carrigan DR, Gayowski T, Marino IR. Human herpesvirus-6 infection in liver transplant recipients: documentation of pathogenicity. Transplantation 1997; 64:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/70\">",
"      Benjamin B, Ward SM. Leukocytic response to measles. Am J Dis Child 1932; 44:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/71\">",
"      Abramowitz A, Tamir I, Livni N, et al. Polymorphonuclear leukocyte-associated antigenemia in measles: demonstration and significance. J Med Virol 1984; 13:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/72\">",
"      Yetgin S, Altay C. Defective bactericidal function of polymorphonuclear neutrophils in children with measles. Acta Paediatr Scand 1980; 69:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/73\">",
"      Thatte UM, Gangal PS, Kulkarni MR, et al. Polymorphonuclear and monocyte functions in measles. J Trop Pediatr 1991; 37:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/74\">",
"      Anderson R, Rabson AR, Sher R, Koornhof HJ. Defective neutrophil motility in children with measles. J Pediatr 1976; 89:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/75\">",
"      Black FL, Sheridan SR. Blood leukocyte response to live measles vaccine. Am J Dis Child 1967; 113:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/76\">",
"      HILLENBRAND FK. The blood picture in rubella; its place in diagnosis. Lancet 1956; 271:66.",
"     </a>",
"    </li>",
"    <li>",
"     Arvin AM. Varicella-Zoster virus. In: Nelson Textbook of Pediatrics, 15th ed, Behman RE, Kliegman RM, Arvin AM (Eds), WB Saunders, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/78\">",
"      Koumbourlis AC, Heldrich FJ. Varicella infection with profound neutropenia, multisystem involvement and no sequelae. Pediatr Infect Dis J 1988; 7:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/79\">",
"      Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997; 176:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/80\">",
"      Halstead SB. Dengue: hematologic aspects. Semin Hematol 1982; 19:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/81\">",
"      JOHNSON ES, NAPOLI VM, WHITE WC. Colorado tick fever as a hematologic problem. Am J Clin Pathol 1960; 34:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/82\">",
"      Philipp CS, Callaway C, Chu MC, et al. Replication of Colorado tick fever virus within human hematopoietic progenitor cells. J Virol 1993; 67:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/83\">",
"      Oshiro LS, Dondero DV, Emmons RW, Lennette EH. The development of Colorado tick fever virus within cells of the haemopoietic system. J Gen Virol 1978; 39:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/84\">",
"      Bartelloni PJ, Tesh RB. Clinical and serologic responses of volunteers infected with phlebotomus fever virus (Sicilian type). Am J Trop Med Hyg 1976; 25:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10473/abstract/85\">",
"      Sabin AB, et al. Phlebotomus (pappataci or sandfly) liver. JAMA 1944; 125:603.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8372 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10473=[""].join("\n");
var outline_f10_14_10473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13221343\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1155994\">",
"      DEFINITIONS AND INFECTIOUS RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACTERIAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Shigella enteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Brucellosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tularemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PARASITIC INFESTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Kala azar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RICKETTSIAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      VIRAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4002046\">",
"      Common childhood viral infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Human immunodeficiency virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Epstein-Barr virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hepatitis virus group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Human herpesvirus-6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Viral exanthematous diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Measles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Rubella",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Varicella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13221343\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8372\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8372|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/62/11246\" title=\"figure 1\">",
"      Hospitalization for neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/6/12398\" title=\"figure 2\">",
"      Neutrophil count in measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8372|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/19/10555\" title=\"table 1\">",
"      Neutropenia and infectious risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23525?source=related_link\">",
"      Biology of ehrlichiae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=related_link\">",
"      Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=related_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=related_link\">",
"      Diagnostic approach to the adult presenting with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=related_link\">",
"      Evaluation and management of fever in children with non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to systemic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44039?source=related_link\">",
"      Hematologic manifestations of HIV infection: Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=related_link\">",
"      Neutrophil functions other than movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=related_link\">",
"      Normal neutrophil development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4394?source=related_link\">",
"      Overview of non-falciparum malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=related_link\">",
"      Pathogenesis of dengue virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/59/25521?source=related_link\">",
"      Patient information: Neutropenia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=related_link\">",
"      Risk assessment of adults with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=related_link\">",
"      Risk of infection in children with fever and non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_14_10474="Screening for ovarian cancer";
var content_f10_14_10474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for ovarian cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/14/10474/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/14/10474/contributors\">",
"     Karen J Carlson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/14/10474/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/14/10474/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/14/10474/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/14/10474/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/14/10474/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/14/10474/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian cancer is the leading cause of death from gynecologic malignancy in the United States. Approximately 22,240 cases are expected to be diagnosed in the United States in 2013 with an expected 14,030 deaths attributable to ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/1\">",
"     1",
"    </a>",
"    ]. The lifetime probability of a woman in the US developing ovarian cancer is less than 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/2\">",
"     2",
"    </a>",
"    ]. Worldwide in 2008, ovarian cancer was the seventh most common cancer in women, and incidence rates are highest in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/3\">",
"     3",
"    </a>",
"    ]. There were 225,500 new cases of ovarian cancer worldwide. The incidence of ovarian cancer increases with age; the highest proportion of cases are diagnosed in women 50 to 59 years of age.",
"   </p>",
"   <p>",
"    Interest in early detection as a method of reducing mortality has grown with the discovery of serum tumor markers associated with ovarian malignancies (particularly CA 125) and with improved diagnostic accuracy of pelvic ultrasonography. Intensive research is ongoing to identify additional markers and a cost-effective screening strategy. One large-scale prospective clinical screening trial found that screening did not reduce mortality from ovarian cancer but did result in harm from consequent follow-up; two other large trials are in progress to determine whether screening by blood tests",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ultrasound reduces mortality from ovarian cancer. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Multimodal screening'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    There is a consensus that women at average risk for ovarian cancer should NOT undergo screening. Despite evidence to the contrary, a cross-sectional survey of physicians in the US found that one in three believed that screening for ovarian cancer was effective and commonly offered testing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with a family history of ovarian cancer or familial ovarian cancer syndromes are at higher risk of the disease. Evidence suggests screening is appropriate for some of these women. Screening recommendations for higher-risk women depend on whether or not there is a known or suspected hereditary cancer syndrome.",
"   </p>",
"   <p>",
"    This topic will review the risks and benefits of screening for ovarian cancer in asymptomatic women. The issue of testing for ovarian cancer in women with nonspecific symptoms that may be associated with ovarian cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=see_link\">",
"     \"Early detection of epithelial ovarian cancer: Role of symptom recognition\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additionally, the clinical manifestations of epithelial ovarian cancer, epidemiology and risk factors for ovarian cancer, and surveillance for patients who have been treated for ovarian cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"     \"Epithelial ovarian cancer: Pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25847?source=see_link\">",
"     \"Epithelial ovarian cancer: Second look surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOLOGICAL BASIS FOR SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival from ovarian cancer is related to the stage at diagnosis; five-year survival is over 90 percent for the minority of women with stage I disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/5\">",
"     5",
"    </a>",
"    ]. This number drops to about 75 to 80 percent for regional disease and 25 percent for those with distant metastases.",
"   </p>",
"   <p>",
"    Despite the good prognosis associated with early stage disease, overall five-year survival in women with ovarian cancer is less than 45 percent. This poor survival rate in large part is due to the spread of cancer beyond the ovary at the time of clinical detection in 75 percent of patients. Mortality from ovarian cancer has decreased only slightly in the past 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little is known about the mechanism or timing of progression from localized to disseminated ovarian cancer. The model of unifocal disease progressing to diffuse disease is plausible. However, ovarian cancer also may develop from multiple foci within the abdomen since carcinomatosis can develop even after the removal of normal ovaries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/6\">",
"     6",
"    </a>",
"    ]. Additionally, it has been proposed that a substantial number of ovarian cancers may be multifocal and extra-ovarian at their earliest recognizable state so that early detection efforts focused only on the ovary may miss many tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ninety percent of ovarian malignancies are epithelial tumors (including serous, mucinous, endometrioid, and clear cell tumors); the remainder arise from germ cell and other tissues. A subgroup of epithelial tumors, known as \"borderline tumors\" or \"cystadenomas of low malignant potential,\" have a more favorable prognosis. Benign cystadenomas, another subgroup of epithelial tumors, have a low rate of malignant transformation. The benefit of identifying asymptomatic benign cystadenomas is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of women at high risk for ovarian cancer may help to select a group that would most benefit from screening strategies. A number of risk factors for ovarian cancer have been identified (",
"    <a class=\"graphic graphic_table graphicRef59585 \" href=\"UTD.htm?11/59/12221\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"     \"Epithelial ovarian cancer: Pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetic predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strongest known risk factor for ovarian cancer is a family history, which is present in about 10 to 15 percent of women who develop the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/8\">",
"     8",
"    </a>",
"    ]. When a woman reports that one or more family members has had ovarian cancer, it is important to differentiate the relatively rare occurrence of a \"familial ovarian cancer syndrome\" from the more common \"family history of ovarian cancer\" describing families with isolated members who have had ovarian cancer and no evidence of a hereditary pattern.",
"   </p>",
"   <p>",
"    The risk of ovarian cancer is increased when the family history suggests a sporadic case but is substantially greater when there is a hereditary cancer syndrome. A meta-analysis of pooled case-control studies calculated an odds ratio of 3.1 for developing ovarian cancer in women with one first- or second-degree relative with the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/8\">",
"     8",
"    </a>",
"    ]. Based upon these data, it was estimated that a family history of ovarian cancer in one relative increased the lifetime probability of ovarian cancer in a 35-year-old woman from 1.6 to 5.0 percent. In contrast, women with hereditary ovarian cancer syndromes have a lifetime probability of ovarian cancer of 25 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With wider availability of genetic testing, the identification of women with possible hereditary cancer syndromes has become increasingly important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Familial ovarian cancer syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clues to the presence of a hereditary cancer syndrome include the presentation of ovarian cancer in a first- or second-degree family member (both maternal and paternal lineage) at an early age (under 50 years) or the occurrence of ovarian or related cancers in multiple members (ie, two to four generations) (",
"    <a class=\"graphic graphic_table graphicRef57434 \" href=\"UTD.htm?27/17/27931\">",
"     table 2",
"    </a>",
"    ). A small family size may mask the presence of a hereditable disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"     \"Epithelial ovarian cancer: Pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Familial ovarian cancer syndromes are uncommon, accounting for 5 to 10 percent of ovarian cancer cases in most series [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These hereditary syndromes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Lynch II syndrome (cancers of the colon, breast, endometrium, and ovary with hereditary nonpolyposis colorectal cancer or HNPCC)",
"     </li>",
"     <li>",
"      Breast-ovarian cancer syndrome (usually associated with a BRCA1 or BRCA2 mutation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lynch syndrome, also called hereditary nonpolyposis colorectal cancer (HNPCC), is associated with cancer diagnosis at an early age and the development of multiple cancer types, particularly colon and endometrial cancer. Women with Lynch syndrome have a lifetime risk of ovarian cancer that is 3 to 14 percent (compared with 1.8 percent in the general population) and develop ovarian cancer at an earlier age than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The breast-ovarian cancer syndrome is the most common hereditary ovarian syndrome. Most of these families have germ-line mutations in one of the breast cancer susceptibility genes, BRCA1 or BRCA2. In the United States, carriers of BRCA mutations are rare in the general population (1 in 300 or fewer), but among persons of Ashkenazi Jewish descent the prevalence is estimated to be 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absolute risk of developing ovarian cancer over a lifetime associated with the presence of a BRCA1 mutation is 35 to 45 percent, while it is less for those with BRCA2 mutations (15 to 25 percent) (",
"    <a class=\"graphic graphic_table graphicRef68548 \" href=\"UTD.htm?7/40/7821\">",
"     table 3",
"    </a>",
"    ). This topic is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some experts suggest the threshold for suspecting a familial cancer should be lower in women of Ashkenazi Jewish descent (comprising the great majority of Jewish women in the United States), with consideration of genetic testing if there is a first- or second-degree family member with breast cancer before age 50 or with ovarian cancer at any age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to note, however, that BRCA mutations may not be limited to women with a strong family history. One study of 116 unselected women with ovarian cancer identified 10 women with BRCA1 mutations and a single BRCA2 mutation, which occurred in a patient also carrying a BRCA1 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/18\">",
"     18",
"    </a>",
"    ]. Over one-half of the women with BRCA1 mutations had unremarkable family histories. In addition, the majority of patients who had a family history that was suggestive of a hereditary cancer syndrome (maternal family history of breast or ovarian cancer) tested negative for BRCA gene mutations. BRCA dysfunction, distinct from the recognized germline mutations, also appears to be associated with ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]; however, the utility of testing for BRCA dysfunction has not been proven, and no such test is clinically available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of ovarian cancer increases with age. In women 50 to 75 years of age, the annual incidence is 50 per 100,000 (adjusted for prior oophorectomy), which is approximately twice the rate found in younger women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/21\">",
"     21",
"    </a>",
"    ]. The likelihood that a case of ovarian cancer is attributable to a gene mutation decreases with increasing age at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Reproductive and endocrine factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reproductive factors appear to affect the risk of ovarian cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"     \"Epithelial ovarian cancer: Pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of ovarian cancer appears to be decreased in women with a history of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Use of the oral contraceptive pill",
"     </li>",
"     <li>",
"      Breastfeeding",
"     </li>",
"     <li>",
"      Tubal ligation or hysterectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of ovarian cancer may be increased in patients with a history of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infertility",
"     </li>",
"     <li>",
"      Endometriosis",
"     </li>",
"     <li>",
"      Perimenopausal or postmenopausal hormone therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Large meta-analysis and cohort studies have found that fertility treatment does not independently increase ovarian cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RISKS AND BENEFITS OF SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential benefit of screening is its ability to identify ovarian cancer at a more localized and curable stage, leading to reduced mortality from the disease. Three large randomized controlled trials to determine whether screening for ovarian cancer, compared with no screening, can achieve earlier diagnosis and decreased mortality have been or are being conducted in the United Kingdom, Japan, and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Mortality data from the PLCO trial in the US have been reported and show no change in the stage of cancer detected by screening and no decrease in cancer-specific or overall mortality for women who underwent annual screening (four years of transvaginal ultrasound and six years of CA 125 serum levels) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Multimodal screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The potential risks associated with screening for ovarian cancer must also be considered. A positive screening result for ovarian cancer most often is followed by surgery (either laparoscopy or laparotomy). Invasive procedures are associated with physical and psychological morbidity, a small risk for serious complications, and substantial financial costs. The PLCO trial reported that 15 percent of women who underwent surgery for false positive findings experienced a serious complication related to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although ovarian cancer is an important cause of cancer death, its incidence and prevalence in the general population are relatively low. The problem of false-positive screening tests becomes critically important in diseases with low prevalence. Unless the test or sequence of tests is extremely accurate, a large number of healthy women would be at risk for unnecessary surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=see_link\">",
"     \"Evidence-based approach to prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SCREENING TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most experts feel that a screening protocol for ovarian cancer should have a positive predictive value of at least 10 percent (that is, no more than nine healthy women with false-positive screens would undergo unnecessary procedures for each case of ovarian cancer detected) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The predictive value of a screening test varies according to the prevalence of disease in the population being screened and the sensitivity and specificity of the screening test. Manipulations of these elements have been considered in efforts to design cost-effective screening programs. A screening program that targets all women over age 50 would require a test with a specificity of at least 99.6 percent (assuming a sensitivity of 80 percent) to achieve a positive predictive value of 10 percent.",
"   </p>",
"   <p>",
"    Ovarian tumors are occasionally detected during pelvic examination, although early stage tumors are rarely found due to the deep anatomic location of the ovary. Thus, tumors detected by pelvic examination are usually at an advanced stage and associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/31\">",
"     31",
"    </a>",
"    ]. The Pap smear may occasionally reveal malignant ovarian cells, but its sensitivity for the detection of ovarian cancer is only 10 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tests that may be useful for screening in certain circumstances include measurement of the CA 125 tumor marker or other serologic markers, ultrasonography, and combinations of these modalities. Image-based screening by CT scanning is unlikely to be effective in diagnosing presymptomatic early disease; in one study of incidental adnexal masses detected during screening CT colonography in 2869 women, no ovarian cancers were identified in the 70 women who underwent workup for abnormal CT findings, but four cases of ovarian cancer were diagnosed over the next four years among 2751 women whose initial CT was normal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, the radiation exposure associated with CT scanning is significant and itself potentially oncogenic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor markers have received considerable interest as possible screening tests because they are non-invasive, easily repeated over time, and relatively inexpensive compared to imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     CA 125",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the serum concentration of the CA 125 glycoprotein antigen is the most widely studied biochemical method of screening for ovarian cancer. Serum CA 125 values are elevated in approximately 50 percent of women with early stage disease and in over 80 percent of women with advanced ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the specificity of CA 125 is limited. CA 125 levels are elevated in approximately 1 percent of healthy women and fluctuate during the menstrual cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/33\">",
"     33",
"    </a>",
"    ]. CA 125 is also increased in a variety of benign and malignant conditions, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endometriosis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Uterine leiomyoma",
"     </li>",
"     <li>",
"      Cirrhosis with or without ascites [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pelvic inflammatory disease",
"     </li>",
"     <li>",
"      Cancers of the endometrium, breast, lung, and pancreas [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pleural or peritoneal fluid due to any cause [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mean CA 125 levels further vary with ethnicity and smoking status (lower in non-white women and current smokers) and increase with age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonetheless, a prospective study of asymptomatic postmenopausal women found that an elevated CA 125 concentration (&ge;30",
"    <span class=\"nowrap\">",
"     U/mL)",
"    </span>",
"    was a powerful predictor of subsequent ovarian cancer risk (RR 35.9 at one year and 14.3 at five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of CA 125 in screening for ovarian cancer have focused upon postmenopausal women, since menstrual cycle variations and the prevalence of benign gynecologic conditions in premenopausal women would result in a substantially higher likelihood of false-positive tests. Accumulated evidence suggests that annual CA 125 measurements alone lack sufficient specificity for use in an average-risk population of postmenopausal women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three large screening studies in Sweden and England showed that the specificity of a single CA 125 level for detection of ovarian neoplasms in postmenopausal women ranged from 98.6 to 99.4 percent, resulting in an unacceptably low positive predictive value of 3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/41-43\">",
"       41-43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A more definitive assessment of annual screening with CA 125 and its impact on cancer mortality in a randomized controlled trial was conducted as a component of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) trial [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/44\">",
"       44",
"      </a>",
"      ]. In the ovarian component of PLCO, 78,237 healthy women between 55 and 74 years of age were randomly assigned to screening and control groups; 39,115 women were assigned to screening with annual CA 125 and annual transvaginal ultrasound. Data from the baseline prevalence screen in 28,816 women found an abnormal CA 125 in 436 women (1.5 percent); the positive predictive value for invasive cancer was 3.7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/45\">",
"       45",
"      </a>",
"      ]. At four years of follow-up, the positivity rates of CA 125 remained essentially unchanged from baseline and the positive predictive value was 2.6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The change in CA 125 levels over time appears to be a more promising screening method. A large prospective study in 9233 postmenopausal women, with measurements of CA 125 at two or more times, used a modeling method to estimate risk of ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/47\">",
"     47",
"    </a>",
"    ]. The model incorporates age-specific incidence of cancer, absolute CA 125 level, and rate of change over time. Compared with a specific cutoff value of CA 125, the model improved sensitivity for detection of ovarian cancer from 62 to 86 percent when specificity was fixed at 98 percent. The ongoing randomized trial of screening in the UK uses this algorithm (the Risk of Ovarian Cancer Algorithm) to define an abnormal CA 125 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other biomarkers have been investigated for early detection of ovarian cancer. Studies are ongoing to evaluate combinations of bio-markers complementary to CA 125 that could offer greater sensitivity and specificity than CA 125 alone. Examples of these studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human Epididymis Protein 4 (HE4) appears to have similar sensitivity to CA 125 when comparing serum from ovarian cancer cases to healthy controls, and a higher sensitivity when comparing ovarian cancer cases to benign gynecologic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. In a study of 531 women with pelvic masses, an algorithm using HE4 and CA 125 correctly classified 93.8 percent of cases of epithelial ovarian cancer as high risk [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/51\">",
"       51",
"      </a>",
"      ]. A commercial assay for serum HE4 is available (the Architect HE4 Test, Abbott Laboratories). However, at least in the United States, this assay is approved for monitoring women with ovarian cancer for disease recurrence or progression, but not for screening. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H32#H32\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Posttreatment surveillance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      One study evaluated serum biomarkers using multiplex immunoassays in 2031 healthy women and 1067 women with early and late stage ovarian cancers, benign pelvic tumors, or breast, colorectal, or lung cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/52\">",
"       52",
"      </a>",
"      ]. A four-marker panel (CA 125, HE4, CEA, and VCAM-1) had the highest diagnostic power, with 86 percent sensitivity for early-stage ovarian cancer at 98 percent specificity. These results, while requiring validation, suggest that combinations of biomarkers may provide improved detection as the first step in a multimodal screening protocol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To determine the potential benefit of biomarkers for screening, however, it is important that they be able to discriminate disease before it is clinically diagnosed. Two studies have evaluated newer biomarker panels in serum collected prediagnostically from women who participated in longitudinal cohorts and subsequently developed ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. In a case-control study nested within a randomized lung cancer prevention trial in smokers, tumor markers in stored serum samples were compared between 70 case-matched controls and 34 women who developed ovarian cancer after the trial onset [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/53\">",
"     53",
"    </a>",
"    ]. Three tumor markers (CA 125, mesothelin, and HE4) began to increase three years before the diagnosis of ovarian cancer. CA 125 was most strongly predictive of ovarian cancer, with evidence for some incremental contribution of HE4 and mesothelin to risk prediction. In samples of serum collected from women participating in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, prediagnostic sera from 118 women who subsequently were diagnosed with ovarian cancer were compared with sera from 951 age-matched controls (one-fourth at increased risk due to family history) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/54\">",
"     54",
"    </a>",
"    ]. CA 125 levels were elevated in 61.5 percent of women who were diagnosed with ovarian cancer within the subsequent 12 months; testing with a panel of seven additional biomarkers did not improve the sensitivity of CA 125 alone for preclinical diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ovarian cancer symptom index",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ovarian symptom index has been developed and proposed for screening purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/55\">",
"     55",
"    </a>",
"    ]. The index is considered to be positive in women who report pelvic or abdominal pain, bloating, increased abdominal size, difficulty eating or early satiety occurring more than 12 times a month, with symptoms present for less than one year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=see_link\">",
"     \"Early detection of epithelial ovarian cancer: Role of symptom recognition\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 254 healthy women at high risk for ovarian cancer, and 75 women with ovarian cancer, the combination of symptom index and CA 125 identified more women with cancer than CA 125 alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/55\">",
"     55",
"    </a>",
"    ]. However, the symptom index was positive in 12 percent of high-risk women who did not have ovarian cancer, and thus specificity was low. A case control study, comparing retrospective reports of symptoms in women with ovarian cancer and women in the general population, found a very low positive predictive value for the symptom index (&lt;0.5 percent for early stage disease and &lt;1.1 percent overall), reflecting the low prevalence of ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study in 211 high-risk women found that the combination of the symptom index, CA 125 and HE4 serum markers as a first-line screen had a sensitivity of 83.8 percent and specificity of 98.5 percent when two of the three tests were positive [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If used for screening, a positive symptom index should lead to transvaginal ultrasonography before surgical referral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pelvic ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transabdominal and transvaginal ultrasonography have been evaluated as potential first-line screening methods for ovarian cancer. Transvaginal ultrasonography (TVUS) allows better visualization of the ovaries (independent of body habitus) and shorter examination times.",
"   </p>",
"   <p>",
"    The upper limit of ovarian volume is considered to be 20 cc in premenopausal women and 10 cc in postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/58\">",
"     58",
"    </a>",
"    ]. In addition to size, morphologic characteristics (presence of septae or cyst wall irregularity) are considered in the interpretation of an ultrasound study. There is disagreement about whether the addition of Doppler imaging to ultrasonography improves diagnostic accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity of ultrasonography is in part observer-dependent and has ranged from 80 to 100 percent in studies of women with clinically detected ovarian cancer and in several prospective screening studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/9\">",
"     9",
"    </a>",
"    ]. The test's specificity has ranged from 94 to 99 percent in screening studies, including two studies of women with a family history of ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In screening studies in women at high risk of ovarian cancer, ultrasonography has performed poorly in detecting early-stage epithelial ovarian cancer. In the National Ovarian Cancer Early Detection Program, 4526 women at high risk for ovarian cancer (based on a personal or family history of ovarian or breast cancer, other cancer syndromes, or the presence of a BRCA mutation) were screened with ultrasonography scans starting in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/63\">",
"     63",
"    </a>",
"    ]. After 12,709 scans were performed, all ovarian, peritoneal, and fallopian tubal cancers detected by ultrasonography during the screening period were stage III; no early stage disease was identified.",
"   </p>",
"   <p>",
"    Other studies of screening with ultrasonography in women at lower risk have shown somewhat more favorable results. It is possible that ultrasonography may be more effective in identifying early-stage disease in lower-risk women than in women with hereditary cancer syndromes. Findings to date include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large prospective study from the University of Kentucky evaluated annual transvaginal ultrasonography in 37,293 asymptomatic women aged 50 and older or aged 25 and older with a documented family history of ovarian cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/64\">",
"       64",
"      </a>",
"      ]. The study began in 1987, with follow-up ranging from a few months to 20 years (mean 5.8 years). The protocol evolved over time so that unilocular ovarian cysts &lt;10 cm in women with a normal serum CA 125 were considered to be a normal study as of 2006; multilocular cysts with a normal CA 125 were considered to be a normal finding as of 2009. The specificity and positive predictive value for primary invasive epithelial ovarian cancer were 98.5 and 8.9 percent respectively; 11.1 operations were performed per primary ovarian cancer detected. Seventy percent of the 47 screen-detected invasive cancers were stage I or II. The five-year survival rate for women with screen-detected invasive ovarian cancer was 84.6 percent compared with 53.7 percent for ovarian cancers in unscreened women at the same institution; whether this difference reflects a true mortality difference or biases related to nonrandomized studies (lead time, length time, and healthy volunteer effects) cannot be determined. Additionally, these results reflect findings from a center with high expertise in ultrasound and are not likely to be reproducible in the general community.",
"     </li>",
"     <li>",
"      In the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), the largest study to date, 48,230 women aged 50 to 74 years were randomly assigned to screening with annual TVUS as one arm of a randomized trial comparing multimodal screening (MMS), TVUS, and no screening [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/25\">",
"       25",
"      </a>",
"      ]. Prevalence (initial) screening from this study found 45 primary ovarian and tubal cancers in the TVUS group; 20 tumors were borderline, and 12 of the 25 invasive cancers were stage I or II. The sensitivity, specificity, and positive predictive value were 84.9, 98.2, and 5.3 percent respectively for all primary ovarian and tubal cancers and 75, 98.2, and 2.8 percent for primary invasive cancer. Additional testing was required in 12 percent (5779) of the TVUS participants and surgery was performed in 1.8 percent (845). Specificity was lower for TVUS compared to multimodal screening, resulting in nine times as many surgeries performed for the TVUS compared to the MMS group to detect one cancer. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Multimodal screening'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Multimodal screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three large randomized trials have evaluated combination screening with serum CA 125 and ultrasonography, either performed sequentially (ultrasound only if the CA 125 is elevated) or concurrently. One trial has reported final data [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/27\">",
"     27",
"    </a>",
"    ] and two are ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One component of the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) trial in the United States evaluated cancer mortality as the primary outcome in 68,557 postmenopausal women (aged 55 to 74 years) who had been randomly assigned to receive screening with both CA 125 and transvaginal ultrasound or usual care from their health care practitioner [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/27,45\">",
"       27,45",
"      </a>",
"      ]. Secondary outcomes were incidence of ovarian cancer, cancer stage at diagnosis, complications from screening, and all-cause mortality.",
"      <br/>",
"      <br/>",
"      At baseline the prevalence (initial) screening of 28,816 women found 1740 with either an abnormal CA 125 or ultrasound, and 34 had both [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/45\">",
"       45",
"      </a>",
"      ]. Nearly one in three women who had a positive screening test underwent surgery (at the discretion of their clinicians). Among 570 women who had surgery, 29 tumors were found, of which 20 were invasive (90 percent of these stage III or IV).",
"      <br/>",
"      <br/>",
"      Women in the intervention group received annual screening with CA 125 for six years and transvaginal ultrasound for four years. Management of abnormal test results was at the discretion of their usual clinician. Compliance with screening in the intervention group was 84 to 85 percent at baseline and declined modestly (78 to 79 percent at the fourth screening round, and 73 percent at the last round, which included only CA 125). Positive screening rates for CA 125 ranged from 1.4 to 1.8 percent during the six rounds and from 2.9 to 4.6 percent during the four ultrasound rounds. Subjects were followed for up to 13 years (median 12.4 years) and the trial was stopped prior to scheduled completion because the monitoring board determined futility.",
"      <br/>",
"      <br/>",
"      Ovarian cancer was detected in 212 women (5.7 per 10,000 person-years) in the screening group and 176 women (4.7 per 10,000 person-years) in the usual care group. There was no difference in the stage of ovarian cancer, with advanced disease (stage III or IV) in 77 percent of the cancers in the intervention group and 78 percent in the usual care group. Both the incidence of ovarian cancer and the mortality rate were nonsignificantly greater for women allocated to the intervention (rate ratios 1.21, 95% CI 0.99-1.48 and 1.18, CI 0.91-1.54, respectively). Excluding deaths from ovarian, colorectal, and lung cancer, all-cause mortality was similar in both groups (2924 intervention deaths and 2914 control deaths).",
"      <br/>",
"      <br/>",
"      False-positive results were found in 3285 women and 1080 underwent surgical follow-up. Fifteen percent of women who had surgery for a false-positive finding (166) experienced at least one serious complication. Thus, screening did not reduce mortality, and there was evidence that false-positive findings led to some harm. In addition, more cancers were diagnosed in the intervention group (212) than the usual care group (176), raising the possibility of overdiagnosis.",
"     </li>",
"     <li>",
"      The largest ongoing randomized trial, the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), is based on the results of earlier studies that led to the development of algorithmic guidelines to determine interpretation of CA 125 results and indications for ultrasonography [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/25,43,47,48,65\">",
"       25,43,47,48,65",
"      </a>",
"      ]. The trial randomly assigned 202,638 postmenopausal women aged 50 to 74 years to no screening, annual TVUS, or multimodal screening (MMS) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/25\">",
"       25",
"      </a>",
"      ]. The 50,640 patients in the MMS arm received annual screening with CA 125, followed by TVUS if abnormal, using an algorithmic guideline [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/48\">",
"       48",
"      </a>",
"      ]. Prevalence (initial) screening from this study found 42 primary ovarian and tubal cancers in the MMS group; 8 tumors were borderline and 16 of the 34 invasive cancers (47 percent) were stage I or II. The sensitivity, specificity, and positive predictive value were 89.4, 99.8, and 43.3 percent respectively for all primary ovarian and tubal cancers and 89.5, 99.8, and 35.1 percent for primary invasive cancer. Additional testing was required in 8.7 percent (4355) of the MMS participants and surgery was performed in 0.2 percent (97). Specificity was significantly greater for MMS compared to TVUS. Mortality data for this trial will be collected through 2014.",
"     </li>",
"     <li>",
"      In a randomized controlled trial of 83,000 postmenopausal women in Japan, 42,000 women were invited to participate in annual screening with pelvic ultrasound and CA 125 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/26\">",
"       26",
"      </a>",
"      ]. The control group in the same prefecture received usual care. There was no significant difference in the detection of ovarian cancer, at an average follow-up of 9.2 years, between patients who received screening (27 cases) and control patients (32 cases). There was a non-significant trend toward earlier-stage disease in the screened group. Thirty-three surgeries were performed to detect each case of ovarian cancer. Mortality data are not yet available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two ongoing and one completed randomized trials of screening using CA 125 and ultrasound show somewhat divergent preliminary findings. The UK trial's more favorable results on prevalence screening may reflect differences in trial design. The UK trial defines an abnormal CA 125 according to a sophisticated algorithm to estimate ovarian cancer risk. The screening strategy that combined initial CA 125 with ultrasound as a second-line test was sensitive (89.5 percent) for invasive ovarian and tubal cancers, with 43 percent of cases detected in stages I or II. The strategy was also highly specific (99.8 percent). Although initial results of multimodal screening in the UK trial appear promising, definitive assessment awaits results from subsequent (incidence) screens and the effect on ovarian cancer mortality. In addition, cost effectiveness needs to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     High-risk women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials of screening for women with a familial ovarian cancer syndrome are not likely to be performed, since women at high risk for ovarian cancer, and their clinicians, would not accept assignment to a no screening arm. Therefore, prospective cohort studies provide the available data regarding the impact of screening for this population. Reports from surveillance programs using multimodal screening in women at high risk due to a genetic predisposition or family history have been largely disappointing and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest cohort study, the United Kingdom Familial Ovarian Cancer Screen Study (UK FOCSS), 3563 women with a familial ovarian cancer syndrome (estimated minimum lifetime risk of 10 percent) who had declined or deferred risk reducing salpingo-oophorectomy (RRSO), participants were screened annually for a mean of 3.2 years with a combination of transvaginal ultrasound and CA-125 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/66\">",
"       66",
"      </a>",
"      ]. The reported sensitivity for the detection of incident ovarian",
"      <span class=\"nowrap\">",
"       cancer/fallopian",
"      </span>",
"      tube cancer was 81.0 to 87.5 percent, depending on whether occult cancers detected at the time of RRSO (in women who underwent the procedure prior to the end of the study period) were classified as false negative or true positive. The positive predictive value of incident screening was 25.5 percent, which exceeds the threshold of 10 percent considered necessary for ovarian cancer screening. Four women underwent surgery for each case of detected cancer. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Screening tests'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Among incident screen-detected cancers, 30.8 percent (4 of 13) were stage I or II. Women who had not been screened in the year before cancer diagnosis were more likely to have stage IIIc or higher cancer than women who had been screened in the preceding year (85.7 versus 26.1 percent), suggesting the importance of adherence to the screening schedule. The study was not designed to determine whether screening improves mortality. However, the detection of lower-stage disease in women who adhered to screening has led to a decision to decrease the screening interval to four months for the next phase of this study. Additionally, the Risk of Ovarian Cancer algorithm used in the UKCTOCS will be incorporated into the next phase of this study for determining and following up abnormal results.",
"      <br/>",
"      <br/>",
"      Although RRSO remains the only reliable method of decreasing mortality from ovarian cancer in this high-risk population, this study suggests that screening may have the potential to somewhat reduce risk for women who wish to maintain their childbearing potential until they are ready to undergo surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies of screening in women at high-risk have shown less favorable results, with most cases at late stage at the time of screen detection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort of 888 women carriers of BRCA 1 or 2 mutations who underwent screening with annual transvaginal ultrasound and CA 125, 5 of 10 incident cancers were interval cases diagnosed in women who had had normal screening results 3 to 10 months previously [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/67\">",
"       67",
"      </a>",
"      ]. Eight of the ten cancers were stage III at diagnosis.",
"     </li>",
"     <li>",
"      Data from the PLCO trial through the first four screening examinations (baseline plus three annual screens with CA 125 and ultrasound) include results for high-risk women [",
"      <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/68\">",
"       68",
"      </a>",
"      ]. Women who underwent screening (n = 28,460) were stratified for risk by personal and family history: average risk (no history breast or ovarian cancer), moderate risk (one first-degree relative with breast cancer), or high risk (family history of ovarian cancer, &ge; two relatives with breast cancer, or personal history of breast cancer). After three post-baseline screening exams, the positive predictive value for abnormal screening results was 2.8 percent in the highest-risk group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lack of clear benefit from intensive surveillance programs in women at high risk due to genetic predisposition has led some experts to advocate other interventions to reduce risk in this population, including use of the oral contraceptive pill and prophylactic salpingo-oophorectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost-effectiveness of a multimodal screening protocol using annual CA 125 as a first-line test was less than $100,000 per year of life saved in one study based on computer modeling in a hypothetical cohort of women aged 50 at the start of screening [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/69\">",
"     69",
"    </a>",
"    ]. Another analysis showed that annual screening could be cost-effective (costing less than $100,000 per year of life saved) when the cost of the initial screen was $100 or less [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/70\">",
"     70",
"    </a>",
"    ]. More reliable data on cost-effectiveness await the completion of the ongoing randomized trial in the United Kingdom.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SYNTHESIS OF THE EVIDENCE",
"    </span>",
"   </p>",
"   <p>",
"    A practical clinical approach to the issue of screening is based upon assessment of an individual woman's risk of ovarian cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Women at average risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for ovarian cancer with CA 125 or ultrasound is NOT recommended for premenopausal and postmenopausal women without a family history of ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/71\">",
"     71",
"    </a>",
"    ]. The predictive value of either test alone (less than 3 percent) yields an unacceptably high rate of false-positive results and attendant morbidity and costs. The combination of annual CA 125 testing with ultrasonography did not decrease mortality at 13 year follow-up in a large randomized trial and screening caused harm related to adverse effects from surgery for false-positive findings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Women at increased risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with a family history of ovarian cancer, it is important to differentiate those with a possible rare familial ovarian cancer syndrome and those with the more common presentation of an isolated family member with ovarian cancer, without evidence of a hereditary pattern (",
"    <a class=\"graphic graphic_table graphicRef65717 \" href=\"UTD.htm?41/49/42779\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Lower-risk family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a family history but without evidence of a high-risk pattern should be counseled about their individual risk (considering age, parity, and history of oral contraceptive pill use), about the limited evidence for effectiveness of screening, and about potential adverse effects of screening. There is no evidence to support screening in this group, and decisions regarding screening should be based on individualized considerations involving the patient and clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     High-risk family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a suspected hereditary ovarian cancer syndrome should be referred to a genetic counselor for consideration of testing for BRCA1 and BRCA2 mutations and Lynch mutations; consideration should also be given to referring Ashkenazi Jewish women with a single family member with breast cancer before age 50 or with ovarian cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who are found to have BRCA1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    BRCA2 mutations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Lynch syndrome should discuss risk-reducing surgery, ovarian cancer screening and preventive measures with a clinician experienced in this area, such as a gynecologic oncologist. Protocols in clinical use for surveillance of such women include combinations of pelvic examinations, CA 125 and other tumor marker measurements, vaginal ultrasonography, and color Doppler imaging. Even though evidence for screening effectiveness has not been demonstrated, the decision to screen this patient population is based on their very high lifetime risk of ovarian cancer.",
"   </p>",
"   <p>",
"    The optimal screening protocol, or frequency for screening, has not been determined. In the absence of randomized trials, the American College of Obstetricians and Gynecologists (ACOG) and the National Comprehensive Cancer Network (NCCN) recommend screening women with BRCA mutations, starting at age 30 to 35 years or 5 to 10 years before the earliest diagnosis in a family member, using a combination of serum CA 125 and transvaginal ultrasound every 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. While this may be a reasonable option, the evidence indicates limited effectiveness of screening in this population, and clinicians and patients should not be falsely reassured by negative screening test results.",
"   </p>",
"   <p>",
"    Because of the poor performance of screening in the population, most recommend risk-reducing surgery by age 35 to 40 or when childbearing is completed. Preventive measures for ovarian cancer in women with ovarian cancer syndromes, including use of oral contraceptives or prophylactic oophorectomy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF EXPERT GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No North American expert groups recommend routine screening for ovarian cancer. This position is strengthened by results from the PLCO trial. The US Preventive Services Task Force (USPSTF) recommends against screening for ovarian cancer, with their initial recommendation reaffirmed in 2008 following an updated literature search [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/74\">",
"     74",
"    </a>",
"    ]. A further addendum in 2012 was issued to incorporate the results of the PLCO trial; the 2012 review again reaffirms the USPSTF position that the potential harms of general population screening for ovarian cancer outweigh any potential benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. The Society of Gynecologic Oncology (SGO) has endorsed the 2012 recommendations of the USPSTF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/77\">",
"     77",
"    </a>",
"    ]. Data from the PLCO trial were not available at the time of published recommendations by other groups, including the American College of Obstetricians and Gynecologists (ACOG) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/78\">",
"     78",
"    </a>",
"    ] and the Canadian Task Force on the Periodic Health Examination [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/79\">",
"     79",
"    </a>",
"    ], who also recommend against routine screening for ovarian cancer in asymptomatic women.",
"   </p>",
"   <p>",
"    Outside North America, professional societies in Australia and New Zealand have endorsed a position statement that there is no evidence to support population screening for ovarian cancer in asymptomatic women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For women with identified hereditary ovarian cancer syndromes, SGO and the National Comprehensive Cancer Network (NCCN) recommend screening every six months with CA 125 and TVUS beginning between the ages of 30 and 35 years or 5 to 10 years earlier than the earliest age of first diagnosis of ovarian cancer in the family [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/73,81\">",
"     73,81",
"    </a>",
"    ]. ACOG states that there is no evidence that screening improves survival in women high-risk populations, but also cites the NCCN guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/82\">",
"     82",
"    </a>",
"    ]. The National Cancer Institute finds there is not sufficient evidence to support screening for ovarian cancer in any population, including women at increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/14/10474/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/14/27874?source=see_link\">",
"       \"Patient information: Ovarian cancer screening (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/26/27043?source=see_link\">",
"       \"Patient information: Genetic testing for breast and ovarian cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=see_link\">",
"       \"Patient information: Ovarian cancer screening (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"       \"Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ovarian cancer is the leading cause of death from gynecologic malignancy in the United States, and worldwide is the seventh leading cause of cancer death in women. Survival is much improved for earlier-stage disease. However, most cancers have spread beyond the ovary at the time of diagnosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Biological basis for screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The strongest known risk factor for ovarian cancer is a family history. Familial ovarian cancer syndromes (the Lynch syndrome and breast-ovarian cancer syndromes related to BRCA1 or BRCA2 mutations) occur rarely, but present much greater risk than a sporadic family history of ovarian cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One of three randomized trials of screening with annual CA 125 and TVUS in average-risk postmenopausal women has shown no decrease in mortality from ovarian cancer. Two other large trials are ongoing. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Risks and benefits of screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CA 125, the most widely studied tumor marker for ovarian cancer screening, is elevated in 50 to 90 percent of women with early ovarian cancer, but also can be elevated in numerous other conditions. We recommend NOT screening with a single measurement of CA 125 alone, either in average- or high-risk women (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'CA 125'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serial measurements of CA 125, panels of other tumor markers or proteomic patterns, or the incorporation of an ovarian cancer symptom index, may improve the positive predictive value of screening, but none sufficiently to incorporate into clinical practice at this time. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Screening tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transvaginal ultrasonography (TVUS), when used as a sole screening intervention for higher-risk women, has not been effective in identifying early-stage cancer. TVUS may be more effective when used as part of multimodal screening, in conjunction with CA 125. However, the positive predictive value for multimodal screening in high risk groups remains low. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pelvic ultrasonography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Multimodal screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend NOT screening average-risk women for ovarian cancer (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Synthesis of the evidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest periodically screening women with a familial ovarian cancer syndrome, who have not undergone prophylactic oophorectomy, with a combination of CA 125 and transvaginal ultrasound (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). While there are no high-quality data on which to base recommendations regarding timing of screening, some have suggested initiation at age 35 years or 5 to 10 years earlier than the earliest age of first diagnosis of ovarian cancer in the family. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Synthesis of the evidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with a family history of ovarian cancer who do not have a confirmed ovarian cancer syndrome, we suggest management as for women at average risk (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Synthesis of the evidence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/healthprofessional. (Accessed on July 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/3\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/4\">",
"      Baldwin LM, Trivers KF, Matthews B, et al. Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations? Ann Intern Med 2012; 156:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/5\">",
"      Barnholtz-Sloan JS, Schwartz AG, Qureshi F, et al. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003; 189:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/6\">",
"      Tobacman JK, Greene MH, Tucker MA, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982; 2:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/7\">",
"      Kurman RJ, Visvanathan K, Roden R, et al. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008; 198:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/8\">",
"      Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 1992; 80:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/9\">",
"      Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med 1994; 121:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/10\">",
"      Daly M, Obrams GI. Epidemiology and risk assessment for ovarian cancer. Semin Oncol 1998; 25:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/11\">",
"      Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/12\">",
"      Weitzel JN, Lagos VI, Cullinane CA, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 2007; 297:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/13\">",
"      Smith SA, Richards WE, Caito K, et al. BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study. Gynecol Oncol 2001; 83:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/14\">",
"      Stratton JF, Gayther SA, Russell P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997; 336:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/15\">",
"      Lynch HT, Bewtra C, Lynch JF. Familial ovarian carcinoma. Clinical nuances. Am J Med 1986; 81:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/16\">",
"      Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009; 75:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/17\">",
"      Khoury-Collado F, Bombard AT. Hereditary breast and ovarian cancer: what the primary care physician should know. Obstet Gynecol Surv 2004; 59:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/18\">",
"      Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998; 178:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/19\">",
"      Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002; 94:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/20\">",
"      Hilton JL, Geisler JP, Rathe JA, et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002; 94:1396.",
"     </a>",
"    </li>",
"    <li>",
"     The Surveillance Program, Division of Cancer Prevention and Control. Cancer Statistics Review 1973; 87, Publication no. 90-2789. National Cancer Institute, Washington, DC 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/22\">",
"      Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/23\">",
"      Bristow RE, Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril 1996; 66:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/24\">",
"      Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 2004; 103:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/25\">",
"      Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009; 10:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/26\">",
"      Kobayashi H, Yamada Y, Sado T, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 2008; 18:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/27\">",
"      Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011; 305:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/28\">",
"      Jacobs I. Genetic, biochemical, and multimodal approaches to screening for ovarian cancer. Gynecol Oncol 1994; 55:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/29\">",
"      Rosenthal AN, Menon U, Jacobs IJ. Screening for ovarian cancer. Clin Obstet Gynecol 2006; 49:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/30\">",
"      Moore RG, MacLaughlan S, Bast RC Jr. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol 2010; 116:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/31\">",
"      Smith LH, Oi RH. Detection of malignant ovarian neoplasms: a review of the literature. III. Immunological detection and ovarian cancer-associated antigens. Obstet Gynecol Surv 1984; 39:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/32\">",
"      Pickhardt PJ, Hanson ME. Incidental adnexal masses detected at low-dose unenhanced CT in asymptomatic women age 50 and older: implications for clinical management and ovarian cancer screening. Radiology 2010; 257:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/33\">",
"      Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/34\">",
"      Mol BW, Bayram N, Lijmer JG, et al. The performance of CA-125 measurement in the detection of endometriosis: a meta-analysis. Fertil Steril 1998; 70:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/35\">",
"      Zuckerman E, Lanir A, Sabo E, et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 1999; 94:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/36\">",
"      Devarbhavi H, Kaese D, Williams AW, et al. Cancer antigen 125 in patients with chronic liver disease. Mayo Clin Proc 2002; 77:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/37\">",
"      Sj&ouml;vall K, Nilsson B, Einhorn N. The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol Oncol 2002; 85:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/38\">",
"      Topalak O, Saygili U, Soyturk M, et al. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol 2002; 85:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/39\">",
"      Johnson CC, Kessel B, Riley TL, et al. The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol Oncol 2008; 110:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/40\">",
"      Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996; 313:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/41\">",
"      Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988; 42:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/42\">",
"      Einhorn N, Sj&ouml;vall K, Knapp RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992; 80:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/43\">",
"      Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993; 306:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/44\">",
"      Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21:273S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/45\">",
"      Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005; 193:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/46\">",
"      Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009; 113:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/47\">",
"      Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003; 21:206s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/48\">",
"      Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005; 23:7919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/49\">",
"      Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009; 361:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/50\">",
"      Shah CA, Lowe KA, Paley P, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev 2009; 18:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/51\">",
"      Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/52\">",
"      Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010; 28:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/53\">",
"      Anderson GL, McIntosh M, Wu L, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010; 102:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/54\">",
"      Moore LE, Pfeiffer RM, Zhang Z, et al. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 2012; 118:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/55\">",
"      Andersen MR, Goff BA, Lowe KA, et al. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer 2008; 113:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/56\">",
"      Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst 2010; 102:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/57\">",
"      Andersen MR, Goff BA, Lowe KA, et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol 2010; 116:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/58\">",
"      Pavlik EJ, DePriest PD, Gallion HH, et al. Ovarian volume related to age. Gynecol Oncol 2000; 77:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/59\">",
"      Shy K, Dubinsky T. Is color Doppler ultrasound useful in diagnosing ovarian cancer? Clin Obstet Gynecol 1999; 42:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/60\">",
"      Kinkel K, Hricak H, Lu Y, et al. US characterization of ovarian masses: a meta-analysis. Radiology 2000; 217:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/61\">",
"      Bourne TH, Campbell S, Reynolds KM, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 1993; 306:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/62\">",
"      Karlan BY, Raffel LJ, Crvenkovic G, et al. A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results. Am J Obstet Gynecol 1993; 169:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/63\">",
"      Fishman DA, Cohen L, Blank SV, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol 2005; 192:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/64\">",
"      van Nagell JR Jr, Miller RW, DeSimone CP, et al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol 2011; 118:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/65\">",
"      Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/66\">",
"      Rosenthal AN, Fraser L, Manchanda R, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol 2013; 31:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/67\">",
"      Hermsen BB, Olivier RI, Verheijen RH, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007; 96:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/68\">",
"      Lacey JV Jr, Greene MH, Buys SS, et al. Ovarian cancer screening in women with a family history of breast or ovarian cancer. Obstet Gynecol 2006; 108:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/69\">",
"      Urban N, Drescher C, Etzioni R, Colby C. Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials 1997; 18:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/70\">",
"      Havrilesky LJ, Sanders GD, Kulasingam S, Myers ER. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Gynecol Oncol 2008; 111:179.",
"     </a>",
"    </li>",
"    <li>",
"     www.cancer.gov/cancertopics/pdq/screening/ovarian/healthprofessional/allpages (Accessed on August 24, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/72\">",
"      American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins--Gynecology, ACOG Committee on Genetics, Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009; 113:957.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     www.ahrq/gov/clinic/3rduspstf/ovariancan/ovcanrs.htm (Accessed on August 24, 2009).",
"    </li>",
"    <li>",
"     file://www.uspreventiveservicestaskforce.org/uspstf12/ovarian/ovarartaddend.htm (Accessed on June 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/76\">",
"      Moyer VA, U.S. Preventive Services Task Force. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2012; 157:900.",
"     </a>",
"    </li>",
"    <li>",
"     file://campaign.r20.constantcontact.com/render?llr=65mauybab&amp;v=001-VufbrhO4aadFDnJTbyN09ViVj3jkTJ_HTKrI7tz4ROKSpiyEdS8IGdXFEWGWQCY9P3rldvwIUjj69wtTwvLNDziaynNC5j3fjEZYsWaLXEi5_syyBpqY3ALvetmf4TafTwtPXvlWt3aujdXjtyObZ_UfeVI3dk0JQ5hkJncIfXWMoM8PIAs8i-7hecEYOz7AVz4Y6AxTvLx5EpckmDwGGtFHF9ZqZBqNaaSiq7oat (Accessed on September 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/78\">",
"      ACOG Committee on Gynecologic Practice. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Gynecol Oncol 2002; 87:237.",
"     </a>",
"    </li>",
"    <li>",
"     Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive care. Canada Communication Group, Ottawa 1994. p.869. Available at: www.ctfphc.org/ (Accessed on August 24, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/80\">",
"      Nelson AE, Francis JE, Zorbas H, National Breast and Ovarian Cancer Centre. Population screening and early detection of ovarian cancer in asymptomatic women. Aust N Z J Obstet Gynaecol 2009; 49:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/14/10474/abstract/81\">",
"      Schorge JO, Modesitt SC, Coleman RL, et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010; 119:7.",
"     </a>",
"    </li>",
"    <li>",
"     www.acog.org/from_home/publicationspress_releases/nr03-20-09.cfm (Accessed on August 24, 2009).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7563 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10474=[""].join("\n");
var outline_f10_14_10474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOLOGICAL BASIS FOR SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetic predisposition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Familial ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Reproductive and endocrine factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RISKS AND BENEFITS OF SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SCREENING TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - CA 125",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ovarian cancer symptom index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pelvic ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Multimodal screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - High-risk women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SYNTHESIS OF THE EVIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Women at average risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Women at increased risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Lower-risk family history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - High-risk family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      RECOMMENDATIONS OF EXPERT GROUPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7563\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7563|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/59/12221\" title=\"table 1\">",
"      Risk factors ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/17/27931\" title=\"table 2\">",
"      BRCA testing USPSTF guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/40/7821\" title=\"table 3\">",
"      Cancer risks BRCA1 and BRCA2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/49/42779\" title=\"table 4\">",
"      Risk assess crit breast ovar CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=related_link\">",
"      Early detection of epithelial ovarian cancer: Role of symptom recognition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25847?source=related_link\">",
"      Epithelial ovarian cancer: Second look surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=related_link\">",
"      Evidence-based approach to prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=related_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/26/27043?source=related_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=related_link\">",
"      Patient information: Ovarian cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/14/27874?source=related_link\">",
"      Patient information: Ovarian cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=related_link\">",
"      Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_14_10475="Predispositions for aspiration";
var content_f10_14_10475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions that predispose to aspiration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Altered consciousness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alcoholism, seizures, cerebrovascular accident, head trauma, general anesthesia, drug overdose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Dysphagia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Esophageal disorders including stricture, neoplasm, diverticula, tracheoesophageal fistula, incompetent cardiac sphincter",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Neurologic disorder",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multiple sclerosis, Parkinson disease, myasthenia gravis, pseudobulbar palsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Mechanical disruption of the usual defense barriers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nasogastric tube, endotracheal intubation, tracheostomy, upper gastrointestinal endoscopy, bronchoscopy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Protracted vomiting, gastric outlet obstruction, large-volume nasogastric tube feedings, pharyngeal anesthesia, general debility, recumbent position",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10475=[""].join("\n");
var outline_f10_14_10475=null;
var title_f10_14_10476="Dis prog small int GIST";
var content_f10_14_10476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disease progression rate for small intestinal gastrointestinal stromal tumors (GIST)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle1\">",
"       Tumor size, cm",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mitotic rate",
"      </td>",
"      <td class=\"subtitle1\">",
"       Prognostic group",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"      <td class=\"subtitle1\">",
"       Observed rate of progressive disease",
"       <sup>",
"        [1]",
"       </sup>",
"       , percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IA",
"      </td>",
"      <td>",
"       &le;5",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       1, 2",
"      </td>",
"      <td>",
"       0-2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       II",
"      </td>",
"      <td>",
"       &gt;5-10",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       3a",
"      </td>",
"      <td>",
"       23",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       IIIA",
"      </td>",
"      <td>",
"       &gt;10",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       3b",
"      </td>",
"      <td>",
"       49",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &le;2",
"      </td>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       50",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       IIIB",
"      </td>",
"      <td>",
"       &gt;2-5",
"      </td>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       73",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;5",
"      </td>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       6a",
"      </td>",
"      <td>",
"       72",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;10",
"      </td>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       6b",
"      </td>",
"      <td>",
"       89",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <ol>",
"      <li>",
"       Miettinen M, Makhlouf HR, Sobin LH, Lasota J. Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum - a clinicopathologic, immunohistochemical and molecular genetic study of 906 cases prior to imatinib with long-term follow-up. Am J Surg Pathol. 206; 30:477-89, with permission from Lippincott Williams &amp; Wilkins.",
"      </li>",
"     </ol>",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10476=[""].join("\n");
var outline_f10_14_10476=null;
var title_f10_14_10477="Metropolitan Life Insurance Company height-weight tables";
var content_f10_14_10477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F71826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F71826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Metropolitan Life Insurance Company height-weight tables",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Height-weight for women, according to height",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Height wearing shoes (feet and inches)*",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Weight range (pounds)",
"        <sup>",
"         &bull;&Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4'10\"",
"       </td>",
"       <td>",
"        109-121",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4'11\"",
"       </td>",
"       <td>",
"        111-123",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'0\"",
"       </td>",
"       <td>",
"        113-126",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'1\"",
"       </td>",
"       <td>",
"        115-129",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'2\"",
"       </td>",
"       <td>",
"        118-132",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'3\"",
"       </td>",
"       <td>",
"        121-135",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'4\"",
"       </td>",
"       <td>",
"        124-138",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'5\"",
"       </td>",
"       <td>",
"        127-141",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'6\"",
"       </td>",
"       <td>",
"        130-144",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'7\"",
"       </td>",
"       <td>",
"        133-147",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'8\"",
"       </td>",
"       <td>",
"        136-150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'9\"",
"       </td>",
"       <td>",
"        139-153",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'10\"",
"       </td>",
"       <td>",
"        142-156",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'11\"",
"       </td>",
"       <td>",
"        145-159",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6'0\"",
"       </td>",
"       <td>",
"        148-162",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Height-weight for men, according to height",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Height wearing shoes (feet and inches)*",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Weight range (pounds)",
"        <sup>",
"         &bull;&Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'2\"",
"       </td>",
"       <td>",
"        131-141",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'3\"",
"       </td>",
"       <td>",
"        133-143",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'4\"",
"       </td>",
"       <td>",
"        135-145",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'5\"",
"       </td>",
"       <td>",
"        137-148",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'6\"",
"       </td>",
"       <td>",
"        139-151",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'7\"",
"       </td>",
"       <td>",
"        142-154",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'8\"",
"       </td>",
"       <td>",
"        145-157",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'9\"",
"       </td>",
"       <td>",
"        148-160",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'10\"",
"       </td>",
"       <td>",
"        151-163",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5'11\"",
"       </td>",
"       <td>",
"        154-166",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6'0\"",
"       </td>",
"       <td>",
"        157-170",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6'1\"",
"       </td>",
"       <td>",
"        160-174",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6'2\"",
"       </td>",
"       <td>",
"        164-178",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6'3\"",
"       </td>",
"       <td>",
"        167-182",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6'4\"",
"       </td>",
"       <td>",
"        171-187",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In shoes with 1\" heels.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Weight (pounds), at age 25 to 59 years, wearing indoor clothing weighing 5 pounds for men, 3 pounds for women.",
"      <br>",
"       &Delta; Listed weight ranges represent ideal body weight. Minimally acceptable weights are generally calculated as 85 to 90 percent of ideal.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Metropolitan Life Insurance Company. 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983; 64:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10477=[""].join("\n");
var outline_f10_14_10477=null;
var title_f10_14_10478="Rectal cancer BE";
var content_f10_14_10478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rectal cancer as seen on barium enema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double-contrast barium enema shows an eccentric mass arising from the anterior wall of the rectum (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10478=[""].join("\n");
var outline_f10_14_10478=null;
var title_f10_14_10479="Aortogram showing descending thoracic aortic dissection";
var content_f10_14_10479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortogram showing descending thoracic aortic dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This aortogram demonstrates dissection of the descending thoracic aorta, arising immediately distal to the origin of the left subclavian artery. An oblique lucency is noted within the lumen of the aorta, which is a diagnostic feature (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_14_10479=[""].join("\n");
var outline_f10_14_10479=null;
